CA2407449A1 - Novel compounds - Google Patents

Abstract

Polypeptides and polynucleotides of the genes set forth in Table I and metho ds for producing such polypeptides by recombinant techniques are disclosed. Als o disclosed are methods for utilizing polypeptides and polynucleotides of the genes set forth in Table I in diagnostic assays.

Description

Novel Compounds Field of Invention This invention relates to newly identified polypeptides and polynucleotides encoding such polypeptides, to their use in diagnosis and in identifying compounds that may be agonists, antagonists that are potentially useful in therapy, and to production of such polypeptides and polynucleotides. The polynucleotides and polypeptides of the present invention also relate to proteins with signal sequences which allow them to be secreted extracellularly or membrane-associated (hereinafter often referred collectively as secreted proteins or secreted polypeptides).
Background of the Invention The drug discovery process is currently undergoing a fundamental revolution as it embraces "functional genomics", that is, high throughput genome- or gene-based biology.
This approach as a means to identify genes and gene products as therapeutic targets is rapidly superseding earlier approaches based on "positional cloning". A
phenotype, that is a biological function or genetic disease, would be identified and this would then be tracked back to the responsible gene, based on its genetic map position.
Functional genomics relies heavily on high-throughput DNA sequencing technologies and the various tools of bioinformatics to identify gene sequences of potential interest from the many molecular biology databases now available. There is a continuing need to identify and characterise further genes and their related polypeptides/proteins, as targets for drug discovery.
Proteins and polypeptides that are naturally secreted into blood, lymph and other body fluids, or secreted into the cellular membrane are of primary interest for pharmaceutical research and development. The reason for this interest is the relative ease to target protein therapeutics into their place of action (body fluids or the cellular membrane).
The natural pathway for protein secretion into extracellular space is the endoplasmic reticulum in eukaryotes and the inner membrane in prokaryotes (Palade, 1975, Science, 189, 347; Milstein, Brownlee, Harrison, and Mathews, 1972, Nature New Biol., 239, 117;
Blobel, and Dobberstein, 1975, J. Cell. Biol., 67, 835). On the other hand, there is no known natural pathway for exporting a protein from the exterior of the cells into the cytosol (with the exception of pinocytosis, a mechanism of snake venom toxin intrusion into cells).
Therefore targeting protein therapeutics into cells poses extreme difficulties.

The secreted and membrane-associated proteins include but are not limited to all peptide hormones and their receptors (including but not limited to insulin, growth hormones, chemokines, cytokines, neuropeptides, integrins, kallikreins, lamins, melanins, natriuretic hormones, neuropsin, neurotropins, pituitiary hormones, pleiotropins, prostaglandins, secretogranins, selectins, thromboglobulins, thymosins), the breast and colon cancer gene products, leptin, the obesity gene protein and its receptors, serum albumin, superoxide dismutase, spliceosome proteins, 7TM (transmembrane) proteins also called as G-protein coupled receptors, immunoglobulins, several. families of serine proteinases (including but not limited to proteins of the blood coagulation cascade, digestive enzymes), deoxyribonuclease I, etc.
Therapeutics based on secreted or membrane-associated proteins approved by FDA or foreign agencies include but are not limited to insulin, glucagon, growth hormone, chorionic gonadotropin, follicle stimulating hormone, luteinizing hormone, calcitonin, adrenocorticotropic hormone (ACTH), vasopressin, interleukines, interferones, immunoglobulins, lactoferrin (diverse products marketed by several companies), tissue-type plasminogen activator (Alteplase by Genentech), hyaulorindase (Wydase by Wyeth-Ayerst), dornase alpha (Pulmozyme\ by Genentech), Chymodiactin (chymopapain by Knoll), alglucerase (Ceredase by Genzyme), streptokinase (Kabikinase by Pharmacia) (Streptase by Astray, etc.
This indicates that secreted and membrane-associated proteins have an established, proven history as therapeutic targets. Clearly, there is a need for identification and characterization of further secreted and membrane-associated proteins which can play a role in preventing, ameliorating or correcting dysfunction or disease, including but not limited to diabetes, breast-, prostate-, colon cancer and other malignant tumors, hyper- and hypotension, obesity, bulimia, anorexia, growth abnormalities, asthma, manic depression, dementia, delirium, mental retardation, Huntington's disease, Tourette's syndrome, schizophrenia, growth, mental or sexual development disorders, and dysfunctions of the blood cascade system including those leading to stroke. The proteins of the present invention which include the signal sequences are also useful to further elucidate the mechanism of protein transport which at present is not entirely understood, and thus can be used as research tools.
Summary of the Invention The present invention relates to particular polypeptides and polynucleotides of the genes set forth in Table I, including recombinant materials and methods for their production.
Such polypeptides and polynucleotides are of interest in relation to methods of treatment of certain diseases, including, but not limited to, the diseases set forth in Tables III and V, hereinafter referred to as "diseases of the invention". In a further aspect, the invention relates to methods for identifying agonists and antagonists (e.g., inhibitors) using the materials provided by the invention, and treating conditions associated with imbalance of polypeptides andlor polynucleotides of the genes set forth in Table I with the identified compounds. In still a further aspect, the invention relates to diagnostic assays for detecting diseases associated with inappropriate activity or levels the genes set forth in Table I.
Another aspect of the invention concerns a polynucleotide comprising any of the nucleotide sequences set forth in the Sequence Listing and a polypeptide comprising a polypeptide encoded by the nucleotide sequence. In another aspect, the invention relates to a polypeptide comprising any of the polypeptide sequences set forth in the Sequence Listing and recombinant materials and methods fox their production. Another aspect of the invention relates to methods for using such polypeptides and polynucleotides. Such uses include the treatment of diseases, abnormalities and disorders (hereinafter simply referred to as diseases) caused by abnormal expression, production, function and or metabolism of the genes of this invention, and such diseases are readily apparent by those skilled in the art from the homology to other proteins disclosed for each attached sequence. In still another aspect, the invention relates to methods to identify agonists and antagonists using the materials provided by the invention, and treating conditions associated with the imbalance with the identified compounds. Yet another aspect of the invention relates to diagnostic assays for detecting diseases associated with inappropriate activity or levels of the secreted proteins of the present invention.
Description of the Invention In a first aspect, the present invention relates to polypeptides the genes set forth in Table I. Such polypeptides include:
(a) an isolated polypeptide encoded by a polynucleotide comprising a sequence set forth in the Sequence Listing, herein when refernng to polynucleotides or polypeptides of the Sequence Listing, a reference is also made to the Sequence Listing referred to in the Sequence Listing;
(b) an isolated polypeptide comprising a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to a polypeptide sequence set forth in the Sequence Listing;

(c) an isolated polypeptide comprising a polypeptide sequence set forth in the Sequence Listing;
(d) an isolated polypeptide having at least 95%, 96%, 97%, 98%, or 99%
identity to a polypeptide sequence set forth in the Sequence Listing;
(e) a polypeptide sequence set forth in the Sequence Listing; and (f) an isolated polypeptide having or comprising a polypeptide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to a polypeptide sequence set forth in the Sequence Listing;
(g) fragments and variants of such polypeptides in (a) to (f).
Polypeptides of the present invention are believed to be members of the gene families set forth in Table II . They are therefore of therapeutic and diagnostic interest for the reasons set forth in Tables III and V. The biological properties of the polypeptides and polynucleotides of the genes set forth in Table I are hereinafter referred to as "the biological activity" of polypeptides and polynucleotides of the genes set forth in Table I. Preferably, a polypeptide of the present invention exhibits at least one biological activity of the genes set forth in Table I.
Polypeptides of the present invention also include variants of the aforementioned polypeptides, including all allelic forms and splice variants. Such polypeptides vary from the reference polypeptide by insertions, deletions, and substitutions that may be conservative or non-conservative, or any combination thereof. Particularly preferred variants are those in which several, for instance from 50 to 30, from 30 to 20, from 20 to 10, from 10 to 5, from 5 to 3, from 3 to 2, from 2 to 1 or 1 amino acids are inserted, substituted, or deleted, in any combination.
Preferred fragments of polypeptides of the present invention include an isolated polypeptide comprising an amino acid sequence having at least 30, 50 or 100 contiguous amino acids from an amino acid sequence set forth in the Sequence Listing, or an isolated polypeptide comprising an amino acid sequence having at least 30, 50 or 100 contiguous amino acids truncated or deleted from an amino acid sequence set forth in the Sequence Listing. Preferred fragments are biologically active fragments that mediate the biological activity of polypeptides and polynucleotides of the genes set forth in Table I, including those with a similar activity or an improved activity, or with a decreased undesirable activity. Also preferred are those fragments that are antigenic or immunogenic in an animal, especially in a human.
Fragments of a polypeptide of the invention may be employed for producing the corresponding full-length polypeptide by peptide synthesis; therefore, these variants may be employed as intermediates for producing the full-length polypeptides of the invention. A
polypeptide of the present invention may be in the form of the "mature"
protein or may be a part of a larger protein such as a precursor or a fusion protein. It is often advantageous to include an additional amino acid sequence that contains secretory or leader sequences, pro-s sequences, sequences that aid in purification, for instance multiple histidine residues, or an additional sequence for stability during recombinant production.
Polypeptides of the present invention can be prepared in any suitable manner, for instance by isolation form naturally occurnng sources, from genetically engineered host cells comprising expression systems (vide infra) or by chemical synthesis, using for instance automated peptide synthesizers, or a combination of such methods. Means for preparing such polypeptides are well understood in the art.
In a further aspect, the present invention relates to polynucleotides of the genes set forth in Table I. Such polynucleotides include:
(a) an isolated polynucleotide comprising a polynucleotide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to a polynucleotide sequence set forth in the Sequence Listing;
(b) an isolated polynucleotide comprising a polynucleotide set forth in the Sequence Listing;
(c) an isolated polynucleotide having at least 95%, 96%, 97%, 98%, or 99%
identity to a polynucleotide set forth in the Sequence Listing;
(d) an isolated polynucleotide set forth in the Sequence Listing;
(e) an isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to a polypeptide sequence set forth in the Sequence Listing;
(f) an isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide set forth in the Sequence Listing;
(g) an isolated polynucleotide having a polynucleotide sequence encoding a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to a polypeptide sequence set forth in the Sequence Listing;
(h) an isolated polynucleotide encoding a polypeptide set forth in the Sequence Listing;
(i) an isolated polynucleotide having or comprising a polynucleotide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to a polynucleotide sequence set forth in the Sequence Listing;

(j) an isolated polynucleotide having or comprising a polynucleotide sequence encoding a polypeptide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to a polypeptide sequence set forth in the Sequence Listing; and polynucleotides that are fragments and variants of the above mentioned polynucleotides or that are complementary to above mentioned polynucleotides, over the entire length thereof.
Preferred fragments of polynucleotides of the present invention include an isolated polynucleotide comprising an nucleotide sequence having at least 15, 30, 50 or contiguous nucleotides from a sequence set forth in the Sequence Listing, or an isolated polynucleotide comprising a sequence having at least 30, 50 or 100 contiguous nucleotides truncated or deleted from a sequence set forth in the Sequence Listing.
Preferred variants of polynucleotides of the present invention include splice variants, allelic variants, and polymorphisms, including polynucleotides having one or more single nucleotide polymorphisms (SNPs).
Polynucleotides of the present invention also include polynucleotides encoding polypeptide variants that comprise an amino acid sequence set forth in the Sequence Listing and in which several, for instance from 50 to 30, from 30 to 20, from 20 to 10, from 10 to 5, from 5 to 3, from 3 to 2, from 2 to 1 or 1 amino acid residues are substituted, deleted or added, in any combination.
In a further aspect, the present invention provides polynucleotides that are RNA transcripts of the DNA sequences of the present invention. Accordingly, there is provided an RNA
polynucleotide that:
(a) comprises an RNA transcript of the DNA sequence encoding a polypeptide set forth in the Sequence Listing;
(b) is a RNA transcript of a DNA sequence encoding a polypeptide set forth in the Sequence Listing;
(c) comprises an RNA transcript of a DNA sequence set forth in the Sequence Listing; or (d) is a RNA transcript of a DNA sequence set forth in the Sequence Listing;
and RNA polynucleotides that are complementary thereto.
The polynucleotide sequences set forth in the Sequence Listing show homology with the polynucleotide sequences set forth in Table II. A polynucleotide sequence set forth in the Sequence Listing is a cDNA sequence that encodes a polypeptide set forth in the Sequence Listing. A polynucleotide sequence encoding a polypeptide set forth in the Sequence Listing may be identical to a polypeptide encoding a sequence set forth in the Sequence Listing or it may be a sequence other than a sequence set forth in the Sequence Listing, which, as a result of the redundancy (degeneracy) of the genetic code, also encodes a polypeptide set forth in the Sequence Listing. A polypeptide of a sequence set forth in the Sequence Listingis related to other proteins of the gene families set forth in Table II, having homology and/or structural similarity with the polypeptides set forth in Table II. Preferred polypeptides and polynucleotides of the present invention are expected to have, ir2ter alia, similar biological functions/properties to their homologous polypeptides and polynucleotides. Furthermore, preferred polypeptides and polynucleotides of the present invention have at least one activity of the genes set forth in Table I.
Polynucleotides of the present invention may be obtained using standard cloning and screening techniques from a cDNA library derived from mRNA from the tissues set forth in Table IV (see for instance, Sambrook et al., Molecular Cloning: A
Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
(1989)).
Polynucleotides of the invention can also be obtained from natural sources such as genomic DNA libraries or can be synthesized using well known and commercially available techniques.
When polynucleotides of the present invention are used for the recombinant production of polypeptides of the present invention, the polynucleotide may include the coding sequence for the mature polypeptide, by itself, or the coding sequence for the mature polypeptide in reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein sequence, or other fusion peptide portions. For example, a marker sequence that facilitates purification of the fused polypeptide can be encoded. In certain preferred embodiments of this aspect of the invention, the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz et al., Proc Natl Acad Sci USA (1989) 86:821-824, or is an HA tag. A polynucleotide may also contain non-coding 5' and 3' sequences, such as transcribed, non-translated sequences, splicing and polyadenylation signals, ribosome binding sites and sequences that stabilize mRNA.
Polynucleotides that are identical, or have sufficient identity to a polynucleotide sequence set forth in the Sequence Listing, may be used as hybridization probes for cDNA
and genomic DNA or as primers for a nucleic acid amplification reaction (for instance, PCR). Such probes and primers may be used to isolate full-length cDNAs and genomic clones encoding polypeptides of the present invention and to isolate cDNA and genomic clones of other genes (including genes encoding paralogs from human sources and orthologs and paralogs from other species) that have a high sequence similarity to sequences set forth in the Sequence Listing, typically at least 95% identity. Preferred probes and primers will generally comprise at least 15 nucleotides, preferably, at least 30 nucleotides and may have at least 50, if not at least 100 nucleotides. Particularly preferred probes will have between 30 and 50 nucleotides. Particularly preferred primers will. have between 20 and 25 nucleotides.
A polynucleotide encoding a polypeptide of the present invention, including homologs from other species, may be obtained by a process comprising the steps of screening a library under stringent hybridization conditions with a labeled probe having a sequence set forth in the Sequence Listing or a fragment thereof, preferably of at least 15 nucleotides; and isolating full-length cDNA and genomic clones containing the polynucleotide sequence set forth in the Sequence Listing. Such hybridization techniques are well known to the skilled artisan. Preferred stringent hybridization conditions include overnight incubation at 42°C in a solution comprising: 50% formamide, SxSSC (150mM
NaCI, lSmM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10 % dextxan sulfate, and 20 microgram/ml denatured, sheared salmon sperm DNA;
followed by washing the filters in O.lx SSC at about 65°C. Thus the present invention also includes isolated polynucleotides, preferably with a nucleotide sequence of at least 100, obtained by screening a library under stringent hybridization conditions with a labeled probe having the sequence set forth in the Sequence Listing or a fragment thereof, preferably of at least 15 nucleotides.
The skilled artisan will appreciate that, in many cases, an isolated cDNA
sequence will be incomplete, in that the region coding for the polypeptide does not extend all the way through to the 5'terminus. This is a consequence of reverse transcriptase, an enzyme with inherently low "processivity" (a measure of the ability of the enzyme to remain attached to the template during the polymerisation reaction), failing to complete a DNA
copy of the mRNA template during first strand cDNA synthesis.
There are several methods available and well known to those skilled in the art to obtain full-length cDNAs, or extend short cDNAs, for example those based on the method of Rapid Amplification of cDNA ends (RACE) (see, for example, Frohman et al., Proc Nat Acad Sci USA 85, 8998-9002, 1988). Recent modifications of the technique, exemplified by the Marathon (trade mark) technology (Clontech Laboratories Inc.) for example, have significantly simplified the search for longer cDNAs. In the Marathon (trade mark) technology, cDNAs have been prepared from mRNA extracted from a chosen tissue and an 'adaptor' sequence ligated onto each end. Nucleic acid amplification (PCR) is then carried out to amplify the "missing" 5' end of the cDNA using a combination of gene specific and adaptor specific oligonucleotide primers. The PCR reaction is then repeated using 'nested' primers, that is, primers designed to anneal within the amplified product (typically an adapter specific primer that anneals further 3' in the adaptor sequence and a gene specific primer that anneals further 5' in the known gene sequence). The products of this reaction can then be analyzed by DNA sequencing and a full-length cDNA constructed either by joining the product directly to the existing cDNA to give a complete sequence, or carrying out a separate full-length PCR using the new sequence information for the design of the 5' primer.
Recombinant polypeptides of the present invention may be prepared by processes well known in the art from genetically engineered host cells comprising expression systems.
Accordingly, in a further aspect, the present invention relates to expression systems comprising a polynucleotide or polynucleotides of the present invention, to host cells which are genetically engineered with such expression systems and to the production of polypeptides of the invention by recombinant techniques. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA
constructs of the present invention.
For recombinant production, host cells can be genetically engineered to incorporate expression systems or portions thereof for polynucleotides of the present invention.
Polynucleotides may be introduced into host cells by methods described in many standard laboratory manuals, such as Davis et al., Basic Methods in Molecular Biology (1986) and Sambrook et al.(ibid). Preferred methods of introducing polynucleotides into host cells include, for instance, calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, micro-injection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection.
Representative examples of appropriate hosts include bacterial cells, such as Streptococci, Staphylococci, E, coli, Streptonayces and Bacillus subtilis cells; fungal cells, such as yeast cells and Aspergillus cells; insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, HEK 293 and Bowes melanoma cells; and plant cells.
A great variety of expression systems can be used, for instance, chromosomal, episomal and virus-derived systems, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids. The expression systems may contain control regions that regulate as well as engender expression.
Generally, any system or vector that is able to maintain, propagate or express a polynucleotide to produce a polypeptide in a host may be used. The appropriate polynucleotide sequence may be inserted into an expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook et al., (ibis.
Appropriate secretion signals may be incorporated into the desired polypeptide to allow secretion of the translated protein into the lumen of the endoplasmic reticulum, the periplasmic space or the extracellular environment. These signals may be endogenous to the polypeptide or they may be heterologous signals.
If a polypeptide of the present invention is to be expressed for use in screening assays, it is generally preferred that the polypeptide be produced at the surface of the cell.
Tn this event, the cells may be harvested prior to use in the screening assay.
If the polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the polypeptide. If produced intracellularly, the cells must first be lysed before the polypeptide is recovered.
Polypeptides of the present invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during intracellular synthesis, isolation and/or purification.
Polynucleotides of the present invention may be used as diagnostic reagents, through detecting mutations in the associated gene. Detection of a mutated form of a gene is characterized by the polynucleotides set forth in the Sequence Listing in the cDNA or genomic sequence and which is associated with a dysfunction. Will provide a diagnostic tool that can add to, or define, a diagnosis of a disease, or susceptibility to a disease, which results from under-expression, over-expression or altered spatial or temporal expression of the gene. Individuals carrying mutations in the gene may be detected at the DNA level by a variety of techniques well known in the art.
Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or it may be amplified enzymatically by using PCR, preferably RT-PCR, or other amplification techniques prior to analysis. RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labeled nucleotide sequences of the genes set forth in Table I. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence difference may also be detected by alterations in the electrophoretic mobility of DNA
fragments in gels, with or without denaturing agents, or by direct DNA sequencing (see, for instance, Myers et al., Science (1985) 230:1242). Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and Sl protection or the chemical cleavage method (see Cotton et al., Proc Natl Acad Sci USA (1985) 85: 4397-4401).
An array of oligonucleotides probes comprising polynucleotide sequences or fragments thereof of the genes set forth in Table I can be constructed to conduct efficient screening of e.g., genetic mutations. Such arrays are preferably high density arrays or grids.
Array technology methods are well known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability, see, for example, M. Chee et al., Science, 274, 610-613 (1996) and other references cited therein.
Detection of abnormally decreased or increased levels of polypeptide or mRNA
expression may also be used for diagnosing or determining susceptibility of a subject to a disease of the invention. Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, nucleic acid amplification, for instance PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods. Assay techniques that can be used to determine levels of a protein, such as a polypeptide of the present invention, in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radio-immunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.
Thus in another aspect, the present invention relates to a diagnostic kit comprising:
(a) a polynucleotide of the present invention, preferably the nucleotide sequence set forth in the Sequence Listing , or a fragment or an RNA transcript thereof;
(b) a nucleotide sequence complementary to that of (a);
(c) a polypeptide of the present invention, preferably the polypeptide set forth in the Sequence Listing or a fragment thereof; or (d) an antibody to a polypeptide of the present invention, preferably to the polypeptide set forth in the Sequence Listing .

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component. Such a kit will be of use in diagnosing a disease or susceptibility to a disease, particularly diseases of the invention, amongst others.
The polynucleotide sequences of the present invention are valuable for chromosome localisation studies. The sequences set forth in the Sequence Listing are specifically targeted to, and can hybridize with, a particular location on an individual human chromosome. The mapping of relevant sequences to chromosomes according to the present invention is an important first step in correlating those sequences with gene associated disease. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found in, for example, V. McKusick, Mendelian Inheritance in Man (available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (co-inheritance of physically adjacent genes). Precise human chromosomal localisations for a genomic sequence (gene fragment etc.) can be determined using Radiation Hybrid (RH) Mapping (Walter, M. Spillett, D., Thomas, P., Weissenbach, J., and Goodfellow, P., (1994) A method for constructing radiation hybrid maps of whole genomes, Nature Genetics 7, 22-28). A number of RH panels are available from Research Genetics (Huntsville, AL, USA) e.g. the GeneBridge4 RH panel (Hum Mol Genet 1996 Mar;S(3):339-46 A radiation hybrid map of the human genome. Gyapay G, Schmitt K, Fizames C, Jones H, Vega-Czarny N, Spillett D, Muselet D, Prud~omme JF, Dib C, Auffray C, Morissette J, Weissenbach J, Goodfellow PN). To determine the chromosomal location of a gene using this panel, 93 PCRs are performed using primers designed from the gene of interest on RH DNAs. Each of these DNAs contains random human genomic fragments maintained in a hamster background (human / hamster hybrid cell lines). These PCRs result in 93 scores indicating the presence or absence of the PCR
product of the gene of interest. These scores are compared with scores created using PCR
products from genomic sequences of known location. This comparison is conducted at http:/lwww.genome.wi,mit.edu/.
The polynucleotide sequences of the present invention are also valuable tools for tissue expression studies. Such studies allow the determination of expression patterns of polynucleotides of the present invention which may give an indication as to the expression patterns of the encoded polypeptides in tissues, by detecting the mRNAs that encode them.
The techniques used are well known in the art and include in situ hydridization techniques to clones arrayed on a grid, such as cDNA microarray hybridization (Schena et al, Science, 270, 467-470, 1995 and Shalon et al, Genome Res, 6, 639-645, 1996) and nucleotide amplification techniques such as PCR. A preferred method uses the TAQMAN
(Trade mark) technology available from Perkin Elmer. Results from these studies can provide an indication of the normal function of the polypeptide in the organism. In addition, comparative studies of the normal expression pattern of mRNAs with that of mRNAs encoded by an alternative form of the same gene (for example, one having an alteration in polypeptide coding potential or a regulatory mutation) can provide valuable insights into the role of the polypeptides of the present invention, or that of inappropriate expression thereof in disease. Such inappropriate expression may be of a temporal, spatial or simply quantitative nature.
A further aspect of the present invention relates to antibodies. The polypeptides of the invention or their fragments, or cells expressing them, can be used as immunogens to produce antibodies that are immunospecific for polypeptides of the present invention. The term "immunospecific" means that the antibodies have substantially greater affinity for the polypeptides of the invention than their affinity for other related polypeptides in the prior art.
Antibodies generated against polypeptides of the present invention may be obtained by administering the polypeptides or epitope-bearing fragments, or cells to an animal, preferably a non-human animal, using routine protocols. For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (I~ohler, G.
and Milstein, C., Nature (1975) 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor et al., Immunology Today (1983) 4:72) and the EBV-hybridoma technique (Cole et al., Monoclonal Antibodies and Cancer Therapy, 77-96, Alan R. Liss, Inc., 1985).
Techniques for the production of single chain antibodies, such as those described in U.S. Patent No. 4,946,778, can also be adapted to produce single chain antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms, including other mammals, may be used to express humanized antibodies.
The above-described antibodies may be employed to isolate or to identify clones expressing the polypeptide or to purify the polypeptides by affinity chromatography.
Antibodies against polypeptides of the present invention may also be employed to treat diseases of the invention, amongst others.
Polypeptides and polynucleotides of the present invention may also be used as vaccines. Accordingly, in a further aspect, the present invention relates to a method for inducing an immunological response in a mammal that comprises inoculating the mammal with a polypeptide of the present invention, adequate to produce antibody andlor T cell immune response, including, for example, cytokine-producing T cells or cytotoxic T cells, to protect said animal from disease, whether that disease is already established within the individual or not. An immunological response in a mammal may also be induced by a method comprises delivering a polypeptide of the present invention via a vector directing expression of the polynucleotide and coding for the polypeptide in vivo in order to induce such an immunological response to produce antibody to protect said animal from diseases of the invention. One way of administering the vector is by accelerating it into the desired cells as a coating on particles or otherwise. Such nucleic acid vector may comprise DNA, RNA, a modified nucleic acid, or a DNA/RNA hybrid. For use a vaccine, a polypeptide or a nucleic acid vector will be normally provided as a vaccine formulation (composition). The formulation may further comprise a suitable carrier. Since a polypeptide may be broken down in the stomach, it is preferably administered parenterally (for instance, subcutaneous, intra-muscular, intravenous, or intra-dermal injection). Formulations suitable for parenteral administration include aqueous and non-aqueous steritle injection solutions that may contain anti-oxidants, buffers, bacteriostats and solutes that render the formulation instonic with the blood of the recipient; and aqueous and non-aqueous sterile suspensions that may include suspending agents or thickening agents. The formulations may be presented in unit-dose or mufti-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use. The vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.
Polypeptides of the present invention have one or more biological functions that are of relevance in one or more disease states, in particular the diseases of the invention hereinbefore mentioned. It is therefore useful to identify compounds that stimulate or inhibit the function or level of the polypeptide. Accordingly, in a further aspect, the present invention provides fox a method of screening compounds to identify those that stimulate or inhibit the function or level of the polypeptide. Such methods identify agonists or antagonists that may be employed for therapeutic and prophylactic purposes for such diseases of the invention as hereinbefore mentioned. Compounds may be identified from a variety of sources, for example, cells, cell-free preparations, chemical libraries, collections of chemical compounds, and natural product mixtures. Such agonists or antagonists so-identified may be natural or modified substrates, Iigands, receptors, enzymes, etc., as the case may be, of the polypeptide; a structural or functional mimetic thereof (see Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991)) or a small molecule. Such small molecules preferably have a molecular weight below 2,000 daltons, more preferably between 300 and 1,000 daltons, and most preferably between 400 and 700 daltons. It is preferred that these small molecules are organic molecules.
The screening method may simply measure the binding of a candidate compound to the polypeptide, or to cells or membranes bearing the polypeptide, or a fusion protein thereof, by means of a label directly or indirectly associated with the candidate compound.
Alternatively, the screening method may involve measuring or detecting (qualitatively or quantitatively) the competitive binding of a candidate compound to the polypeptide against a labeled competitor (e.g. agonist or antagonist). Further, these screening methods may test whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells bearing the polypeptide.
Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist by the presence of the candidate compound is observed.
Further, the screening methods may simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide of the present invention, to form a mixture, measuring an activity of the genes set forth in Table I in the mixture, and comparing activity of the mixture of the genes set forth in Table I to a control mixture which contains no candidate compound.
Polypeptides of the present invention may be employed in conventional low capacity screening methods and also in high-throughput screening (HTS) formats. Such HTS formats include not only the well-established use of 96- and, more recently, 384-well micotiter plates but also emerging methods such as the nanowell method described by Schullek et al, Anal Biochem., 246, 20-29, (1997).
Fusion proteins, such as those made from Fe portion and polypeptide of the genes set forth in Table I, as hereinbefore described, can also be used for high-throughput screening assays to identify antagonists for the polypeptide of the present invention (see D.
Bennett et al., J
Mol Recognition, 8:52-58 (1995); and K. Johanson et al., J Biol Chem, 270(16):9459-9471 ( 1995)).
The polynucleotides, polypeptides and antibodies to the polypeptide of the present invention may also be used to configure screening methods for detecting the effect of added compounds on the production of mRNA and polypeptide in cells. For example, an ELISA
assay may be constructed for measuring secreted or cell associated levels of polypeptide using monoclonal and polyclonal antibodies by standard methods known in the art. This can be used to discover agents that may inhibit or enhance the production of polypeptide (also called antagonist or agonist, respectively) from suitably manipulated cells or tissues.
A polypeptide of the present invention may be used to identify membrane bound or soluble receptors, if any, through standard receptor binding techniques known in the art.
These include, but are not limited to, ligand binding and crosslinking assays in which the polypeptide is labeled with a radioactive isotope (for instance, 1251), chemically modified (for instance, biotinylated), or fused to a peptide sequence suitable for detection or purification, and incubated with a source of the putative receptor (cells, cell membranes, cell supernatants, tissue extracts, bodily fluids). Other methods include biophysical techniques such as surface plasmon resonance and spectroscopy. These screening methods may also be used to identify agonists and antagonists of the polypeptide that compete with the binding of the polypeptide to its receptors, if any. Standard methods for conducting such assays are well understood in the art.
Examples of antagonists of polypeptides of the present invention include antibodies or, in some cases, oligonucleotides or proteins that are closely related to the ligands, substrates, receptors, enzymes, etc., as the case may be, of the polypeptide, e.g., a fragment of the ligands, substrates, receptors, enzymes, etc.; or a small molecule that bind to the polypeptide of the present invention but do not elicit a response, so that the activity of the polypeptide is prevented.
Screening methods may also involve the use of transgenic technology and the genes set forth in Table I. The art of constructing transgenic animals is well established. For example, the genes set forth in Table I may be introduced through microinjection into the male pronucleus of fertilized oocytes, retroviral transfer into pre- or post-implantation embryos, or injection of genetically modified, such as by electroporation, embryonic stem cells into host blastocysts. Particularly useful transgenic animals are so-called "knock-in"
animals in which an animal gene is replaced by the human equivalent within the genome of that animal. Knock-in transgenic animals are useful in the drug discovery process, for target validation, where the compound is specific for the human target. Other useful transgenic animals are so-called "knock-out" animals in which the expression of the animal ortholog of a polypeptide of the present invention and encoded by an endogenous DNA
sequence in a cell is partially or completely annulled. The gene knock-out may be targeted to specific cells or tissues, may occur only in certain cells or tissues as a consequence of the limitations of the technology, or may occur in all, or substantially all, cells in the animal. Transgenic animal technology also offers a whole animal expression-cloning system in which introduced genes are expressed to give large amounts of polypeptides of the present invention Screening kits for use in the above described methods form a further aspect of the present invention. Such screening kits comprise:
(a) a polypeptide of the present invention;
(b) a recombinant cell expressing a polypeptide of the present invention;
(c) a cell membrane expressing a polypeptide of the present invention; or (d) an antibody to a polypeptide of the present invention;
which polypeptide is preferably that set forth in the Sequence Listing.
It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component.
Glossary The following definitions are provided to facilitate understanding of certain terms used frequently hereinbefore.
"Antibodies" as used herein includes polyclonal and monoclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, including the products of an Fab or other immunoglobulin expression library.
"Isolated" means altered "by the hand of man" from its natural state, i.e., if it occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living organism is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein.
Moreover, a polynucleotide or polypeptide that is introduced into an organism by transformation, genetic manipulation or by any other recombinant method is "isolated" even if it is still present in said organism, which organism may be living or non-living.
"Secreted protein activity or secreted polypeptide activity" or "biological activity of the secreted protein or secreted polypeptide" refers to the metabolic or physiologic function of said secreted protein including similar activities or improved activities or these activities with decreased undesirable side-effects. Also included are antigenic and immunogenic activities of said secreted protein.
"Secreted protein gene" refers to a polynucleotide comprising any of the attached nucleotide sequences or allelic variants thereof and/or their complements.

"Polynucleotide" generally refers to any polyribonucleotide (RNA) or polydeoxribonucleotide (DNA), which may be unmodified or modified RNA or DNA.
"Polynucleotides" include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, "polynucleotide" refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term "polynucleotide" also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons.
"Modified"
bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications may be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells.
"Polynucleotide" also embraces relatively short polynucleotides, often referred to as oligonucleotides.
o "Polypeptide" refers to any polypeptide comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres.
"Polypeptide" refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins.
Polypeptides may contain amino acids other than the 20 gene-encoded amino acids. "Polypeptides"
include amino acid sequences modified either by natural processes, such as post-translational processing, or by chemical modification techniques that are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications may occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present to the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched and branched cyclic polypeptides may result from post-translation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, biotinylation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination (see, for instance, Proteins - Structure and Molecular Properties, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993; Wold, F., Post-translational Protein Modifications: Perspectives and Prospects, 1-12, in Post-translational Covalent Modification of Proteins, B. C. Johnson, Ed., Academic Press, New York, 1983; Seifter et al., "Analysis for protein modifications and nonprotein cofactors", Meth Enzymol, 182, 626-646, 1990, and Rattan et al., "Protein Synthesis: Post-translational Modifications and Aging", Ann NY Acad Sci, 663, 48-62, 1992).
"Fragment" of a polypeptide sequence refers to a polypeptide sequence that is shorter than the reference sequence but that retains essentially the same biological function or activity as the reference polypeptide. "Fragment" of a polynucleotide sequence refers to a polynucleotide sequence that is shorter than the reference sequence set forth in the Sequence Listing.
"Variant" refers to a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide, but retains the essential properties thereof. A
typical variant of a polynucleotide differs in nucleotide sequence from the reference polynucleotide.
Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from the reference polypeptide.
Generally, alterations are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, insertions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. Typical conservative substitutions include Gly, Ala; Val, Ile, Leu; Asp, Glu; Asn, Gln; Ser, Thr; Lys, Arg; and Phe and Tyr. A variant of a polynucleotide or polypeptide may be naturally occurnng such as an allele, or it may be a variant that is not known to occur naturally. Non-naturally occurnng variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis.
Also included as variants are polypeptides having one or more post-translational modifications, for instance glycosylation, phosphorylation, methylation, ADP ribosylation and the like.
Embodiments include methylation of the N-terminal amino acid, phosphorylations of serines and threonines and modification of C-terminal glycines.
"Allele" refers to one of two or more alternative forms of a gene occurnng at a given locus in the genome.
"Polymorphism" refers to a variation in nucleotide sequence (and encoded polypeptide sequence, if relevant) at a given position in the genome within a population.
"Single Nucleotide Polymorphism" (SNP) refers to the occurrence of nucleotide variability at a single nucleotide position in the genome, within a population. An SNP may occur within a gene or within intergenic regions of the genome. SNPs can be assayed using Allele Specific Amplification (ASA). For the process at least 3 primers are required. A
common primer is used in reverse complement to the polymorphism being assayed.
This common primer can be between 50 and 1500 bps from the polymorphic base. The other two (or more) primers are identical to each other except that the final 3' base wobbles to match one of the two (or more) alleles that make up the polymorphism. Two (or more) PCR
reactions are then conducted on sample DNA, each using the common primer and one of the Allele Specific Primers.
"Splice Variant" as used herein refers to cDNA molecules produced from RNA
molecules initially transcribed from the same genomic DNA sequence but which have undergone alternative RNA splicing. Alternative RNA splicing occurs when a primary RNA transcript undergoes splicing, generally for the removal of introns, which results in the production of more than one mRNA molecule each of that may encode different amino acid sequences. The term splice variant also refers to the proteins encoded by the above cDNA
molecules.
"Identity" reflects a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, determined by comparing the sequences. In general, identity refers to an exact nucleotide to nucleotide or amino acid to amino acid correspondence of the two polynucleotide or two polypeptide sequences, respectively, over the length of the sequences being compared.
"% Identity" - For sequences where there is not an exact correspondence, a "%
identity" may be determined. In general, the two sequences to be compared are aligned to give a maximum correlation between the sequences. This may include inserting "gaps" in either one or both sequences, to enhance the degree of alignment. A % identity may be determined over the whole length of each of the sequences being compared (so-called global alignment), that is particularly suitable for sequences of the same or very similar length, or over shorter, defined lengths (so-called local alignment), that is more suitable for sequences of unequal length.
"Similarity" is a further, more sophisticated measure of the relationship between two polypeptide sequences. In general, "similarity" means a comparison between the amino acids of two polypeptide chains, on a residue by residue basis, taking into account not only exact correspondences between a between pairs of residues, one from each of the sequences being compared (as for identity) but also, where there is not an exact correspondence, whether, on an evolutionary basis, one residue is a likely substitute for the other. This likelihood has an associated "score" from which the "% similarity" of the two sequences can then be determined.
Methods for comparing the identity and similarity of two or more sequences are well known in the art. Thus for instance, programs available in the Wisconsin Sequence Analysis Package, version 9.1 (Devereux J et al, Nucleic Acids Res, 12, 387-395, 1984, available from Genetics Computer Group, Madison, Wisconsin, USA), for example the programs BESTFIT and GAP; may be used to determine the % identity between two polynucleotides and the % identity and the % similarity between two polypeptide sequences.
BESTFIT uses the "local homology" algorithm of Smith and Waterman (J Mol Biol, 147,195-197, 1981, Advances in Applied Mathematics, 2, 482-489, 1981) and finds the best single region of similarity between two sequences. BESTFIT is more suited to comparing two polynucleotide or two polypeptide sequences that are dissimilar in length, the program assuming that the shorter sequence represents a portion of the longer. In comparison, GAP
aligns two sequences, finding a "maximum similarity", according to the algorithm of Neddleman and Wunsch (J Mol Biol, 48, 443-453, 1970). GAP is more suited to comparing sequences that are approximately the same length and an alignment is expected over the entire length. Preferably, the parameters "Gap Weight" and "Length Weight"
used in each program are 50 and 3, for polynucleotide sequences and 12 and 4 for polypeptide sequences, respectively. Preferably, % identities and similarities are determined when the two sequences being compared are optimally aligned.
Other programs for determining identity and/or similarity between sequences are also known in the art, for instance the BLAST family of programs (Altschul S F
et al, J Mol Biol, 215, 403-410, 1990, Altschul S F et al, Nucleic Acids Res., 25:389-3402, 1997, available from the National Center for Biotechnology Information (NCBI), Bethesda, Maryland, USA and accessible through the home page of the NCBI at www.ncbi.nlm.nih.gov) and FASTA (Pearson W R, Methods in Enzymology, 183, 63-99, 1990; Pearson W R and Lipman D J, Proc Nat Acad Sci USA, 85, 2444-2448,1988, available as part of the Wisconsin Sequence Analysis Package).
Preferably, the BLOSUM62 amino acid substitution matrix (Henikoff S and Henikoff J G, Proc. Nat. Acad Sci. USA, 89, 10915-10919, 1992) is used in polypeptide sequence comparisons including where nucleotide sequences are first translated into amino acid sequences before comparison.
Preferably, the program BESTFIT is used to determine the % identity of a query polynucleotide or a polypeptide sequence with respect to a reference polynucleotide or a polypeptide sequence, the query and the reference sequence being optimally aligned and the parameters of the program set at the default value, as hereinbefore described.
"Identity Index" is a measure of sequence relatedness which may be used to compare a candidate sequence (polynucleotide or polypeptide) and a reference sequence.
Thus, for instance, a candidate polynucleotide sequence having, for example, an Identity Index of 0.95 compared to a reference polynucleotide sequence is identical to the reference sequence except that the candidate polynucleotide sequence may include on average up to five differences per each 100 nucleotides of the reference sequence. Such differences are selected from the group consisting of at least one nucleotide deletion, substitution, including transition and transversion, or insertion. These differences may occur at the 5' or 3' terminal positions of the reference polynucleotide sequence or anywhere between these terminal , positions, interspersed either individually among the nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence. In other words, to obtain a polynucleotide sequence having an Identity Index of 0.95 compared to a reference polynucleotide sequence, an average of up to 5 in every 100 of the nucleotides of the in the reference sequence may be deleted, substituted or inserted, or any combination thereof, as hereinbefore described. The same applies mutatis mutandis for other values of the Identity Index, for instance 0.96, 0.97, 0.98 and 0.99.
Similarly, for a polypeptide, a candidate polypeptide sequence having, for example, an Identity Index of 0.95 compared to a reference polypeptide sequence is identical to the reference sequence except that the polypeptide sequence may include an average of up to five differences per each 100 amino acids of the reference sequence. Such differences are selected from the group consisting of at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion. These differences may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between these terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence. In other words, to obtain a polypeptide sequence having an Identity Index of 0.95 compared to a reference polypeptide sequence, an average of up to 5 in every 100 of the amino acids in the reference sequence may be deleted, substituted or inserted, or any combination thereof, as hereinbefore described. The same applies mutatis mutandis for other values of the Identity Index, for instance 0.96, 0.97, 0.98 and 0.99.
The relationship between the number of nucleotide or amino acid differences and the Identity Index may be expressed in the following equation:
na _< xa - (xa ~ ~, in which:
na is the number of nucleotide or amino acid differences, xa is the total number of nucleotides or amino acids in a sequence set forth in the Sequence Listing, I is the Identity Index, ~ is the symbol for the multiplication operator, and in which any non-integer product of xa and I is rounded down to the nearest integer prior to subtracting it from xa.
"Homolog" is a generic term used in the art to indicate a polynucleotide or polypeptide sequence possessing a high degree of sequence relatedness to a reference sequence. Such relatedness may be quantified by determining the degree of identity and/or similarity between the two sequences as hereinbefore defined. Falling within this generic term are the terms "ortholog", and "paralog". "Ortholog" refers to a polynucleotide or polypeptide that is the functional equivalent of the polynucleotide or polypeptide in another species. "Paralog" refers to a polynucleotideor polypeptide that within the same species which is functionally similar.
"Fusion protein" refers to a protein encoded by two, often unrelated, fused genes or fragments thereof. In one example, EP-A-0 464 533-A discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, employing an immunoglobulin Fc region as a part of a fusion protein is advantageous for use in therapy and diagnosis resulting in, for example, improved pharmacokinetic properties [see, e.g., EP-A 0232 262]. On the other hand, for some uses it would be desirable to be able to delete the Fc part after the fusion protein has been expressed, detected and purified.
All publications and references, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference in their entirety as if each individual publication or reference were specifically and individually indicated to be incorporated by reference herein as being fully set forth. Any patent application to which this application claims priority is also incorporated by reference herein in its entirety in the manner described above for publications and references.
Table I.
GSK Nucleic Acid Corresponding Protein Gene Name Gene ID SEQ ID NO's SEQ ID NO's sb 318680DNase 318680 SEQ ID NO:l SEQ ID N0:40 sbg237038SA 237038 SEQ ID N0:2 SEQ ID N0:41 SEQ ID N0:3 SEQ ID N0:42 sb 340871GPV 340871 SEQ ID N0:4 SEQ ID N0:43 sbg293416HNKS 293416 SEQ ID N0:5 SEQ ID NO:44 SEQ ID N0:6 SEQ ID N0:45 sb 257418ZP 257418 SEQ ID N0:7 SEQ ID N0:46 sbg319185CDa 319185 SEQ ID N0:8 SEQ ID N0:47 SEQ ID N0:9 SEQ ID N0:48 sb 323307KIAAa 323307 SEQ ID NO:10 SEQ ID N0:49 sbg315953GPPa 315953 SEQ ID NO:l 1 SEQ ID N0:50 SEQ ID N0:12 SEQ ID N0:51 sb 3184860NC 318486 SEQ ID N0:13 SEQ ID N0:52 sb 299359LIP0 299359 SEQ ID N0:14 SEQ ID N0:53 sbg230022NGa 230022 SEQ ID N0:15 SEQ ID N0:54 SEQ 1D N0:16 SEQ ID N0:55 sbg297169BGP 297169 SEQ ID NO:17 SEQ ID N0:56 SEQ ID NO:18 SEQ ID N0:57 sbg253919HSCCAa253919 SEQ ID N0:19 SEQ ID N0:58 SEQ ID N0:20 SEQ ID N0:59 sbg2281370LF 228137 SEQ ID N0:21 SEQ ID N0:60 SEQ ID N0:22 SEQ ID N0:61 sbg378514Netrin378514 SEQ ID N0:23 SEQ ID N0:62 SEQ ID N0:24 SEQ ID N0:63 sbg253227.mucous253227 SEQ ID N0:25 SEQ ID N0:64 matrix lycoprotein SEQ ID N0:26 SEQ ID N0:65 sbg262831SIAa 262831 SEQ ID N0:27 SEQ ID N0:66 SEQ ID N0:28 SEQ ID N0:67 sb 233728LIPASE233728 SEQ ID N0:29 SEQ ID N0:68 sb 400455.CRF 400455 SEQ ID N0:30 SEQ ID N0:69 sb 400612KINASEa400612 SEQ ID N0:31 SEQ ID N0:70 sb 381373ACRP 381373 SEQ ID N0:32 SEQ ID N0:71 sbg401294MEX-3401294 SEQ ID N0:33 SEQ ID N0:72 SEQ ID N0:34 SEQ ID N0:73 sbg247722Cadherin247722 SEQ ID N0:35 SEQ ID N0:74 SEQ ID N0:36 SEQ ID N0:75 sbg391057THIPa391057 SEQ ID N0:37 SEQ ID N0:76 SEQ ID N0:38 SEQ ID N0:77 sb 378067TGFc 378067 SEQ ID N0:39 SEQ ID N0:78 Table II
Gene Gene FamilyClosest PolynuclotideClosest PolypeptideCell by by Name homology homology Localization (by homolo ) sbg318680-DNase GB:AC022471 Human DNase Secreted I I-like DNase Sbmitted (04-FEB-2000)endonuclease, by Lita Annenberggi:5803007 Hazen Genome SequencingParrish JE, Ciccodicola Center, Cold SpringA, Wehhert M, Cox Harbor Laboratory,GF, Chen E, 1 and Bungtown Road, Nelson DL; 1995;
Cold Spring Harbor, Hum. Mol. Genet.
NY 11724, USA. 4:1557-1564.

sbg237038-SA proteinGB:AC023292 Human SA gene, Secreted SA Submitted (11-FEB-2000)gi:2988399 by Whitehead Loftus,B.J.
et al.

Institute/MIT Genomics 60 Center for (3), 295-Genome Research, 308 (1999) Charles Street, Cambridge, MA 02141, USA.

sbg340871-Platelet GB:AC025389 Rat platelet Secreted GPV glycoproteinSubmitted (08-MAR-2000)glycoprotein V (GPV) (GPV) by Whitehead precursor, gi:6980974 Institute/MIT Ravanat C, Morales Center for M, Genome Research, Azorsa DO, Moog 320 S, Charles Street, Schuhler S, Cambridge, Grunert P, MA 02141, USA. Loew D, Van Dorsselaer A, Cazenave JP, Lanza F;
1997;

Blood 89:3253-62.

sbg293416-HNK-1 JGI:LLNL-R 241B6 Human GaINAc Secreted HNKS sulfotransferaJoint Genome Institute,sulfotransferase, se Department of gi:11990885 Energy, USA Okuda,T., Mita,S., Yamauchi,S., Fukuta,M., Nakano,H., Sawada,T. and Habuchi,0. J.
Biol.

Chem. 275 (51), 40613 (2000) sbg257418-Zona GB:AP000777 Mouse zona pellucidaSecreted ZP pellucidaSubmitted (25-NOV-1999)glycoprotein, protein to the gi:6677653 DDBJ/EMBL/GenBankEpifano,0., Liang,L.F., databases. MasahiraFamilari,M., Moos,M.C.

Hattori, The InstituteJr. and Dean,J.;
of 1995;

Physical and ChemicalDevelopment 121:1947-Research (RIKEN),1956.

Genomic Sciences Center (GSC); Kitasato Univ., 1-45-1 Kitasato, Sagamihara, Kanagawa 228-8555, Ja an.

Table II (cont).
Gene Gene FamilyClosest PolynuclotideClosest PolypeptideCell by by Name homology homology Localization (by homolo ) sbg319185-LeukocyteGB:AC024004 Human leukocyteSecreted CDa differentiatioSubmitted (20-FEB-2000)differentiation antigen n antigenby Whitehead Institute/MITCD84 isoform CD84s, Center for Genomegi:6650112 Research, 320 Submitted (20-Charles Street, Cambridge,MAR-1998) by MA Servei 02141, USA d~mmunologia, Hospital Clinic, Villarroel 170, Barcelona 08036, S ain sbg32330Slit-likeGB:AL160156, Human unnamed Secreted 7-KIAAa Submitted (IO-MAR-2000)protein, gi:10439289 by Sanger Centre,Submitted (29-AUG-Hinxton, Cambridgeshire, 2000) by Sumio CB IO

1SA, UK. Sugano, Institute of Medical Science, University of Tokyo, Laboratory of Genome Structure Analysis, Human Genome Center; Shirokane-dai, 4-6-1, Minato-ku, Tokyo 108-8639, Ja an sbg31595GranulocyteGB:AC011666 Human hypotheticalSecreted 3-GPPa peptide Submitted (09-OCT-1999)protein SBBI67, A

by Department gi:9966869 Of Chemistry And Submitted (08-MAR-Biochemistry, 2000) by Department of The University Immunology, Of Second Oklahoma, 620 Military Medical Parrington Oval, Room 208, University &
Norman, Shanghai OK 73019, USA Brilliance Biotechnology Institute, 800 Xiangyin Rd., Shanghai 200433, P.R.

China sbg31848OncotrophoblGB:AC022045 Canine ST4 tumour-Secreted 6-ONC ast Submitted (25-JAN-2000)associated antigen' glycoproteinby tehead Institute/MITgeneseqp:Y94351 Center for GenomeSubmitted by Research, 320 OXFORD
Charles Street, Cambridge,BIOMEDICA UK
MA LTD

02141, USA. Publication number and date: W0200029428-A2, 25-MAY-00 Table II (cont).
Gene Gene FamilyClosest PolynuclotideClosest PolypeptideCeII
by by Name homology homology Localization (by homolo ) sbg29935LipocalinSC:AL139041 Mouse majox Secreted urinary 9-LIPO Submitted (16-NOV-2000)protein (MUP) 4, by Sanger Centre,gi:6678968 Hinxton, Cambridgeshire, Shahan K, Gilmartin CB 10 M, 1SA, UK and Derman E;
1987;

Mol Cell Biol 7:1938-1946.

sbg23002PlasmacytomaGB:AC066608 Rat neural cellMembrane-adhesion 2-NGa -associatedGB:AC022002 protein BIG-2 bound neuronal Submitted (25-APR-2000)precursor, gi :1016012 glycoproteinand (24-JAN-2000)Yoshihara,Y., by Human Genomic Kawasaki,M., Center, Institute of Genetics,Tamada,A., Nagata,S., Chinese Academy Kagamiyama,H.
of and Sciences, Datun Mori,K. J. Neurobiol.
Road, Beijing, Beijing 28 (1), 51-69 100101, (1995) P.R.China sbg29716Biliary JGI: CITB- Mouse biliary Secreted 9-BGP glycoprotienEl_2616J11 glycoprotein (BGP), (BGP) Submitted by gi:312584 Joint Genome Institute,McCuaig K, Department of Rosenberg M, Energy, USA Nedellec P, Turbide C, and Beauchemin N;

1993; Gene 127:173-83.

sbg25391Human GB:AC019355 Human Secreted 9- squamous Submitted (02-JAN-2000)squamous cell cell HSCCAa carcinomaby Whitehead carcinoma antigen antigen Institute/MIT (SCCA-2) (LEUPIN).
Center for (SCCA) Genome Research, gi:1710877.

Charles Street, Schneider,S.S., Cambridge, MA 02141, USA Schick,C., Fish,K.E., Miller,E., Pena,J.C., Treter,S.D., Hui,S.M.

and Silverman,G.A.

Proc. Natl.
Acad. Sci.

U.S.A. 92 (8), 3151 (1995).

sbg22813OlfactomedinGB:AC022606 Rat neuronal Secreted 7-OLF -related Submitted (06- olfactomedin-related protein FEB-2000) by Whiteheadprotein precursor, Institute/MIT gi:3024210 Center for Genome Research, Danielson,P.E., 320 Forss-Charles Street, Petter,S., Cambridge, MA 02141, USA Battenberg,E.L., deLecea,L., Bloom,F.E., and Sutcliffe,J.G., 1994, J.

Neurosci. Res.
38:468-478.

Table II fcontl.
Gene Gene FamilyClosest PolynuclotideClosest PolypeptideCell by by Name homology homology Localization (by homolo ) sbg378514-Netrin SC:BA5N16 Mouse Netrin-GlaSecreted Netrin precursorSubmitted (09-APR-2001)protein by Sanger Centre,gi:9909148 Hinxton, Cambridgeshire, Nakashiba,T., CB 10 Ikeda,T., 1SA, UK. Nishimura,S., Tashiro,K., Honjo,T., Culotti,J.G.
and Ttohara,S. J.
Neurosci.

20 (17), 6540-6550 (2000) sbg253227.ExtracellularGB:AC011647 Human colon Secreted specific mucous mucous Submitted (08-OCT-1999)protein, matrix matrix by Whitehead geneseqp:Y54368 glycoproteiglycoproteinInstitute/MIT Submitted by Center for n (EMMG) Genome Research, DIADEXUS LLC

Charles Street, Publication Cambridge, number and MA 02141, USA date: W09960161-Al, sbg262831-SialoadhesinJGI:CITB- Human sialic Secreted acid SIAa E1 3073N11 binding Found at Joint immunoglobulin-like Genome Institute lectin 8 long splice variant, gi:

Foussias,G., Yousef,G.M.
and Diamandis,E.P.

Biochem. Biophys.
Res.

Commun. 278 (3), 775-781 (2000) sbg233728-PancreaticGB:AC011098 Human pancreaticSecreted lipase LIPASE lipase Submitted (O1-OCT-1999)precursor, gi:126318 by Whitehead Lowe ME, Rosenblum Institute/MIT JL, and Strauss Center for AW;

Genome Research, 1989; J Biol 320 Chem Charles Street, 264:20042-8.
Cambridge, MA 02141, USA.

sbg400455.Clq-relatedGB:AC024339 MouseGliacolin,Secreted -CRF factor Submitted (28-FEB-2000)gi:10566471 (CRF) by Whitehead Koide,T., Aso,A., Institute/MIT Yorihuzi,T.
Center for and Genome Research, Nagata,K. J.
320 Biol.

Charles Street, Chem. 275 (36), Cambridge, 27957-MA 02141, USA 27963 (2000) 2,8 Table II (cont).
Gene Gene Closest PolynuclotideClosest PolypeptideCell by by Name Family homology homology Localization (by homolo ) sbg400612-Protein GB:AP001615 Murine proteinSecreted KINASEa kinase Submitted (04-APR-2000)kinase/ankyrin to the homologue, DDBJ/EMBL/GenBankgeneseqp:Y76079 databases. NobuyoshiSubmitted by Shimizu, Keio GENESIS RES
University, & DEV

School of CORP LTD

Medicine, Publication Molecular Biology;number and 35 date:

Shinanomachi, W09955865-Al Shinjuku-ku, Tok o I60-8582,04-NOV-99 Ja an sbg381373-AdipocyteJGI:RPCI-11_161M6Human adipocyteSecreted ACRP complementFound at Joint Complement-Related Genome -related Institute, DepartmentProtein (ACRP30R2), of protein Energy, USA geneseqp:Y44487.

(ACRP30) Submitted by SMITHKLINE

BEECHAM CORP

Publication number and date:

W09964629-A1, sbg401294-MEX- GB:AC026956 CaenorhabditisCyto MEX-3 3(IAP) Submitted (25-MAR-2000)elegans solic (RNA-by Whitehead Institute/MEX-3, gi:1644450binding MIT Center for Draper,B.W., protein) Genome Research, 320 Mello,C.C., Charles Street, Cambridge,Bowerman,B., MA

02141, USA Hardin,J. and Priess,J.R.
Cell 87 (2), 205-216(1996) sbg247722-OB- GB:AL132780 Human OB-cadherin-Secreted CadherinCadherin Submitted (02-NOV-1999)1, gi:1377894 by Genoscope - Okazaki,M., Centre National de SequencageTakeshita,S., :

BP 191 91006 EVRYKawai,S., Kikuno,R., cedex - FRANCE Tsujimura,A., Kudo,A. and Amann,E.

J. Biol. Chem.

(16),12092-12098 (1994) Table II (cont).
Gene Gene FamilyClosest PolynuclotideClosest PolypeptideCell Name by by homology Localization homology (by homolo ) sbg39I057-Thyroid SC:AL158153, Human TANGO Secreted 239, THIPa hormone SC:AL392044 geneseqp:B01432 induced Submitted (22-MAR-2001)Submitted by protein and (02-MAR-2001)MILLENNIUM
by Sanger Centre, PHARM INC
Hinxton, Cambridgeshire, Publication 1SA, UK. number and date:

W0200039284-Al, sbg378067-TGF beta SC:AL162502 Human persephinSecreted TGFc (transformingSubmitted (06-APR-2001)growth factor, growth by Sanger Centre,geneseqp:Y16714 factor Hinxton, beta) Cambridgeshire, Submitted by 1SA, UK. WASHINGTON

Publication number and date:

W09914235-Al Table III.
Gene Uses Associated Diseases Name sbg318680-An embodiment of the invention is Cancer, infection, the use of sbg318680-DNase Dnase to treat respiratory diseases autoimmune disorder, and target parasites or cancer cells as a chromosome degradinghematopoietic agent to cause death disorder, of those cells. Close homologues wound healing of sbg318680-DNase are DNases. DNase can be used to treat disorders, inflammation respiratory diseases, such as pneumonia, cystic fibrosis and respiratory and asthma, by reducing diseases viscosity of bronchopulmonary secretions (MacConnachie AM; 1999; Intensive Crit Care Nurs 14:101-2).

sbg237038-An embodiment of the invention is Cancer, infection, the use of sbg237038SA

SA in blood pressure control. A close autoimmune disorder, homologue of sbg237038SA is the rat SA gene. The hematopoietic SA gene is expressed disorder, at higher levels in the kidney of wound healing genetically hypertensive rats (Yang T, Hassan SA, Singh I, Smart disorders, inflammation, A, Brosius FC, Holzman LB, Schnermann JB, Briggs and hypertension JP; 1996;

Hy ertension 27:541-51).

sbg340871-An embodiment of the invention is Cancer, infection, the use of sbg340871-GPV GPV in hemostasis and platelet aggregation.autoimmune disorder, A close homologue of sbg340871-GPV is platelethematopoietic glycoprotein (GP) disorder, V. wound healing Platelet glycoprotein (GP) V is a disorders, inflammation, major surface protein which is cleaved by thrombin during plateletand Bernard-Soulier activation, and associates with GPIb-IX complex to disease form GPIb-V-IX, a receptor for von Willebrand factor and thrombin. Its functional role in hemostasis is possibly related to thrombin-induced platelet aggregation (Ravanat C, Morales M, Azorsa DO, Moog S, Schuhler S, Grunert P, Loew D, Van Dorsselaer A, Cazenave JP, Lanza F; 1997; Blood 89:3253-62).

sbg293416-An embodiment of the invention is Cancer, infection, the use of sbg293416-HNKS HNKS in cell interactions and the autoimmune disorder, development of the nervous system. Close homologues hematopoietic of sbg293416-HNKS disorder, are sulfotransferases. Sulfotransferaseswound healing are considered to be key enzymes in the biosynthesis of disorders, inflammation, the HNK-1 carbohydrate epitope, which is expressed on severaland peripheral neural adhesion glycoproteins and as a glycolipid, neuropathies and is involved in cell interactions (Bakker,H., Friedmann,L, Oka,S., Kawasaki,T., Nifant ev,N., Schachner,M. and Mantei,N., 1997, J. Biol.

Chem. 272:29942-29946). The HNK-1 epitope is spatially and temporally regulated during the development of the nervous system. The biological function of the HNK-1 sulfotransferase may be related to the development of the nervous system, and also may be involved in the preferential reinervation of muscle nerves by motor axons after lesion (Jungalwala FB, 1994, Neurochem Res 19:945-57).

Table III (cont).
Gene Uses Associated Diseases Name sbg257418-An embodiment of the invention is Infertility the use of sbg257418ZP

ZP in fertilization. A close homologue of sbg257418ZP is zona pellucida. Zona pellucida protein is an extracellular matrix that surrounds growing oocytes, ovulated eggs, and early embryos and it is critically involved in fertilization (Epifano,0., Liang,L.F., Familari,M., Moos,M.C. Jr. and Dean,J.; 1995; Development 121:1947-1956).
The zona pellucida also provides a post-fertilization block to polyspermy and protects the growing embryo as it passes down the oviduct (Rankin T, and Dean J; 1996; Mol Hum Re rod 2:889-94).

sbg319185-An embodiment of the invention is Cancer, autoimmune the use of CDa sbg319185CDa, a secreted protein, disorders, in the diagnosis and wound treatment of cancer and autoimmune healing disorders, disorders. Close homologues of sbg319185CDa are leukocyteinfections differentiation and antigen CD84 isoforms. hematopoietic disorders CD84's are members of the immunoglobulin superfamily, show high homology with several molecules belonging to the CD2 family of differentiation antigens and is proposed to be useful in the diagnosis and treatment of cancer and autoimmune disorders (Palou E, Pirotto F, Sole J, Freed JH, Peral B, Vilardell C, Vilella R, Vives J, Gaya A. Genomic characterization of CD84 reveals the existence of five isoforms differing in their cytoplasmic domains.
Tissue Antigens 2000 Feb;55(2):118-27)).

sbg323307-An embodiment of the invention is Cancer, autoimmune the use of sbg323307-KIAAa I~IAAa, a secreted protein, to regulatedisorders, cell signaling, motility, infections, and nucleic acid management. A closewound healing homologue of sbg323307-KIAAa is human KIAA0918 disorders and protein. Human KIAA0918 protein, a slit-like proteinhematopoietic is functionally related to disorders cell signaling/communication, cell structure/motility and nucleic acid management (Nagase,T., Ishikawa,I~., Suyama,M., Kikuno,R., Hirosawa,M., Miyajima,N., Tanaka,A., Kotani,H., Nomura,N. and Ohara,0. I~iAA0918 protein [Homo Sapiens], DNA Res.
5 (6), 355-364 (1998)).

Table III (cont).
Gene Uses Associated Diseases Name sbg315953-An embodiment of the invention is Infections, the use of cancer, GPPa sbg315953GPPa, a secreted protein, autoimmune to treat disorders associated with lipopolysaccharides.disorders, A close homologue to wounder sbg315953GPPa is Bovine granulocyte healing disorders peptide A precursor. and Bovine granulocyte peptide A precursorshematopoietic are used in human and veterinary medicine, particularlydisorders.
to treat disorders associated with lipopolysaccharides, e.g. sepsis and endotoxaemia (1. Selsted ME, Bovine granulocyte peptide A

precursor (antimicrobial BGP-A).
Accession Number W23722, Publication Date 21-AUG-97. 2. Yount NY, Yuan J, Tarver A, Castro T, Diamond G, Tran PA, Levy JN, McCullough C, Cullor JS, Bevins CL, Selsted ME.
Cloning and expression of bovine neutrophil beta-defensins.
Biosynthetic profile during neutrophilic maturation and localization of mature peptide to novel cytoplasmic dense granules.
J Biol Chem 1999 Sep 10;274(37):26249-58)).

sbg318486-An embodiment of the invention is Cancer, infection, the use of ONC sbg3184860NC in the growth and invasionautoimmune events of disorder, trophoblast and tumor cells. A closehematopoietic homologue to sbg3184860NC is oncotrophoblast glycoproteins.disorder, It has wound been shown that oncotrophoblast proteinhealing disorders, was expressed by and tumor cells with metastatic spread, inflammation suggesting a role in invasion during cancer (King,K.W., Sheppard,F.C., Westwater,C., Stern,P.L. and Myers,K.A.;
1999; Biochim.

Bio hys. Acta 1445, 257-270).

sbg299359-An embodiment of the invention is Cancer, infection, the use of LIPO sbg299359LIP0 in sperm maturation, autoimmune taste recognition, and disorder, transportation of some molecules hematopoietic across the blood brain barrier. A close homologue to sbg299359LIP0disorder, is Lipocalin. wound Lipocalins transport small hydrophobichealing disorders, molecules such as and steroids, bilins, retinoids, and inflammation lipids, and they have various effects on a number of tissues. It has been shown that lipocalins are involved in sperm maturation, taste recognition, and transportation of some molecules across the blood brain barrier (Newcomer M.E.;
1993; Structure 1:7-18; Achen M.G., Harms P.J., Thomas T., Richardson S.J., Wettenhall R.E.H., Schreiber G.;
1992; J. Biol. Chem.

267:23170-23174) Table III (cont).
Gene Uses Associated Diseases Name sbg230022-An embodiment of the invention is Cancer, infections, the use of sbg230022Nga NGa in the formation and maintenance autoimmune of neuron type-specific networks in the brain. Close homologuesdisorders, to sbg230022Nga wound are mouse plasmacytoma-associated healing disorders neuronal glycoprotein and and rat BIG-1 protein. Mouse plasmacytoma-associatedhematopoietic neuronal glycoprotein, is ectopically activateddisorders by intracisternal A-type particle long terminal repeats in murine plasmacytomas. Rat BIG-1 protein, is a TAG-1/F3-related member of the immunoglobulin superfamily with neurite outgrowth-promoting activity and involved in the formation and maintenance of neuron type-specific networks in the brain (1.

Connelly MA, Grady RC, Mushinski JF, Marcu KB. PANG, a gene encoding a neuronal glycoprotein, is ectopically activated by intracisternal A-type particle long terminal repeats in murine plasmacytomas. Proc Natl Acad Sci U S A 1994 Feb 15;91(4):1337-41 2. Yoshihara Y, Kawasaki M, Tani A, Tamada A, Nagata S, Kagamiyama H, Mori K. BIG-1: a new TAG-1/F3-related member of the immunoglobulin superfamily with neurite outgrowth-promoting activity. Neuron 1994 Aug;13(2):415-26).

sbg297169-An embodiment of the invention is Cancer, infection, the use of BGP sbg297169BGP in renewal and/or differentiationautoimmune of disorder, epithelial cells. A close homologuehematopoietic to sbg297169BGP is BGP protein. BGP proteins are expresseddisorder, wound at the cell surface and function ira vitro as cell adhesionhealing disorders, molecules. The expression of the many BGP isoformsinflammation at the surface of epithelial cells, such as the colon, suggests that these proteins play a major role in renewal and/or differentiation of their epithelia (McCuaig K, Rosenberg M, Nedellec P, Turbide C, and Beauchemin N; 1993;
Gene 127:173-83).

Table III (contl.
Gene Uses Associated Diseases Name sbg253919-An embodiment of the invention is Cancers, such the use of sbg253919- as HSCCAa HSCCAa for treatment of cancer or squamous cell psoriasis or in development of more aggressive squamouscarcinomas cell carcinomas.

Close homologues of sbg253919-HSCCAa are Psoriastatin type II and a human leupin precursor.
Psoriastatin type II, is claimed to modulate activity of psoriastatin type I and II genes, e.g. using (ant)agonists, useful for treatment of cancer or psoriasis. The other, a human leupin precursor, contains a tandem duplication of the human squamous cell carcinoma antigen gene playing a causal role in development of more aggressive squamous cell carcinomas (1. Goetinck PF, Hibino T, Takahashi T and Baciu PC. Modulating cell proliferation or apoptosis - by modulating activity of psoriastatin type I and II

genes, e.g. using (ant) agonists, useful for treatment of cancer or psoriasis. Accession Number W 15242, publication date 24-APR-97. 2. Schneider SS, Schick C, Fish KE, Miller E, Pena JC, Treter SD, Hui SM, Silverman GA.
A serine proteinase inhibitor locus at 18q21.3 contains a tandem duplication of the human squamous cell carcinoma antigen gene. Proc Natl Acad Sci U S A 1995 Apr 11;92(8):3147-51.
3. Barnes RC, Worrall DM. Identification of a novel human serpin gene; cloning sequencing and expression of leupin.
FEBS Lett 1995 Oct 2;

373 (1): 61-5).

sbg228137-An embodiment of the invention is Cancer, infection, the use of sbg2281370LF

OLF in functinal roles in chemoreception autoimmune and in the central nervous system. A close homologue to sbg228137OLFdisorder, is olfactomedin. hematopoietic Olfactomedin is a glycoprotein, and disorder, reacts with proteins of wound olfactory cilia. It was originally healing disorders, discovered at the mucociliary surface of the amphibian olfactory inflammation, neuroepithelium and and subsequently found throughout the nervous system mammalian brain (Danielson,P.E., Forss-Petter,S., disorders Battenberg,E.L., deLecea,L., Bloom,F.E., and Sutcliffe,J.G., 1994, J. Neurosci. Res.

38:468-478). Its noticeable deposition at the chemosensory surface of the olfactory neuroepithelium suggest a role for this protein in chemoreception (Snyder DA, Rivers AM, Yokoe H, Menco BP, and Anholt RR, 1991, Biochemistry 30:9143-53).

The widespread occurrence of olfactomedin among mammalians in the brains also suggests its new functions in the central nervous system (Karavanich CA, and Anholt RR, 1998, Mol Biol Evol 15:718-26).

Table III (cont).
Gene Uses Associated Diseases Name sbg378514-An embodiment of the invention is Cancer, infection, the use of sbg378514-Netrin Netrin in roles of the central nervousautoimmune system. disorder, A close homologue to sbg378514-Netrinhematopoietic is Netrin.

Netrins possess commissural axon disorder, wound outgrowth-promoting activity, and control guidance of healing disorders, CNS commissural axons and peripheral motor axons (Serafiniinflammation, T, Kennedy TE, Galko MJ, Mirzayan C, Jessell TM, and Tessier-Lavigneand nervous M; system 1994; Cel178:409-24). Diffusible disorder and substrate-bound cues, including netrins and their receptors, can guide axonal pathway choice via attractive and repulsive signals (Tear G;

1998; Essa s Biochem 33:1-13).

sbg253227.An embodiment of the invention is Hematopoietic the use of sbg253227.-mucous mucous matrix glycoprotein for the disorder, wound treatment of matrix gastrointestinal.disorders and cancer.healing disorder, Close homologues of viral glycoproteinsbg253227.mucous matrix glycoproteinand bacterial have been used in combination for treatment of infectionsinfection, associated with cancer, EMMG. EMMG is useful for the treatmentautoimmune of diseases gastrointestinal disorders and cancer,Neurological e.g. dysphagia, abdominal angina, pancreatitis, colonicdisorders, carcinoma, Crohn's disease and the Mallory-Weiss syndromegastrointestinal (US5929033-A, CORLEY NC, TANG YT, Submitted by disorders,dysphagia, INCYTE PHARM

INC. Reference number, WPI; 99-429518/36,abdominal angina, 1999).

pancreatitis, colonic carcinoma,Crohn's disease and the Mallory-Weiss syndrome.

sbg262831-An embodiment of the invention is Cancer, autoimmune the use of SIAa sbg262831SIAa to mediate sialic acid-dependentdisorders, ligand infection, recognition and to function as an wound healing inhibitory receptor in human natural killer cells. disorders, and A close homologue of sbg262831SIAa hematopoietic is human QA79 membrane protein. QA79 belongs to disorders.
the sialoadhesin family and is proposed to mediate sialic acid-dependent ligand recognition and to function as an inhibitory receptor in human natural killer cells (Falco,M., Biassoni,R., Bottino,C., Vitale,M., Sivori,S., Augugliaro,R., Moretta,L.

and Moretta,A. Identification and molecular cloning of p75lAIRMI, a novel member of the sialoadhesin family that functions as an inhibitory receptor in human natural killer cells. J Ex Med 1999 Sep 20;190(6):793-802).

Table III (cont).
Gene Uses Associated Name Diseases sbg233728-An embodiment of the invention is Cancer, infection, the use of LIPASE sbg233728LIPASE to treat pancreatitisautoimmune via replacement therapy. A close homologue of sbg233728-LIPASEdisorder, is pancreatic lipase. Pancreatic lipase hematopoietic can be used as replacement enzymes for patients with chronic disorder, pancreatitis. Pancreatic wound lipase hydrolyzes dietary long chain healing disorders, triacylglycerol to free fatty acids and monoacylglycerols in the inflammation, intestinal lumen (Lowe and ME, Rosenblum JL, and Strauss AW; pancreatitis.
1989; J Biol Chem 264:20042-8). Pancreatic steatorrhea and pancreatic diabetes are the dominant symptoms of patients in a certain stage of chronic pancreatitis. In this stage, the nutritional state is greatly disturbed and hypoglycemia and labile infection are involved. Pancreatic enzyme replacement therapy is the principal treatment method for pancreatic steatorrhea.

(Nakamura T, Takeuchi T, and Tando Y; 1998; Pancreas 16:329-36).

sbg400455.An embodiment of the invention is Hematopoietic the use of sbg400455.CRF

-CRF in the areas of the nervous system disorder, involved in motor function, wound such as the Purkinje cells of the healing disorder, cerebellum, the accessory olivary nucleus, the pons, and the viral and red nucleus. Close bacterial homologues of sbg400455.CRF include infection, CRF transcripts. CRF cancer, transcripts are most abundant in areasautoimmune of the nervous system and have been used to develop productsdiseases, for modulating energy energy balance or insulin production in mammalshomeostasis ((W09639429-A2) Schere, P.E.; Submitted by Whithead disorder Institute of Biomedical and Research; Berube NG, Swanson XH, Bertramobesity MJ, Kittle JD, Didenko V, Baskin DS,Smith JR and Pereira-Smith OM., Brain Res. Mol. Brain Res. 63 (2), 233-240 (1999)).

sbg400612-An embodiment of the invention is Cancer, wound the use of sbg400612-KINASEa KINASEa in the treatment of inflammation,healing disorders, cancer, neurological diseases, growth and developmental autoimmune defects, skin wounds, and hair follicle disorders. A close homologuedisorders, of sbg400612-KINASEa is marine protein kinase/ hematopoietic ankyrin homologue. Marine protein kinasel ankyrin homologue disorders can stimulate the growth and and motility of keratinocytes, inhibit infection the growth of cancer cells, modulate angiogenesis and tumour vascularisation, modulate skin inflammation and epithelial cell growth and inhibit binding of HIV-1 to leukocytes. Marine protein kinase/ ankyrin homologue can also be used to treat inflammation, cancer, neurological diseases, growth and developmental defects, skin wounds, and hair follicle disorders (Kumble A, Murison JG, Onrust R, Sleeman M, Strachan L and Watson JD.
Novel polynucleotides useful for the treatment of various conditions including wounds and cancer. Accession Number: Y76079 Publication Date: 04-NOV-99).

Table III (cont).
Gene Uses Associated Diseases Name sbg381373-An embodiment of the invention is Cancer, infection, the use of sbg381373-ACRP ACRP in the complex balanced systemautoimmune disorder, of energy homeostasis involving food intake, hematopoietic carbohydrate disorder, catabolism, and lipid catabolism. wound healing A close homologue of sbg381373-ACRP is ACRP30 protein. disorders, ACRP30 protein may be a factor that participates inflammation, in the complex balanced obesity, system of energy homeostasis involvingand diabetes food intake, carbohydrate catabolism, and lipid catabolism. ACRP30 is structurally similar to complement factor Clq, and it forms large homo-oligomers that undergo a series of post-translational modifications (Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF;
1995; J Biol Chem 270:26746-9).

sbg401294-An embodiment of the invention is Hematopoietic the use of sbg401294-MEX-3 MEX-3 to develop products for diagnosisdisorder, wound and therapy of disease states such as tumor formation,healing disorder, apoptosis regulation viral in cells to reduce or increase apoptosisand bacterial and for infection, pharmacological screening. cancer, tumor formation, autoimmune diseases, inhibition of apoptosis sbg247722-An embodiment of the invention is Hematopoietic the use of sbg247722-CadherinCadherin for treatment and diagnosisdisorder, wound of bone metabolic diseases. A close homologue of sbg247722-Cadherinhealing disorder, is viral cadherin, a Ca2+ dependent cell and bacterial adhesion protein. infection, cancer, autoimmune diseases, energy homeostasis disorder and bone metabolic disease sbg391057-An embodiment of the invention is Autoimmune disorders, the use of sbg391057-THIPa THIPa in controlling thyroid hormonewound healing synthesis. A close homologue of sbg391057-THIPa is disorders, cancer, xenopus laevis thyroid hormone-induced protein. Xenopus infection and laevis thyroid hormone-induced protein has been implicatedhematopoietic in controlling thyroid disorders hormone synthesis in Xenopus tadpoles and provided insights into the biology of metamorphosis (Brown,D.D., Wang,Z., Furlow,J.D., I~anamori,A., Schwartzman, R.A., Remo,B.F. and Pinder,A. The thyroid hormone-induced tail resorption program during Xenopus laevis metamorphosis.

Proc Natl Acad Sci U S A 1996 Mar 5;93(5):1924-9).

Table III (cont).
Gene Uses Associated Diseases Name sbg378067-An embodiment of the Cancer, infection, autoimmune invention is the disorder, TGFc use of sbg378067-TGFc hematopoietic disorder, in cellular wound healing growth control in the disorder, inflammation, etiology of cancer preventing or and cell differentiationtreating cellular degeneration and development. or The sbg378067-TGFc proteininsufficiency, e.g. neuronal contains a close approximation of degeneration resulting the prosite from peripheral consensus pattern (PDOC00223)neuropathy, amyotrophic for lateral TGF-beta family members.sclerosis, Alzheimer's TGF-beta disease, proteins have been knownParkinson's disease, to be involved Huntington's in growth control and disease, ischemic stroke, hence the etiology acute brain of cancer (Anticancer injury, acute spinal Res 1999 Nov- cord injury, nervous Dec;l9(6A):4791-807), system tumours, multiple cell sclerosis, or differentiation and development.infection (viral, bacterial, A fungal, TGF-beta signaling pathwayparasitic), hematopoietic constitutes cell a tumor suppressor path degeneration or insufficiency (Cytokirze resulting Growth Factor Rev 2000 from eosinopenia, anemias, Apr 1;11(1-2):159-168). A close thrombocytopenia, or homologue of stem-cell 'sbg378067-TGFc is TGF-betainsufficiences, cardiac protein. muscle degeneration or insufficiency resulting from cardiomyopathy or congestive heart failure, peripheral nerve trauma or injury, exposure to neurotoxins, metabolic diseases such as diabetes or renal dysfunctions and damage caused by infectious a ents Table IV. Quantitative, Tissue-specific mRNA expression detected using SybrMan Quantitative, tissue-specific, mRNA expression patterns of the genes were measured using SYBR-Green Quantitative PCR (Applied Biosystems, Foster City, CA; see Schmittgen T.D. et al., Analytical Biochemistry 285:194-204, 2000} and human cDNAs prepared from various human S tissues. Gene-specific PCR primers were designed using the first nucleic acid sequence listed in the Sequence List for each gene. Results are presented as the number of copies of each specific gene's mRNA detected in lng mRNA pool from each tissue. Two replicate mRNA
measurements were made from each tissue RNA.
Tissue-Specific mRNA
Expression Gene Name (co ies er n mRNA;
av .
ran a for data points er tissue) Brain HeartLung Liver Kid- Skele-Intes-SpleePla- Testis ney tal tine n/lymcenta muscl ph a sb 237038SAI41 271 39I 140 181 120 213 452 193 409 sbg340871-00 200 363 -96 3313 9317 749 3059 2902 364 sbg293416-553 651 394 274 391 381 534 2259 430 1089 sbg2574I8ZP373 286 60 -123 -42 197 152 52 102 605 sbg319185-545 1133 696 9537 317 708 540 5987 3262 258 CDa 140 31 30 64 158 31 sbg323307-2938 633 1269 151 1365 266 1400 3312 632 196 KIAAa 15 58 91 12 10 sbg315953-232 160 542 16 147 48 153 994 617 1266 GPPa 31 sbg318486-527 32 80 40 42 21 62 17 41 1229 ONC

sbg2993S9-1701 390 6014 211 135 413 492 267 405 1382 Table IV (cont.) Tissue-Specific mRNA
Expression Gene (co Name ies er n mRNA;
av .
ran a for data oints er tissue) Brain HeartLung LiverKid- Skele-Intes-SpleenPla- estis ney tal tine /lymphcenta muscle sbg230022-3443 684 386 712 1956 360 588 1293 437 358 NGa 112 2 7 16 63 7 17 2 sbg297169-417 141 236 170 3220 744 231 3700 223 968 sbg253919--51 11 21 -142 -100 -43 01 61 43 119 HSCCAa 9 sbg228137-5174 584 995 93 637 167 980 7199 328 674 sbg253227.50 111 211 01 282 10 132 243 264 118 mucous 1 matrix Iyco rotein sbg262831-91 61 591 591 50 -42 134 2657 454 250 SIAa 6 97 sbg233728-21 61 42 62 10 40 13 12 32 283 LIPASE

sbg400455.-8735 345 434 191 4038 705 379 847 434 978 sbg400612-100 244 276 145 431 70 595 234 829 343 KINASEa 87 2 10 sbg381373-112 113 155 145 102 118 144 -38 62 118 sbg401294-498 392 122 359 1518 65 161 153 718 683 sbg247722-2626 1140 1733 784 2007 213 1175 1701 3487 1814 Cadherin18 22 62 12 52 47 167 -!-26330 sbg391057-3323 3010 8567 136 1013 1499 2469 3512 1393 2408 THIPa 30 84 1 90 172 86 23 32 174 sbg378067-338 586 524 31 481 4922 214 116 742 594 TGFc 28 4 Table V. Additional diseases based on mRNA expression in specific tissues Tissue Additional Diseases Expression Brain Neurological and psychiatric diseases, including Alzheimers, parasupranuclear palsey, Huntington's disease, myotonic dystrophy, anorexia, depression, schizophrenia, headache, amnesias, anxiety disorders, sleep disorders, multiple sclerosis Heart Cardiovascular diseases, including congestive heart failure, dilated cardiomyopathy, cardiac arrhythmias, Hodgson's Disease, myocardial infarction, cardiac arrhythmias Lung Respiratory diseases, including asthma, Chronic Obstructive Pulmonary Disease, cystic fibrosis, acute bronchitis, adult res iratory distress syndrome Liver Dyslipidemia, hypercholesterolemia, hypertriglyceridemia, cirrhosis, hepatic encephalopathy, fatty hepatocirrhosis, viral and nonviral hepatitis, Type II Diabetes Mellitis, im aired lucose tolerance Kidney Renal diseases, including acute and chronic renal failure, acute tubular necrosis, cystinuria, Fanconi's Syndrome, glomerulonephritis, renal cell carcinoma, renovascular h ertension Skeletal Eulenburg's Disease, hypoglycemia, obesity, tendinitis, muscle periodic paralyses, mali nant by erthermia, aramyotonia congenita, myotonia con enita Intestine Gastrointestinal diseases, including Myotonia congenita, Ileus, Intestinal Obstruction, Tro ical S rue, Pseudomembranous Enterocolitis Spleen/lymphLymphangiectasia, hypersplenism, angiomas, ankylosing spondylitis, Hodgkin's Disease, macro lobulinemia, mali nant lym homas, rheumatoid arthritis Placenta Choriocarcinoma, hydatidiform mole, placenta previa Testis Testicular cancer, male reproductive diseases, including low testosterone and male infertility Pancreas Diabetic ketoacidosis, Type 1 & 2 diabetes, obesity, impaired glucose tolerance SEQUENCE LISTING
<110> SMITHKLINE BEECHAM CORPORATION
SMITHKLINE BEECHAM p.l.c.
<120> NOVEL COMPOUNDS
<130> GP50025 <140> TO BE ASSIGNED
<141> 2001-04-26 <150> 60/199,963 <151> 2000-04-27 <150> 60/203,336 <151> 2000-05-11 <150> 60/207,087 <151> 2000-05-25 <150> 60/207,546 <151> 2000-05-26 <160> 78 <170> FastSEQ for Windows Version 3.0 <210> 1 <211> 831 <212> DNA
<213> Homo Sapiens <400> 1 atgcgtggccttgttatggctcccctgctcattctcctggttggtgggactgaagccttt60 cgtatctgtgccttcaatgcccacagactgacactggcca.agctaaccaaggagtcagtg120 atggataccttagttcagatcctagcccgatgtgatatcatggtgcttcaggaggtagta180 gattcttcccagaatactgtcccctttctgcttcaaaaacttaaaagttccaggagttac240 agcttcctaaacagctcattgctggggcgcagcacatacaaggaaaagtatgtgtatatc300 tacaggtctgacaagacacaggtcctaaatttctaccaatacaacgacacagatgatatt360 tttgcccgagaaccatttgtggcccatttcactctccctagcaaaactcttccaagtgtg420 gtgctggttcctctccacaccactcccaaggatgttgagaaggagctgaatgccctctat480 gatgtgtttctggatgtctaccagcgctggcagaatgagaatgtgattctgcttggagac540 ttcaatgcagactgtgcatcgctgacaaaaaaacgtctgaaaagcctgctactccggact600 aaggcaggcttccactgggtgattcctgatggggaggatactacagtgcgggccagtact660 aactgtacctatgaccgaattgtggtgcatggacagggctgccaaatgctgctgaaggct720 gcagctacctttgactttcccaagaggtttcagctgactgaggaagaggctctccgcatc780 agtgaccattatcctgtagaagtggaactgagccaggccactccactgagt 831 <210> 2 <211> 1443 <212> DNA
<213> Homo Sapiens <400> 2 atgctaggcc gatttcaacc cttctccttg gtccggagtt tcagactggg atttggagcc 60 tgctgctatc caaaccaaaa atgtgctact cagaccatca gaccccctga ctccaggtgc 120 ctagtccaag cagtttctca gaactttaat tttgcaaagg atgtgttgga tcagtggtcc 180 cagctggaaaaggacggactcagagggccttaccccgccctctggaaggttagtgccaaa240 ggagaagaggacaaatggagctttgaaaggatgactcaactctccaagaaggccgccagc300 atcctctcagacacctgtgcccttagccatggagaccggctgatgataatcttgccccca360 acacctgaagcctactggatctgcctggcctgtgtgcgcttgggaatcacctttgtgcct420 gggagcccccagctgactgccaagaaaattcgctatcaattacgcatgtctaaggcccag480 tgcattgtggctaatgaagctatggccccagttgtaaactctgccgtgtccgactgcccc540 accttgaaaaccaagctcctggtgtcagataagagctatgatgggtggttggatttcaag600 aagttgattcaagttgcccctccaaagcagacctacatgaggaccaaaagccaagatcca660 atggccatattcttcaccaagggtacaacaggagctcccaaaatggtcgagtattcccag720 tatggtttgggaatgggattcagccaggcttccagacggtggatggatctccagccaaca780 gatgtcttgtggagtctgggtgatgcctttggtggatctttatccctgagcgctgtcttg840 ggaacttggttccaaggagcctgtgtgtttctgtgtcacatgccaaccttctgccctgag900 actgttctaaatgtcctgtccagatttcccatcaccactctatctgcaaatccagagatg960 taccaggaactgcttcagcacaagtgtttcaccagctacagattcaagagtctgaagcag1020 tgtgtggctgcaggaggacccatcagccctggggtgattgaggactggaaacgcatcact1080 aagttggacatctatgaaggctatgggcagacggaaactggtctactctgtgccacttcc1140 aaaacaataaaattgaagccaagctctctggggaagccattgccaccttatattgtccag1200 attgtggatgaaaactcaaatctcctgcctccaggggaagaaggaaatattgcaatccgc1260 ataaaactaaaccaacctgcttctctgtactgtccacacatggtgagctgggaggaatat1320 gcttcagcaagaggccacatgctttacctcacaggtgacagagggatcatggatgaagac1380 ggctacttctggtggtctggtagagttgatgatgttgccaatgcattgggtcagagattg1440 tga 1443 <210> 3 <211> 1752 <212> DNA
<213> Homo Sapiens <400> 3 atgctaggccgatttcaacccttctccttggtccggagtttcagactgggatttggagcc60 tgctgctatccaaaccaaaaatgtgctactcagaccatcagaccccctgactccaggtgc120 ctagtccaagcagtttctcagaactttaattttgcaaaggatgtgttggatcagtggtcc180 cagctggaaaaggacggactcagagggccttaccccgccctctggaaggttagtgccaaa240 ggagaagaggacaaatggagctttgaaaggatgactcaactctccaagaaggccgccagc300 atcctctcagacacctgtgcccttagccatggagaccggctgatgataatcttgccccca360 acacctgaagcctactggatctgcctggcctgtgtgcgcttgggaatcacctttgtgcct420 gggagcccccagctgactgccaagaaaattcgctatcaattacgcatgtctaaggcccag480 tgcattgtggctaatgaagctatggccccagttgtaaactctgccgtgtccgactgcccc540 accttgaaaaccaagctcctggtgtcagataagagctatgatgggtggttggatttcaag600 aagttgattcaagttgcccctccaaagcagacctacatgaggaccaaaagccaagatcca660 atggccatattcttcaccaagggtacaacaggagctcccaaaatggtcgagtattcccag720 tatggtttgggaatgggattcagccaggcttccagacggtggatggatctccagccaaca780 gatgtcttgtggagtctgggtgatgcctttggtggatctttatccctgagcgctgtcttg840 ggaacttggttccaaggagcctgtgtgtttctgtgtcacatgccaaccttctgccctgag900 actgttctaaatgtcctgtccagatttcccatcaccactctatctgcaaatccagagatg960 taccaggaactgcttcagcacaagtgtttcaccagctacagattcaagagtctgaagcag1020 tgtgtggctgcaggaggacccatcagccctggggtgattgaggactggaaacgcatcact1080 aagttggacatctatgaaggctatgggcagacggaaactggtctactctgtgccacttcc1140 aaaacaataaaattgaagccaagctctctggggaagccattgccaccttatattgtccag1200 attgtggatgaaaactcaaatctcctgcctccaggggaagaaggaaatattgcaatccgc1260 ataaaactaaaccaacctgcttctctgtactgtccacacatggtgagctgggaggaatat1320 gcttcagcaagaggccacatgctttacctcacaggtgacagagggatcatggatgaagac1380 ggctacttctggtggtctggtagagttgatgatgttgccaatgcattgggtcagagattt1440 tctcgccccggggcggcggcggcggcaagtgcggtgggagcgccgcctggaggctggcac2500 tcattatgtgcctctgttcccattctgcaggtggtgaagccccctaatgtcctgactcca1560 cagttcctgtcccatgaccagggccagctcaccaaagagctacagcagcacataaagtca1620 gtgacaggcccatgcaagtaccaaaggaaggtggagtttgtcccagagctgccaaaaacc1680 gtcactggcaagattaaacgggaacttcaagtttggtcagatgtagtcagcagtgaactc1740 agaaatgactga 1752 SIAa 6 97 <210> 4 <211> 1746 <212> DNA
<213> Homo sapiens <400>

atgccactgaagcattatctccttttgctggtgggctgccaagcctggggtgcagggttg60 gcctaccatggctgccctagcgagtgtacctgctccagggcctcccaggtggagtgcacc120 ggggcacgcattgtggcggtgcccacccctctgccctggaacgccatgagcctgcagatc280 ctcaacacgcacatcactgaactcaatgagtccccgttcctcaatatttcagccctcatc240 gccctgaggattgagaagaatgagctgtcgcgcatcacgcctggggccttccgaaacctg300 ggctcgctgcgctatctcagcctcgccaacaacaagctgcaggttctgcccatcggcctc360 ttccagggcctggacagccttgagtctctccttctgtccagtaaccagctgttgcagatc420 cagccggcccacttctcccagtgcagcaacctcaaggagctgcagttgcacggcaaccac480 ctggaatacatccctgacggagccttcgaccacctggtaggactcacgaagctcaatctg540 ggcaagaatagcctcacccacatctcacccagggtcttccagcacctgggcaatctccag600 gtcctccggctgtatgagaacaggctcacggatatccccatgggcacttttgatgggctt660 gttaacctgcaggaactggctctacagcagaaccagattggactgctctcccctggtctc720 ttccacaacaaccacaacctccagagactctacctgtccaacaaccacatctcccagctg780 ccacccagcatcttcatgcagctgccccagctcaaccgtcttactctctttgggaattcc840 ctgaaggagctctctctggggatcttcgggcccatgcccaacctgcgggagctttggctc900 tatgacaaccacatctcttctctacccgacaatgtcttcagcaacctccgccagttgcag960 gtcctgattcttagccgcaatcagatcagcttcatctccccgggtgccttcaacgggcta1020 acggagcttcgggagctgtccctccacaccaacgcactgcaggacctggacgggaatgtc1080 ttccgcatgttggccaacctgcagaacatctccctgcagaacaatcgcctcagacagctc1140 ccagggaatatcttcgccaacgtcaatggcctcatggccatccagctgcagaacaaccag1200 ctggagaacttgcccctcggcatcttcgatcacctggggaaactgtgtgagctgcggctg1260 tatgacaatccctggaggtgtgactcagacatccttccgctccgcaactggctcctgctc1320 aaccagcctaggttagggacggacactgtacctgtgtgtttcagcccagccaatgtccga1380 ggccagtccctcattatcatcaatgtcaacgttgctgttccaagcgtccatgtacctgag1440 gtgcctagttacccagaaacaccatggtacccagacacacccagttaccctgacaccaca1500 tccgtctcttctaccactgagctaaccagccctgtggaagactacactgatctgactacc1560 attcaggtcactgatgaccgcagcgtttggggcatgacccatgcccatagcgggctggcc1620 attgccgccattgtaattggcattgtcgccctggcctgctccctggctgcctgcgtcggc1680 tgttgctgctgcaagaagaggagccaagctgtcctgatgcagatgaaggcacccaatgag1740 tgttaa 1746 <210> 5 <211> 1887 <212> DNA
<213> Homo Sapiens <400>

atgcccggtgctccagactggagccttaattcctccagaaatgcacgcagcctggagggg 60 ctgcctctgtgtccgtggtgggctctcttcgtcccgagagcagctgcgctggttggactt 120 caaaggaagcaggaaaacagctcagatatcttctttagctctcctttcacggtgacccca 180 gacgccctaccaacagccattacatgggagcacattccgtttgcaaagctggcgggtcta 240 attgcagggcctttggtggagatgtgcaggcagaggctaagcaaagagtttgaggccttg 300 aaaggggaattcagggacctcgggcactgtcttccaggagcccagcgagggaacagaatc 360 actaaacgaaacaagtgcggtcagagccgtcaggcgctcatcggccagagacaggaagat 420 gcaggctccgctcctctgcagatgcaccccagtgtcgctgcgctgggggcaggagctgcg 480 ctgcgggagattcagcccctgcaaagggaaccagagctgtcatcagggcccaggaacagc 540 cggctcctgtgctggggcagccctgccacctggaaccccacgtacctgtcccgtgtccta 600 gggcagcaggtggccgtgactgtgacagaggctggtctccaggctgtgccctggggaccc 660 agcagagaatttaatgccaagggctctagctcagcgagcattagagtgggacagccccag 720 aagcttaggctcagagtccagaggtccaggagacagtgtccccctgtccagtcctcacag 780 gacctcccaccaggcggctcccaggatggtgacttgaaggaacccacagagagggtcact 840 cgggacttatccagtggggccccgaggggccgcaacctgccagcgcctgaccagcctcaa 900 cccccgctgcagaggggaacccgtctgcggctccgccagcgccgtcgccgtctgctcatc960 aagaaaatgccagctgcggcgaccatcccggccaacagctcggacgcgcccttcatccgg1020 ccgggacccgggacgctggatggccgctgggtcagcctgcaccggagccagcaggagcgc1080 aagcgggtgatgcaggaggcctgcgccaagtaccgggcgagcagcagccgccgggccgtc1140 acgccccgccacgtgtcccgtatcttcgtggaggaccgccaccgcgtgctctactgcgag1200 gtgcccaaggccggctgctccaattggaagcgggtgctcatggtgctggccggcctggcc1260 tcgtccactgccgacatccagcacaacaccgtccactatggcagcgctctcaagcgcctg1320 gacaccttcgaccgccagggtatcttgcaccgtctcagcacctacaccaagatgctcttt1380 gtccgcgagcccttcgagaggctggtgtccgccttccgcgacaagtttgagcaccccaac1440 agctactatcacccggtcttcggcaaggccatcctggcccggtaccgcgccaatgcctct1500 cgggaggccctgcggaccggctctggggtgcgttttcccgagttcgtccagtacctgctg1560 gacgtgcaccggcccgtggggatggacattcactgggaccatgtcagccggctctgcagc1620 ccctgcctcatcgactacgatttcgtaggcaagttcgagagcatggaggacgatgccaac1680 ttcttcctgagcctcatccgcgcgccgcggaacctgaccttcccccggttcaaggaccgg1740 cactcgcaggaggcgcggaccacagcgaggatcgcccaccagtacttcgcccaactctcg1800 gccctgcaaaggcagcgcacctacgacttctactacatggattacctgatgttcaactat1860 tccaagccctttgcagatctgtactga 1887 <210> 6 <211> 1275 <212> DNA
<213> Homo sapiens <400> 6 atgaccctgcgacctggaacaatgcggctggcctgcatgttctcttccatcctgctgttc60 ggagctgcaggcctcctcctcttcatcagcctgcaggaccctacggagctcgccccccag120 caggtgccaggaataaagttcaacatcaggccaaggcagccccaccacgacctcccacca180 ggcggctcccaggatggtgacttgaaggaacccacagagagggtcactcgggacttatcc240 agtggggccccgaggggccgcaacctgccagcgcctgaccagcctcaacccccgctgcag300 aggggaacccgtctgcggctccgccagcgccgtcgccgtctgctcatcaagaaaatgcca360 gctgcggcgaccatcccggccaacagctcggacgcgcccttcatccggccgggacccggg420 acgctggatggccgctgggtcagcctgcaccggagccagcaggagcgcaagcgggtgatg480 caggaggcctgcgccaagtaccgggcgagcagcagccgccgggccgtcacgccccgccac540 gtgtcccgtatcttcgtggaggaccgccaccgcgtgctctactgcgaggtgcccaaggcc600 ggctgctccaattggaagcgggtgctcatggtgctggccggcctggcctcgtccactgcc660 gacatccagcacaacaccgtccactatggcagcgctctcaagcgcctggacaccttcgac720 cgccagggtatcttgcaccgtctcagcacctacaccaagatgctctttgtccgcgagccc780 ttcgagaggctggtgtccgccttccgcgacaagtttgagcaccccaacagctactatcac840 ccggtcttcggcaaggccatcctggcccggtaccgcgccaatgcctctcgggaggccctg900 cggaccggctctggggtgcgttttcccgagttcgtccagtacctgctggacgtgcaccgg960 cccgtggggatggacattcactgggaccatgtcagccggctctgcagcccctgcctcatc1020 gactacgatttcgtaggcaagttcgagagcatggaggacgatgccaacttcttcctgagc1080 ctcatccgcgcgccgcggaacctgaccttcccccggttcaaggaccggcactcgcaggag1140 gcgcggaccacagcgaggatcgcccaccagtacttcgcccaactctcggccctgcaaagg1200 cagcgcacctacgacttctactacatggattacctgatgttcaactattccaagcccttt1260 gcagatctgtactga 1275 <210> 7 <211> 1917 <212> DNA
<213> Homo sapiens <400> 7 atggcaggaggctcagccacgacctggggttaccctgtggccctgctactgctggttgcc60 accctggggctgggtaggtggctccagcccgaccctggcctcccaggcctccggcacagc120 tacgactgtgggatcaagggaatgcagctgctggtgttccccaggccaggccagactctc180 cgcttcaaggtggtggatgaatttgggaaccgatttgatgtcaacaactgctccatctgc240 taccactgggtcacctccaggccgcaggagcctgcagtcttctcggccgattacagaggc300 tgccacgtgctggagaaggatgggcgtttccacctgagggtgttcatggaggctgtgctg360 cccaatggtcgtgtggatgtggcacaagacgctactctgatctgtcccaaacctgacccc 420 tcccggactctggactcccagctggcaccacccgccatgttctctgtctcaaccccacaa 480 accctttccttcctccccacctctggccatacctcccaaggctctggccatgcctttccc 540 agcccactggacccagggcacagctctgtccacccaacccctgctttaccatcccctgga 600 cctggacctaccctcgccaccctggctcaaccccactggggcaccttggaacactgggat 660 gtgaacaaacgagattacataggtacccacctgagccaggagcagtgccaggtggcctca 720 gggcacctcccctgcatcgtgagaagaacttcaaaagaagcctgtcagcaggctggctgc 780 tgctatgacaacaccagagaggttccctgttactatggcaacacagctactgtccagtgc 840 ttcagagatggctacttcgtcctcgtagtgtcccaagaaatggccttgacacacaggatc 900 acactggccaacatccacctggcctatgcccccaccagctgctccccaacacagcacacg 960 gaagctttcgtggtcttctacttccctctcacccactgtggaaccacaatgcaggtggct 1020 ggcgaccagctcatctatgagaactggctggtgtctggcatccacatccaaaaggggcca 1080 cagggttccatcacgcgggacagcaccttccagcttcatgtgcgctgtgtcttcaacgcc 1140 agtgacttcctgcccattcaggcatccattttcccacccccatcgcctgctcctatgacc 1200 cagcccggccccctgcggcttgagctgcggattgccaaagacgagaccttcagctcgtac 1260 tatggggaggatgactatcccatcgtgaggctgctccgagaaccagtccatgtggaggtc 1320 cggcttctgcagaggacagaccccaacctggtcctgctgctgcaccagtgctggggcgct 1380 cccagtgccaaccccttccagcagccccagtggcccatcctgtcagacggatgccctttc 1440 aagggcgacagctacagaacccaaatggtagccttggacggggccacacctttccagtcg 1500 cactaccagcgattcactgttgctaccttcgccctcctggactcaggctcccagagagcc 1560 ctcagaggactggtttacttgttctgcagcacctctgcctgccacacctcagggctggag 1620 acttgctccactgcatgtagcactggcactacaagacagcgacgatcctcaggtcaccgt 1680 aatgacactgccaggccccaggacatcgtgagctctccggggccagtgggctttgaggat 1740 tcttatgggcaggagcccacacttgggcccacagactccaatgggaactccagcctgaga 1800 cctctcctttgggcggtccttttgctgccagctgttgccctggtccttgggtttggtgtc 1860 tttgtgggcctgagccagacctgggcccagaagctctgggaaagcaacagacagtga 1917 <210> 8 <211> 687 <212> DNA
<213> Homo Sapiens <400> 8 atgaaacctcttgctcagcttctcctctttctcctccagtttcagaaagggaatctagtt 60 tcacaaagcagctcaaccccattgatggtgaatggggttctgggggagtcagtaactctt 120 cccctggagtttcctgcaggagagaggatccagttcatcacttggctttgcaatggaaca 180 tcttttgccttcctagaaccctatgaaggcaaaagtccaaaaatctacgtgactcatccg 240 aaatggcaaaagcgactgagcttcacccagtcctactccccgcagctcagcaacctggag 300 atggaaaacataggcttttacagtgcccagatagccacagagacctctgcaaagctgtcc 360 agttacactctgaggatattcaagcagctgccaaggcctcaagttagagtggattctatc 420 atctctgaaaatgggatctgtaatgccatcttgaggtgttctgtggaggaaggaggagag 480 accatcacatatgagtggacatcaatgggaccaggggctgctgtgtcccacgtgggcctt 540 catgacctggattggatctacacttgcacagctctgaatcctgttagctacagcaactct 600 actcttacccttgctgcacagctttgtgcaagtaagagtccccttctggtctctctagca 660 ccccttggaaatgttttgtctggtctc 687 <210> 9 <211> 933 <212> DNA
<213> Homo Sapiens <400> 9 atgaaacctc ttgctcagct tctcctcttt ctcctccagt ttcagaaagg gaatctagtt 60 tcacaaagca gctcaacccc attgatggtg aatggggttc tgggggagtc agtaactctt 120 cccctggagt ttcctgcagg agagaggatc cagttcatca cttggctttg caatggaaca 180 tcttttgcct tcctagaacc ctatgaaggc aaaagtccaa aaatctacgt gactcatccg 240 aaatggcaaa agcgactgag cttcacccag tcctactccc cgcagctcag caacctggag 300 atggaaaaca taggctttta cagtgcccag atagccacag agacctctgc aaagctgtcc 360 agttacactc tgaggatatt caagcagctg ccaaggcctc aagttagagt ggattctatc 420 atctctgaaaatgggatctgtaatgccatcttgaggtgttctgtggaggaaggaggagag 480 accatcacatatgagtggacatcaatgggaccaggggctgctgtgtcccacgtgggcctt 540 catgacctggattggatctacacttgcacagctctgaatcctgttagctacagcaactct 600 actcttacccttgctgcacagctttgtgcaagttccaaggcagctgaaggcacctattgc 660 ccagtgaaatggattttcctggggaacaggcttcttctccttgtgttccttggtgtccta 720 cgaacttggcatattcaggcacaggtgctcagcaaacccttgaggcctaactcaggggaa 780 cttgtgaatctttcctcaatcccatacccttgggaaccatctcacacagctgatgccact 840 tggcttgggaagtggggtggaagtgagggggagagaaagagcacgtggaatataagcacc 900 acgaaaagacactggaaaagcttctataaataa 933 <210> 10 <211> 2526 <212> DNA
<213> Homo sapiens <400>

atgaagctgtggattcatctcttttattcatctctccttgcctgtatatctttacactcc 60 caaactccagtgctctcatccagaggctcttgtgattctctttgcaattgtgaggaaaaa 120 gatggcacaatgctaataaattgtgaagcaaaaggtatcaagatggtatctgaaataagt 180 gtgccaccatcacgacctttccaactaagcttattaaataacggcttgacgatgcttcac 240 acaaatgacttttctgggcttaccaatgctatttcaatacaccttggatttaacaatatt 300 gcagatattgagataggtgcatttaatggccttggcctcctgaaacaacttcatatcaat 360 cacaattctttagaaattcttaaagaggatactttccatggactggaaaacctggaattc 420 ctgcaagcagataacaattttatcacagtgattgaaccaagtgcctttagcaagctcaac 480 agactcaaagtgttaattttaaatgacaatgctattgagagtcttcctccaaacatcttc 540 cgatttgttcctttaacccatctagatcttcgtggaaatcaattacaaacattgccttat 600 gttggttttctcgaacacattggccgaatattggatcttcagttggaggacaacaaatgg 660 gcctgcaattgtgacttattgcagttaaaaacttggttggagaacatgcctccacagtct 720 ataattggtgatgttgtctgcaacagccctccattttttaaaggaagtatactcagtaga 780 ctaaagaaggaatctatttgccctactccaccagtgtatgaagaacatgaggatccttca 840 ggatcattacatctggcagcaacatcttcaataaatgatagtcgcatgtcaactaagacc 900 acgtccattctaaaactacccaccaaagcaccaggtttgataccttatattacaaagcca 960 tccactcaacttccaggaccttactgccctattccttgtaactgcaaagtcctatcccca 1020 tcaggacttctaatacattgtcaggagcgcaacattgaaagcttatcagxatctgagacct 1080 cctccgcaaaatcctagaaagctcattctagcgggaaatattattcacagtttaatgaag 1140 tctgatctagtggaatatttcactttggaaatgcttcacttgggaaacaatcgtattgaa 1200 gttcttgaagaaggatcgtttatgaacctaacgagattacaaaaactctatctaaatggt 1260 aaccacctgaccaaattaagtaaaggcatgttccttggtctccataatcttgaatactta 1320 tatcttgaatacaatgccattaaggaaatactgccaggaacctttaatccaatgcctaaa 1380 cttaaagtcctgtatttaaataacaacctcctccaagttttaccaccacatattttttca 1440 ggggttcctctaactaaggtaaatcttaaaacaaaccagtttacccatctacctgtaagt 1500 aatattttggatgatcttgatttactaacccagattgaccttgaggataacccctgggac 1560 tgctcctgtgacctggttggactgcagcaatggatacaaaagttaagcaagaacacagtg 1620 acagatgacatcctctgcacttcccccgggcatctcgacaaaaaggaattgaaagcccta 1680 aatagtgaaattctctgtccaggtttagtaaataacccatccatgccaacacagactagt 1740 taccttatggtcaccactcctgcaacaacaacaaatacggctgatactattttacgatct 1800 cttacggacgctgtgccactgtctgttctaatattgggacttctgattatgttcatcact 1860 attgttttctgtgctgcagggatagtggttcttgttcttcaccgcaggagaagatacaaa 1920 aagaaacaagtagatgagcaaatgagagacaacagtcctgtgcatcttcagtacagcatg 1980 tatggccataaaaccactcatcacactactgaaagaccctctgcctcactctatgaacag 2040 cacatggtgagccccatggttcatgtctatagaagtccatcctttggtccaaagcatctg 2100 gaagaggaagaagagaggaatgagaaagaaggaagtgatgcaaaacatctccaaagaagt 2160 cttttggaacaggaaaatcattcaccactcacagggtcaaatatgaaatacaaaaccacg 2220 aaccaatcaacagaatttttatccttccaagatgccagctcattgtacagaaacatttta 2280 gaaaaagaaagggaacttcagcaactgggaatcacagaatacctaaggaaaaacattgct 2340 cagctccagcctgatatggaggcacattatcctggagcccacgaagagctgaagttaatg 2400 gaaacattaatgtactcacgtccaaggaaggtattagtggaacagacaaaaaatgagtat 2460 tttgaacttaaagctaatttacatgctgaacctgactatttagaagtcctggagcagcaa 2520 acatag 2526 <210> 11 <211> 726 <212> DNA
<213> Homo Sapiens <400>

atgggaaaccctggcctggcctggctggtgctgctgggcttggtgctgcttctgagctct60 ttcatggagagaggaggccacagtcccagccctgctgccctgtcggccatggaaaaccta120 atcacctatgctgtccagaagggccacctgtcatccagttatgttcagccacttcttgtg180 aaaggcgagaactgcctggcccctcggcagaagacaagcctgaagaaggcttgccccggc240 gttgtcccacggtctgtgtggggagccagggagacccactgtcccaggatgactctccca300 gcgaagtatggcatcattatccacactgccgggaggacctgcaacatttctgatgagtgc360 cgcctgctggtccgggacatccagtctttctacatagacaggctcaagtcatgcgacatt420 ggttataacttcctggtgggccaggatggcgccatttatgaaggggtgggctggaatgtc480 caaggctcctccacccctggctacgatgacattgccctgggcattaccttcatgggcacc540 ttcacaggtataccacccaatgctgcagcactagaggcagcccaagacctgatccagtgt600 gccatggtcaaagggtacctgactcccaactacctgctggtgggccacagtgatgtggcc660 cgaaccttgtctcctgggcaggctttgtacaacatcatcagcacctggcctcatttcaaa720 cactga 726 <210> 12 <211> 1110 <212> DNA
<213> Homo Sapiens <400> 12 atgctgccgtggcttcttgtcttctctgctctgggtctccaggcctggggtgattcctcc60 tggaacaaaacacaagctaaacaggtatcagaggggctccagtacctatttgagaacatc120 tcccagctcactgaaaaagatgtctccaccacggtctctcgcaaggcatggggggcagaa180 gctgttggctgcagtattcagctgaccacgccagtgaatgtccttgttatacaccatgtc240 cctggactggagtgtvacgaccggacagtctgcagccagagactgcgggaactgcaggcc300 catcatgtccacaacaacagtgggtgtgatgtggcctacaacttcctggttggggatgat360 ggcagggtgtatgaaggtgttggctggaatatccaaggagtgcacacccaaggctacaac420 aacatctccctgggctttgccttcttcggcactaagaaaggccacagtcccagccctgct480 gccctgtcggccatggaaaacctaatcacctatgctgtccagaagggccacctgtcatcc540 agttatgttcagccacttcttgtgaaaggcgagaactgcctggcccctcggcagaagaca600 agcctgaagaaggcttgccccggcgttgtcccacggtctgtgtggggagccagggagacc660 cactgtcccaggatgactctcccagcgaagtatggcatcattatccacactgccgggagg720 acctgcaacatttctgatgagtgccgcctgctggtccgggacatccagtctttctacata780 gacaggctcaagtcatgcgacattggttataacttcctggtgggccaggatggcgccatt840 tatgaaggggtgggctggaatgtccaaggctcctccacccctggctacgatgacattgcc900 ctgggcattaccttcatgggcaccttcacaggtataccacccaatgctgcagcactagag960 gcagcccaagacctgatccagtgtgccatggtcaaagggtacctgactcccaactacctg1020 ctggtgggccacagtgatgtggcccgaaccttgtctcctgggcaggctttgtacaacatc1080 atcagcacctggcctcatttcaaacactga 1110 <210> 13 <211> 1149 <212> DNA
<213> Homo Sapiens <400> 13 atggccccgc gcgcgggaca gccggggctc caggggctgc tgctcgtggc ggcggcgctg 60 agccagcccg cggcaccctg ccccttccag tgctactgct tcggcggccc caagctgctg 120 ctgcgctgcg cgtcgggagc cgagctccgc cagcctccgc gggacgtgcc gcccgacgcg 180 cgcaacctca ccatcgtagg cgccaacctg acggtgctgc gcgcggccgc cttcgccggc 240 ggggacgggg acggcgacca ggcggcgggc gtgcgcctgc cgctcctgag cgcgctgcgc 300 ctcacgcaca accacatcga ggtggtggag gacggcgcct tcgacgggct gcccagcctg 360 gcggcgctcgacctcagccacaacccgctgcgcgccctgggcggcggcgccttccgcggg420 ctgcccgcgctgcgctcgctgcagctcaaccacgcgctggtgcgcggcggccccgcgctg480 ctggccgcgctggacgctgcgctggcaccgctggccgagcttcgcctgctgggcctagcg540 ggcaacgcgctgagccgtctgccgccagccgccctgcgcctggcgcgcctggagcagctg600 gacgtgcgcctcaacgcgctggccggcctggaccccgacgagctgcgcgcgctggagcgc660 gatggcggcctccccgggccgcgcctgctgctcgccgacaaccccctgcgctgcggctgt720 gccgcacgccccctgctggcctggctgcgcaacgccacggagcgcgtgcccgactcgcgg780 cgcctgcgctgcgccgccccgcgggcgctgctagaccggccgctactggacctggacggg840 gcgcggcttcgctgcgcggacagcggcgccgacgctcgcggagaggaggcggaggccgcc900 ggcccggagctggaagcctcctacgtgttcttcgggctggtgctggcactcatcggcctc960 atcttcctcatggtgctctacctaaaccgccgcggcatccagcgctggatgcgcaacctg1020 cgcgaggcgtgccgggaccagatggagggctaccactaccgctacgagcaggacgccgac1080 ccgcgccgcgcgcccgcgcccgccgcgcccgcgggctcccgcgccacctccccgggctcg1140 gggctctga <210> 14 <211> 558 <212> DNA
<213> Homo Sapiens <400> 14 atgatgctgctgttgctgtgtctggggttgaccctcgtctgtgcccaggaggaagaaaac60 aatgatgctgtgacaagcaacttcgatctgtcaaagatttcaggagagtggtattcggtt120 ctcttggcctctgactgcagggaaaagatagaagaagatggaagcatgagggtttttgtc180 aaacacattgattacctggggaattcttctctgacttttaaattgcatgaaatagaaaat240 ggaaactgtactgaaattaatttggcttgtaaaccaacagaaaagaatgccatatgtagt300 actgactataacggacttaatgtcattgacatacttgaaacggactatgataattatata360 tatttttataacaagaatatcaagaatggggaaacattcctaatgctggagctctatgtt420 cgaacaccggatgtgagctcacaactcaaggagaggtttgtgaaatattgtgaagaacat480 gggattgataaggaaaacatatttgacttgaccaaagttgatcgctgtctccaggcccga540 gatgagggagcagcctag 558 <210> 15 <211> 1761 <212> DNA
<213> Homo Sapiens <400> 15 atgcattacaaccttcagggtcccacgagaagaatcagaatttctttgttaaacgatgga60 ggactcaaaatagccaatgtgactaaagctgatgctggaacttacacctgcatggcagaa120 aaccagtttgggaaagcaaatggcacaacacatttggttgttacggaaccaacaagaata180 actttggcaccatctaacatggatgtttctgttggtgaaagcgtcatattgccctgccag240 gtacaacatgacccgctgttagacatcatctttacctggtatttcaatggggcccttgca300 gattttaagaaagatggatctcactttgagaaagttggtgggagttcatctggtgattta360 atgatcagaaacattcagctgaaacacagtgggaaatatgtttgtatggtgcaaacgggg420 gtggacagtgtttcatctgctgctgacctcatagtaagaggttcacctggaccaccagaa480 aatgtgaaggtagatgaaattacagacacaacagcccaactctcttggaaagaaggtaaa540 gacaaccatagcccagttatatcctattctatccaggctcggacacctttctccgtgggt600 tggcaaaccgtcacaacagtgcctgaggtcatcgatgggaagacgcacacagccactgta660 gttgagttaaacccatgggtggaatatgaatttcgggttgtagccagtaacaaaattgga720 ggtggagaaccaagtttaccctcagaaaaagtaagaactgaagaggcagttccagaagtg780 cctccttctgaagtcaatggaggaggcggaagccggtctgaacttgtgataacctgggat840 ccagtccctgaagaactacagaatggtgaaggttttgggtatgttgttgctttccgccct900 cttggggttaccacctggatccagacagtggtgacatcccctgacaccccaagatatgtc960 tttaggaatgaaagcatcgtgccatattcaccatatgaagttaaagtgggtgtttataat1020 aacaaaggtgaaggaccatttagcccagtgacaacagtgttctctgcagaagaagagcct1080 acagtggccccatctcaagtctctgcaaatagcctatcttcctcagaaattgaggtttca1140 tggaacaccattccttggaagttgagcaatggacatttactgggctatgaggtgcggtac1200 tggaatgggggtggaaaggaggaatcatccagtaagatgaaagtggcaggaaatgagaca1260 tcagccagactacggggcctgaagagcaacctggcctattacacggctgtccgggcttac1320 aacagtgccggcgctgggccttttagcgccacagttaatgtaaccaccaagaaaacgcct1380 cccagtcagccaccaggaaatgttgtttggaatgccacagacactaaagtgttacttaat1440 tgggagcaagttaaagccatggagaatgagtcagaagtaacaggatataaagttttctat1500 aggactagcagtcaaaataacgtacaagtactgaacacaaataaaacttcagctgaactt1560 gtgctgcccattaaagaggactacattattgaagtcaaggccacaacagatggaggggat1620 gggaccagtagtgaacagatcaggattccacgaataaccagtatggatgcaagaggatcc1680 acttcagccatctcgaatgtccaccctatgtcaagttatatgcctatagtactgttctta1740 attgtatatgtcctgtggtga 1761 <210> 16 <211> 3081 <212> DNA
<213> Homo sapiens <400> 16 atgctggtggtggaaagagtaatggttcttcccattgggttcccccttggtgtgagtgat60 gattccacactgcatggcccgatttttattcaagaaccaagtcctgtaatgttccctttg120 gattctgaggagaaaaaagtgaagctcaattgtgaagttaaaggaaatccaaaacctcat180 atcaggtggaagttaaatggaacagatgttgacactggtatggatttccgctacagtgtt240 gttgaagggagcttgttgatcaataaccccaataaaacccaagatgctggaacgtaccag300 tgcacagcgacaaactcgtttggaacaattgttagcagagaagcaaagcttcagtttgct360 tatcttgacaactttaaaacaagaacaagaagcactgtgtctgtccgtcgaggtcaagga420 atggtgctactgtgtggcccgccaccccattctggagagctgagttatgcctggatcttc480 aatgaatacccttcctatcaggataatcgccgctttgtttctcaagagactgggaatctg540 tatattgccaaagtagaaaaatcagatgttgggaattatacctgtgtggttaccaatacc600 gtgacaaaccacaaggtcctggggccacctacaccactaatattgagaaatgatggagtg660 atgggtgaatatgagcccaaaatagaagtgcagttcccagaaacagttccgactgcaaaa720 ggagcaacggtgaagctggaatgctttgctttaggaaatccagtaccaactattatctgg780 cgaagagctgatggaaagccaatagcaaggaaagccagaagacacaagtcaaatggaatt840 cttgagatccctaattttcagcaggaggatgctggtttatatgaatgtgtagctgaaaat900 tccagagggaaaaatgtagcaaggggacagctaactttctatgctcaacctaattggatt960 caaaaaataaatgatattcacgtggccatggaagaaaatgtcttttgggaatgtaaagca1020 aatggaaggcctaagcctacatacaagtggctaaaaaatggcgaacctctgctaactcgg1080 gatagaattcaaattgagcaaggaacactcaacataacaatagtgaacctctcagatgct1140 ggcatgtatcagtgtttggcagagaataaacatggagttatcttttccaacgcagagctt1200 agtgttatagctgtaggtccagatttttcaagaacactcttgaaaagagtaactcttgtc1260 aaagtgggaggtgaagttgtcattgagtgtaagccaaaagcgtctccaaaacctgtttac1320 acctggaagaaaggaagggatatattaaaagaaaatgaaagaattaccatttctgaagat1380 ggaaacctcagaatcatcaacgttactaaatcagacgctgggagttatacctgtatagcc1440 actaaccattttggaactgctagcagtactggaaacttggtagtgaaagatccaacaagg1500 gtaatggtacccccttccagtatggatgtcactgttggagagagtattgttttaccgtgc1560 caggtaacgcatgatcactcgctagacatcgtgtttacttggtcatttaatggacacctg1620 atagactttgacagagatggggaccactttgaaagagttggaggggattcagctggtgat1680 ttgatgatccgaaacatccaactgaagcatgctgggaaatatgtctgcatggtccaaaca1740 agtgtggacaggctatctgctgctgcagacctgattgtaagaggtcctccaggtccccca1800 gaggctgtgacaatagacgaaatcacagataccactgctcagctctcctggagacccggg1860 cctgacaaccacagccccatcaccatgtatgtcattcaagccaggactccattctccgtg1920 ggctggcaagcagtcagtacagtcccagaactcattgatgggaagacattcacagcgacc1980 gtggtgggtttgaacccttgggttgaatatgaattccgcacagttgcagccaacgtgatt2040 gggattggggagcccagccgcccctcagagaaacggagaacagaagaagctctccccgaa2100 gtcacaccagcgaatgtcagtggtggcggaggcagcaaatctgaactggttataacctgg2160 gagacggtccctgaggaattacagaatggtcgaggctttggttatgtggtggccttccgg2220 ccctacggtaaaatgatctggatgctgacagtgctggcctcagctgatgcctctagatac2280 gtgttcaggaatgagagcgtgcaccccttctctccctttgaggttaaagtaggtgtcttc2340 aacaacaaaggagaaggccctttcagtcccaccacggtggtgtattctgcagaagaagaa2400 cccaccaaaccaccagccagtatctttgccagaagtctttctgccacagatattgaagtt2460 ttctgggcctccccactggagaagaatagaggacgaatacaaggttatgaggttaaatat2520 tggagacatgaagacaaagaagaaaatgctagaaaaatacgaacagttggaaatcagaca2580 tcaacaaaaatcacgaacttaaaaggcagtgtgctgtatcacttagctgtcaaggcatat2640 aattctgctgggacaggcccctctagtgcaacagtcaatgtgacaacccgaaagccacca2700 ccaagtcaaccccccggaaacatcatatggaattcatcagactccaaaattatcctgaat2760 tgggatcaagtgaaggccctggataatgagtcggaagtaaaaggatacaaagtcttgtac2820 agatggaacagacaaagcagcacatctgtcattgaaacaaataaaacatcggtggagctt2880 tctttgcctttcgatgaagattatataatagaaattaagccattcagcgacggaggagat2940 ggcagcagcagtgaacaaattcgaattccaaagatatcaaatgcctacgcgagaggatct3000 ggggcttccacttcgaatgcatgtacgctgtcagccatcagtacaataatgatttccctc3060 acagctaggtccagtttatga 3081 <210> 17 <211> 2535 <212> DNA
<213> Homo sapiens <400>

atggacaacccacaggctctgccactcttcctactcctggcctccttggtagggatcctc 60 accctcagagcctcttctggacttcagcaaaccaacttctcctctgccttctcttcagac 120 tcaaagagctcttcccaggggctgggtgtggaagttccctccatcaaacctcccagctgg 180 aaagttccagatcagttcctggattcaaaagcctctgctggaatctctgattccagctgg 240 tttcctgaggccctgagttccaacatgtctgggtccttctggtcaaatgtttctgctgag 300 ggccaagatttgagcccggtttcccccttctctgaaacccctggttctgaagtatttcct 360 gatatttcggatcctcaagttcctgccaaagaccccaagccttccttcactgttaagacc 420 ccagcttcaaacatttctactcaagtctcccataccaaactgtctgttgaggccccagat 480 tcaaaattctccccggatgatatggatcttaaactctctgcccagagccctgaatccaaa 540 ttttctgcagagacccactcagctgcaagctttccccagcaggtggggggcccactcgct 600 gtgctggtggggaccaccatccggctccccctagtcccaatccccaaccctgggcccccc 660 acctctctggtggtctggcgccggggctcaaaggtgctggcagctgggggcctggggcca 720 ggggcacctctgatcagcctggaccctgctcaccgagaccacctgcgatttgaccaggcc 780 cggggggttctggagctcgcctctgcccagctggacgatgcaggggtctacacggctgag 840 gtcatccgggcaggggtctcccagcagactcacgagttcacggtgggtgtgtatgagccc 900 ctaccccagctgtcggttcagcccaaggctccagagacagaggagggggcggccgagctc 960 cggctgcgctgcctggggtgggggccaggtcgcggggagctgagctggagccgggacgga 1020 cgcgccctggaggcggcggaatcggagggagccgagacgccccggatgcgctcagagggc 1080 gaccagctgctcatcgtgcgccctgtgcgcagcgaccacgcccggtacacttgccgcgtc 1140 cgcagccccttcggccacagggaggctgccgccgacgtcagcgtcttctacggcccggac 1200 ccgccgaccatcacggtctcctcggaccgcgacgccgcgcctgcccgctttgtcaccgcg 1260 ggcagtaacgtgaccttgcgctgcgccgccgcctcgcggccgcccgccgacatcacgtgg 1320 agcctggcggacccggccgaggccgcggtgcccgcggggtcgcgcctcctgctgcccgcg 1380 gtcggaccgggccacgcaggcacctacgcctgcctggcggcgaacccgcgtaccggccgc 1440 cgccgccgctcgctgctcaaccttacagtggcggacctgccccccggggccccacagtgc 1500 tcagttgaagggggtcccggggaccgcagcctccgcttccgctgctcgtggcccggcggg 1560 gcccctgctgcctccctgcagttccagggtctccccgaaggcatccgcgccgggccagtg 1620 tcctctgtgctgctggcggccgtccccgcccacccccggctcagcggcgtccccatcacc 1680 tgccttgctcgccacctggtggccacgcgtacctgcacagtcacgccggaggccccccga 1740 gaggtgctgctgcatccgctggtggcagagacacggttgggggaggcagaggtggcactg 1800 gaggcctctggttgtcccccaccctcacgggcatcctgggcccgggaagggaggcccctg 1860 gctccaggaggcgggagtcgcctgcggctcagtcaagatgggcggaaactccacatcggc 1920 aacttcagcctggattgggacctgggaaattactccgtgctgtgcagtggggcgctgggt 1980 gctggcggtgaccagatcaccctcattgatgggcctgctctgggcaggacttccacctac 2040 agggactgggtctccctgctcatcctggggcctcaggagcggtcagccgtggtgcccctt 2100 ccacctcggaacccagggacctggacctttcggatcctgcccatcctggggggccagcca 2160 gggactccatcacaaagccgggtctaccgggccggccccacgttgagccatggggccatc 2220 gctggcatcgtcctgggctccctgctgggcctggcgctgctagccgtacttctcctcctt 2280 tgcatctgctgcctgtgccgctttcgtggaaagactcctgagaaaaagaagcatccttct 2340 accttggtccccgtggtcaccccctcagaaaagaagatgcatagtgtgaccccagtggag 2400 atttcatggcctctggacctcaaagtccctctggaggaccacagctcaactagggcctac 2460 caagccacagaccccagttcagttgtctctgtaggcggaggctcaaagactgttcgcgca 2520 gccacacaggtgtga 2535 <210> 18 <211> 2349 <212> DNA
<213> Homo Sapiens <400> 18 atggacaacccacaggctctgccactcttcctactcctggcctccttggtagggatcctc60 accctcagagcctcttctggacttcagcaaaccaacttctcctctgccttctcttcagac120 tcaaagagctcttcccaggggctgggtgtggaagttccctccatcaaacctcccagctgg180 aaagttccagatcagttcctggattcaaaagcctctgctggaatctctgattccagctgg240 tttcctgaggccctgagttccaacatgtctgggtccttctggtcaaatgtttctgctgag300 ggccaagatttgagcccggtttcccccttctctgaaacccctggttctgaagtatttcct360 gatatttcggatcctcaagttcctgccaaagaccccaagccttccttcactgttaagacc420 ccagcttcaaacatttctactcaagtctcccataccaaactgtctgttgaggccccagat480 tcaaaattctccccggatgatatggatcttaaactctctgcccagagccctgaatccaaa540 ttttctgcagagacccactcagctgcaagctttccccagcaggtggggggcccactcgct600 gtgctggtggggaccaccatccggctccccctagtcccaatccccaaccctgggcccccc660 acctctctggtggtctggcgccggggctcaaaggtgctggcagctgggggcctggggcca720 ggggcacctctgatcagcctggaccctgctcaccgagaccacctgcgatttgaccaggcc780 cggggggttctggagctcgcctctgcccagctggacgatgcaggggtctacacggctgag840 gtcatccgggcaggggtctcccagcagactcacgagttcacggtgggtgtgtatgagccc900 ctaccccagctgtcggttcagcccaaggctccagagacagaggagggggcggccgagctc960 cggctgcgctgcctggggtgggggccaggtcgcggggagctgagctggagccgggacgga1020 cgcgccctggaggcggcggaatcggagggagccgagacgccccggatgcgctcagagggc1080 gaccagctgctcatcgtgcgccctgtgcgcagcgaccacgcccggtacacttgccgcgtc1140 cgcagccccttcggccacagggaggctgccgccgacgtcagcgtcttctacggcccggac1200 ccgccgaccatcacggtctcctcggaccgcgacgccgcgcctgcccgctttgtcaccgcg1260 ggcagtaacgtgaccttgcgctgcgccgccgcctcgcggccgcccgccgacatcacgtgg1320 agcctggcggacccggccgaggccgcggtgcccgcggggtcgcgcctcctgctgcccgcg1380 gtcggaccgggccacgcaggcacctacgcctgcctggcggcgaacccgcgtaccggccgc1440 cgccgccgctcgctgctcaaccttacagtggcggacctgccccccggggccccacagtgc1500 tcagttgaagggggtcccggggaccgcagcctccgcttccgctgctcgtggcccggcggg1560 gcccctgctgcctccctgcagttccagggtctccccgaaggcatccgcgccgggccagtg1620 tcctctgtgctgctggcggccgtccccgcccacccccggctcagcggcgtccccatcacc1680 tgccttgctcgccacctggtggccacgcgtacctgcacagtcacgccggaggccccccga1740 gaggtgctgctgcatccgctggtggcagagacacggttgggggaggcagaggtggcactg1800 gaggcctctggttgtcccccaccctcacgggcatcctgggcccgggaagggaggcccctg1860 gctccaggaggcgggagtcgcctgcggctcagtcaagatgggcggaaactccacatcggc1920 aacttcagcctggattgggacctgggaaattactccgtgctgtgcagtggggcgctgggt1980 gctggcggtgaccagatcaccctcattggccccacgttgagccatggggccatcgctggc2040 atcgtcctgggctccctgctgggcctggcgctgctagccgtacttctcctcctttgcatc2100 tgctgcctgtgccgctttcgtggaaagactcctgagaaaaagaagcatccttctaccttg2160 gtccccgtggtcaccccctcagaaaagaagatgcatagtgtgaccccagtggagatttca2220 tggcctctggacctcaaagtccctctggaggaccacagctcaactagggcctaccaagcc2280 acagaccccagttcagttgtctctgtaggcggaggctcaaagactgttcgcgcagccaca2340 caggtgtga 2349 <210> 19 <211> 789 <212> DNA
<213> Homo sapiens <400> 19 atggactctcttgttacagcaaacaccaaattttgctttgatctttttcaagagataggc60 aaagatgatcgtcataaaaacatatttttctctcccctgagcctctcagctgcccttggt120 atggtacgcttgggtgctagaagtgacagtgcacatcagattgatgaggctgggtcctta180 aacaatgagagcggactggtcagctgctactttgggcagcttctctccaaattagacagg240 atcaagactgattacacactgagtattgccaacaggctttatggagagcaggaattccca300 tgcatctgctgcctgtgccgctttcgtggaaagactcctgagaaaaagaagcatccttct 2340 atctgtcaggaatacttagatggtgtgattcaattttaccacacgacgattgaaagtgtt 360 gatttccaaaaaaaccctgaaaaatccagacaagagattaacttctgggttgaatgtcaa 420 tcccaaggtaaaatcaaggaactcttcagcaaggacgctattaatgctgagactgtgctg 480 gtactggtgaatgctgtttacttcaaggccaaatgggaaacatactttgaccatgaaaac 540 acggtggatgcacctttctgtctaaatgcgaatgaaaacaagagtgtgaagatgatgacg 600 caaaaaggcctctacagaattggcttcatagaggaggtgaaggcacagatcctggaaatg 660 aggtacaccaaggggaagctcagcatgttcgtgctgctgccatctcactctaaagataac 720 ctgaagggtctggaagaggtaaatcttcatttccacatctctacaaaatatttaatgata 780 gatctttag <210> 20 <211> 1185 <212> DNA
<213> Homo sapiens <400> 20 atggactctcttgttacagcaaacaccaaattttgctttgatctttttcaagagataggc60 aaagatgatcgtcataaaaacatatttttctctcccctgagcctctcagctgcccttggt120 atggtacgcttgggtgctagaagtgacagtgcacatcagattgatgaggtactacacttc180 aacaaaacgacagagcctctggatcagcaggctgggtccttaaacaatgagagcggactg240 gtcagctgctactttgggcagcttctctccaaattagacaggatcaagactgattacaca300 ctgagtattgccaacaggctttatggagagcaggaattcccaatctgtcaggaatactta360 gatggtgtgattcaattttaccacacgacgattgaaagtgttgatttccaaaaaaaccct420 gaaaaatccagacaagagattaacttctgggttgaatgtcaatcccaaggtaaaatcaag480 gaactcttcagcaaggacgctattaatgctgagactgtgctggtactggtgaatgctgtt540 tacttcaaggccaaatgggaaacatactttgaccatgaaaacacggtggatgcacctttc600 tgtctaaatgcgaatgaaaacaagagtgtgaagatgatgacgcaaaaaggcctctacaga660 attggcttcatagaggaggtgaaggcacagatcctggaaatgaggtacaccaaggggaag720 ctcagcatgttcgtgctgctgccatctcactctaaagataacctgaagggtctggaagag780 cttgaaaggaaaatcacctatgaaaaaatggtggcctggagcagctcagaaaacatgtca840 gaagaatcggtggtcctgtccttcccccggttcaccctggaagacagctatgatctcaat900 tccattttacaagacatgggcattacggatatctttgatgaaacgagggctgatcttact960 ggaatctctccaagtcccaatttgtacttgtcaaaaattatccacaaaacctttgtggag1020 gtggatgaaaacggtacccaggcagctgcagccactggggctgttgtctcggaaaggtca1080 ctacgatcttgggtggagtttaatgccaaccacccttttctctttttcattagacacaac1140 aaaacccaaaccattctcttttatggcagggtctgctctccttaa 1185 <210> 21 <211> 1416 <212> DNA
<213> Homo sapiens <400> 21 atgtcggtgccgctgctcaagatcggggtcgtgctgagcaccatggccatgatcactaac60 tggatgtcccagacgctgccctcgctggtgggcctcaacaccaccaagctctcggcggcc120 ggcggcgggacgctggaccgcagcaccggcgtgctgcccaccaaccctgaggagagctgg180 caggtgtacagctctgcccaggacagcgagggcaggtgtatctgcacagtggtcgctcca240 cagcagaccatgtgttcacgggatgcccgcacaaaacagctgaggcagctactggagaag300 gtgcagaacatgtctcaatccatagaggtcttggacaggcggacccagagagacttgcag360 tacgtggagaagatggagaaccaaatgaaaggactggagtccaagttcaaacaggcgata420 aaagcgaaaatggatgaacttaggcctttgatacctgtgttggaagagtacaaggccgat480 gccaaattggtattgcagtttaaagaggaggtccagaatctgacgtcagtgcttaacgag540 ctgcaagaggaaattggcgcctatgactacgatgaacttcagagcagagtgtccaatctt600 gaagaaaggctccgtgcatgcatgcaaaaactagcttgcgggaagttgacgggcatcagt660 gaccccgtgactgtcaagacctccggctcgaggttcggatcctggatgacagaccctctc720 gcccctgaaggcgataaccgggtgtggtacatggacggctatcacaacaaccgcttcgta780 cgtgagtacaagtccatggttgacttcatgaacacggacaatttcacctcccaccgtctc840 ccccacccctggtcgggcacggggcaggtggtctacaacggttctatctacttcaacaag900 ttccagagccacatcatcatcaggtttgacctgaagacagagaccatcctcaagacccgc960 agcctggactatgccggttacaacaacatgtaccactacgcctggggtggccactcggac1020 atcgacctcatggtggacgagagcgggctgtgggccgtgtacgccaccaaccagaacgct1080 ggcaacatcgtggtcagtaggctggaccccgtgtccctgcagaccctgcagacctggaac1140 acgagctaccccaagcgcagcgccggggaggccttcatcatctgcggcacgctgtacgtc1200 accaacggctactcagggggtaccaaggtccactatgcataccagaccaatgcctccacc1260 tatgaatacatcgacatcccattccagaacaaatactcccacatctccatgctggactac1320 aaccccaaggaccgggccctgtatgcctggaacaacggccaccagatcctctacaacgtg1380 accctcttccacgtcatccgctccgacgagttgtag 1416 <210> 22 <211> 1458 <212> DNA
<213> Homo Sapiens <400> 22 atgtcggtgccgctgctcaagatcggggtcgtgctgagcaccatggccatgatcactaac 60 tggatgtcocagacgctgccctcgctggtgggcctcaacaccaccaagctctcggcggcc 120 ggcggcgggacgctggaccgcagcaccggcgtgctgcccaccaaccctgaggagagctgg 180 caggtgtacagctctgcccaggacagcgagggcaggtgtatctgcacagtggtcgctcca 240 cagcagaccatgtgttcacgggatgcccgcacaaaacagctgaggcagctactggagaag 300 gtgcagaacatgtctcaatccatagaggtcttggacaggcggacccagagagacttgcag 360 tacgtggagaagatggagaaccaaatgaaaggactggagtccaagttcaaacaggtggag 420 gagattataagctacacctggcccaggcagtttaaggcgataaaagcgaaaatggatgaa 480 Cttaggcctttgatacctgtgttggaagagtacaaggccgatgccaaattggtattgcag 540 tttaaagaggaggtccagaatctgacgtcagtgcttaacgagctgcaagaggaaattggc 600 gcctatgactacgatgaacttcagagcagagtgtccaatcttgaagaaaggctccgtgca 660 tgcatgcaaaaactagcttgcgggaagttgacgggcatcagtgaccccgtgactgtcaag 720 acctccggctcgaggttcggatcctggatgacagaccctctcgcccctgaaggcgataac 780 cgggtgtggtacatggacggctatcacaacaaccgcttcgtacgtgagtacaagtccatg 840 gttgacttcatgaacacggacaatttcacctcccaccgtctCCCCCaCCCCtggtCgggC 900 acggggcaggtggtctacaacggttctatctacttcaacaagttccagagccacatcatc 960 atcaggtttgacctgaagacagagaccatcctcaagacccgcagcctggactatgccggt 1020 tacaacaacatgtaccactacgcctggggtggccactcggacatcgacctcatggtggac 1080 gagagcgggctgtgggccgtgtacgccaccaaccagaacgctggcaacatcgtggtcagt 1140 aggctggaccccgtgtccctgcagaccctgcagacctggaacacgagctaccccaagcgc 1200 agcgccggggaggccttcatcatctgcggcacgctgtacgtcaccaacggctactcaggg 1260 ggtaccaaggtccactatgcataccagaccaatgcctccacctatgaatacatcgacatc 1320 ccattccagaacaaatactcccacatctccatgctggactacaaccccaaggaccgggcc 1380 ctgtatgcctggaacaacggccaccagatcctctacaacgtgaccctcttccacgtcatc 1440 cgctccgacgagttgtag 1458 <210> 23 <211> 861 <212> DNA
<213> Homo Sapiens <400>

atgctgcatctgctggcgctcttcctgcactgcctccctctggcctctggggactatgac 60 atctgcaaatcctgggtgaccacagatgagggccccacctgggagttctacgcctgccag 120 cccaaggtgatgcgcctgaaggactacgtcaaggtgaaggtggagccctcaggcatcaca 180 tgtggagacccccctgagaggttctgctcccatgagaatccctacctatgcagcaacgag 240 tgtgacgcctccaacccggacctggcccacccgcccaggctcatgttcgacaaggaggag 300 gagggcctggccacctactggcagagcatcacctggagccgctaccccagcccgctggaa 360 gccaacatcaccctttcgtggaacaagaccgtggagctgaccgacgacgtggtgatgacc 420 ttcgagtacggccggcccacggtcatggtcctggagaagtccctggacaacgggcgcacc 480 tggcagccctaccagttctacgccgaggactgcatggaggccttcggtatgtccgcccgc 540 cgggcccgcgacatgtcatcctccagcgcgcaccgcgtgctctgcaccgaggagtactcg 600 cgctgggcaggctccaagaaggagaagcacgtgcgcttcgaggtgcgggaccgcttcgcc 660 atctttgccggccccgacctgcgcaacatggacaacctctacacgcggctggagagcgcc 720 aagggcctca aggagttctt caccctcacc gacctgcgca tgcggctgct gcgcccggcg 780 ctgggcggca cctatgtgca gcgggagaac ctctacaagt acttctacgc catctccaac 840 atcgaggtca tcggcaggta a 861 <210> 24 <211> 1602 <212> DNA
<213> Homo Sapiens <400>

atgctgcatctgctggcgctcttcctgcactgcctccctctggcctctggggactatgac60 atctgcaaatcctgggtgaccacagatgagggccccacctgggagttctacgcctgccag120 cccaaggtgatgcgcctgaaggactacgtcaaggtgaaggtggagccctcaggcatcaca180 tgtggagacccccctgagaggttctgctcccatgagaatccctacctatgcagcaacgag240 tgtgacgcctccaacccggacctggcccacccgcccaggctcatgttcgacaaggaggag300 gagggcctggccacctactggcagagcatcacctggagccgctaccccagcccgctggaa360 gccaacatcaccctttcgtggaacaagaccgtggagctgaccgacgacgtggtgatgacc420 ttcgagtacggccggcccacggtcatggtcctggagaagtccctggacaacgggcgcacc480 tggcagccctaccagttctacgccgaggactgcatggaggccttcggtatgtccgcccgc540 cgggcccgcgacatgtcatcctccagcgcgcaccgcgtgctctgcaccgaggagtactcg600 cgctgggcaggctccaagaaggagaagcacgtgcgcttcgaggtgcgggaccgcttcgcc660 atctttgccggccccgacctgcgcaacatggacaacctctacacgcggctggagagcgcc720 aagggcctcaaggagttcttcaccctcaccgacctgcgcatgcggctgctgcgcccggcg780 ctgggcggcacctatgtgcagcgggagaacctctacaagtacttctacgccatctccaac840 atcgaggtcatcggcaggtgcaagtgcaacctgcacgccaacctgtgctccatgcgcgag900 ggcagcctgcagtgcgagtgcgagcacaacaccaccggccccgactgcggcaagtgcaag960 aagaatttccgcacccggtcctggcgggccggctcctacctgccgctgccccatggctct1020 cccaacgcctgtacgcctccctccccaagggagctgggagcagactgcgaatgctacggt1080 cactccaaccgctgcagctacattgacttcctgaatgtggtgacctgcgtcagctgcaag1140 cacaacacgcgaggtcagcactgccagcactgccggctgggctactaccgcaacggctcg1200 gcagagctggatgatgagaacgtctgcattgagtgtaactgcaaccagataggctccgtg1260 cacgaccggtgcaacgagaccggcttctgcgagtgccgcgagggcgcggcgggccccaag1320 tgcgacgactgcctccccacgcactactggcgccagggctgctaccccaacgtgtgcgac1380 gacgaccagctgctgtgccagaacggaggcacctgcctgcagaaccagcgctgcgcctgc1440 ccgcgcggctacaccggcgtgcgctgcgagcagccccgctgcgaccccgccgacgatgac1500 ggcggtctggactgcgaccgcgcgcccggggccgccccgcgccccgccaccctgctcggc1560 tgcctgctgctgctggggctggccgcccgcctgggccgctga 1602 <210> 25 <211> 1488 <212> DNA
<213> Homo sapiens <400> 25 atgtttgcgaacagtccagggtgctccaacatgcttcattatgtttactgtgcctgtggc 60 catggtttgcagctggtgagaagtgtgtcaagctctgtggatgaaggaggcacatgccat 120 tgtatggttcacctacccaacaaccccatccccctggagcagctggaacagctacaaagt 180 acagctcaggagctcatttgcaagtatgagcagaagctgtctagatgtgcacgcgccatt 240 gaagataaagacaatgaggttctggaaatgagtcacatgctgaagtcctggaatcccagt 300 gcccttgcttctccctatgagaacccaggcttcaacctgctgtgcctggagctggaggga 360 gcacaggagttggtgactcaacttaaagccatgggaggtgttagtgtggctggggacctc 420 ctccaccaacttcagagccaggtgactaacgccagtctcacactcaaacttttggctgac 480 tctgaccagtgcagctttggtgctctccagcaggaggtggatgtccttgagagtcaacta 540 agtgaatgtgagagagaaaaggagaaagaaggcctttggacaccctggaccacccctccc 600 cccgcttcttgtgcccatggaggcctccaggaagttagcaaatcccttgtggtgcagctc 660 actcggagaggcttctcatataaggcaggtccctggggccgagactcagcacccaatcca 720 gcctcttccctttactgggttgctcctctacgtacagatggcaggtactttgactactat 780 cggctgcccccatcctataatgacctcgcactgatgaaaaactatgaagagaggaagatg 840 ggctatggtgatggcagtggaaacgttgtgtacaagaactttatgtactttaactactgt 900 ggcacaagtgacatggccaaaatggacctttcctccaacacactggtgctgtggcgtctg960 ctgcctggtgccacctataacaaccgcttttcctgtgctggtgtgccctggaaggactta1020 gattttgctggtgatgagaaggggctgtgggttctgtatgccactgaggagagcaagggc1080 aacctggttgtgagtcgtctcaacgctagcaccctagaagtggagaaaacctggcgtacc1140 agccagtacaagccagccctgtcaggggccttcatggcctgtggggtgctctatgcctta1200 cactcactgaacacccaccaagaggagatcttctatgcttttgacaccaccaccgggcag1260 gagcgccgcctcagcatcctgttggacaagatgctggaaaagctgcagggcatcaactac1320 tgcccctcagaccacaagccgtatgtcttcagtgatggttacctgataaattatgacctc1380 accttcctgacaatgaagaccaggctaccaagaccacccaccaggaggccctctggggct1440 catgctccaccaaaacctgtcaaacctaacgaggcttccagaccctga 1488 <210> 26 <211> 1053 <212> DNA
<213> Homo Sapiens <400> 26 atgagaaatcataagaaggtgactaacgccagtctcacactcaaacttttggctgactct 60 gaccagtgcagctttggtgctctccagcaggaggtggatgtccttgagagtcaactaagt 120 gaatcttcttgtgcccatggaggcctccaggaagttagcaaatcccttgtggtgcagctc 180 actcggagaggcttctcatataaggcaggtccctggggccgagactcagcacccaatcca 240 gcctcttccctttactgggttgctcctctacgtacagatggcagttatggctgtcaccca 300 ataattctgaatgcagggacttggcctaggtactttgactactatcggctgtgcaaatcc 360 tataatgacctcgcactgctgaaaaactatgaagagaggaagatgggctatggtgatggc 420 agtggaaacgttgtgtacaagaactttatgtactttaactactgtggcacaagtgacatg 480 gccaaaatggacctttcctccaacacactggtgctgtggcgtctgctgcctggtgccacc 540 tataacaaccgcttttcctgtgctggtgtgccctggaaggacttagattttgctggtgat 600 gagaaggggctgtgggttctgtatgccactgaggagagcaagggcaacctggttgtgagt 660 cgtctcaacgctagcaccctagaagtggagaaaacctggcgtaccagccagtacaagcca 720 gccctgtcaggggccttcatggcctgtggggtgctctatgccttacactcactgaacacc 780 caccaagaggagatcttctatgcttttgacaccaccaccgggcaggagcgccgcctcagc 840 atcctgttggacaagatgctggaaaagctgcagggcatcaactactgcccctcagaccac 900 aagccgtatgtcttcagtgatggttacctgataaattatgacctcaccttcctgacaatg 960 aagaccaggctaccaagaccacccaccaggaggccctctggggctcatgctccaccaaaa 1020 ~

cctgtcaaacctaacgaggcttccagaccctga 1053 <210> 27 <211> 1860 <212> DNA
<213> Homo Sapiens <400> 27 atgggccgtggtcgagcccttcttcccattgagatgctgcaactgtccttacgggaagaa 60 agtgacacggcaaggatgggggcccaggagcagattggtctgcaggatgagatacaagct 120 gcaaatgcaggaattagtgggtccccaggagtggacggggtagtggacggtggatcttcc 180 aggggtgacccggccctgacagtgtctgtgtgtgaagttcctcctgtgaggtcaccgttc 240 agaacccacccccaacttcctgtgcggcttcctcgaaatcttgagttctcagttcctgag 300 agaagaaccctgaggaacagacttacctcagcaaccctggcacctccaacccgacacatg 360 ctactgctgctgctactgctgccacccctgctctgtgggagagtgggggctaaggaacag 420 aaggattacctgctgacaatgcagaagtccgtgacggtgcaggagggcctgtgtgtctct 480 gtgctttgctccttctcctacccccaaaatggctggactgcctccgatccagttcatggc 540 tactggttccgggcaggggaccatgtaagccggaacattccagtggccacaaacaaccca 600 gctcgagcagtgcaggaggagactcgggaccgattccacctccttggggacccacagaac 660 aaggattgtaccctgagcatcagagacaccagagagagtgatgcagggacatacgtcttt 720 tgtgtagagagaggaaatatgaaatggaattataaatatgaccagctctctgtgaatgtg 780 acagccctgactcacatgcccaccttctccatcccggggaccctggagtctggccacccc 840 aggaacctgacctgctctgtgccctgggcctgtgaacaggggacgccccccacgatcacc 900 tggatgggggCCtCCgtgtCCtCCCtggaCCCCaCtatCaCtCgCtCCtCgatgctcagc 960 ctcatcccacagccccaggaccatggcaccagcctcacctgtcaggtgaccttgcctggg 1020 gccggcgtgaccatgaccagggctgtccgactcaacatatcctatcctcctcagaacttg 1080 accatgactgtcttccaaggagatggcacagcatccacaaccttgaggaatggctcggcc 1140 ctttcagtcctggagggccagtccctgcaccttgtctgtgctgtcgacagcaatccccct 1200 gccaggctgagctggacctgggggagcctgaccctgagcccctcacagtcctcgaacctt 1260 ggggtgctggagctgcctcgagtgcatgtgaaggatgaaggggaattcacctgccgagct 1320 cagaaccctctaggctcccagcacatttccctgagcctctccctgcaaaacgagtacaca 1380 ggcaaaatgaggcctatatcaggagtgacgctaggggcattcgggggagctggagccaca 1440 gccctggtcttcctgtacttctgcatcatcttcgttgtagtgaggtcctgcaggaagaaa 1500 tcggcaaggccagcagtgggcgtgggggatacaggcatggaggacgcaaacgctgtcagg 1560 ggctcagcctctcagatggaggaaggaactcctgggcctccttcctggatgctctctggt 1620 gcatgctggccccactgctctgcactgactcccttctcttcctccattcagggacccctg 1680 attgaatccccggcagatgacagccccccacaccatgctccgccagccctggccaccccc 1740 tccccagaggaaggagagatccagtatgcatccctcagcttccacaaagcgaggcctcag 1800 tacccacaggaacaggaggccatcggctatgagtactccgagatcaacatccccaagtga 1860 <210> 28 <211> 1473 <212> DNA
<213> Homo Sapiens <400>

atgctactgctgctgctactgctgccacccctgctctgtgggagagtgggggctaaggaa 60 cagaaggattacctgctgacaatgcagaagtccgtgacggtgcaggagggcctgtgtgtc 120 tctgtgctttgctccttctcctacccccaaaatggctggactgcctccgatccagttcat 180 ggctactggttccgggcaggggaccatgtaagccggaacattccagtggccacaaacaac 240 ccagctcgagcagtgcaggaggagactcgggaccgattccacctccttggggacccacag 300 aacaaggattgtaccctgagcatcagagacaccagagagagtgatgcagggacatacgtc 360 ttttgtgtagagagaggaaatatgaaatggaattataaatatgaccagctctctgtgaat 420 gtgacagccctgactcacatgcccaccttctccatcccggggaccctggagtctggccac 480 cccaggaacctgacctgctctgtgccctgggcctgtgaacaggggacgccccccacgatc 540 acctggatgggggcctccgtgtcctccctggaccccactatcactcgctcctcgatgctc 600 agcctcatcccacagccccaggaccatggcaccagcctcacctgtcaggtgaccttgcct 660 ggggccggcgtgaccatgaccagggctgtccgactcaacatatcctatcctcctcagaac 720 ttgaccatgactgtcttccaaggagatggcacagcatccacaaccttgaggaatggctcg 780 gccctttcagtcctggagggccagtccctgcaccttgtctgtgctgtcgacagcaatccc 840 cctgccaggctgagctggacctgggggagcctgaccctgagcccctcacagtcctcgaac 900 cttggggtgctggagctgcctcgagtgcatgtgaaggatgaaggggaattcacctgccga 960 gctcagaaccctctaggctcccagcacatttccctgagcctctccctgcaaaacgagtac 1020 acaggcaaaatgaggcctatatcaggagtgacgctaggggcattcgggggagctggagcc 1080 acagccctggtcttcctgtacttctgcatcatcttcgttgtagtgaggtcctgcaggaag 1140 aaatcggcaaggccagcagtgggcgtgggggatacaggcatggaggacgcaaacgctgtc 1200 aggggctcagcctctcagggacccctgactgaatcctggaaagatggcaaccccctgaag 1260 aagcctcccccagctgttgccccctcgtcaggggaggaaggagagctccattatgcaacc 2320 ctcagcttccataaagtgaagcctcaggacccgcagggacaggaggccactgacagtgaa 1380 tactcggagatcaagatccacaagcgagaaactgcagagactcaggcctgtttgaggaat 1440 cacaacccctccagcaaagaagtcagaggctga 1473 <210> 29 <211> 1389 <212> DNA
<213> Homo Sapiens <400> 29 atgctgccactttggactctttcactgctgctgggagcagtagcaggaaaagaagtttgc 60 tacgaaagactcggctgcttcagtgatgactccccatggtcaggaattacggaaagaccc 120 ctccatatattgccttggtctccaaaagatgtcaacacccgcttcctcctatatactaat 180 gagaacccaaacaactttcaagagatcagtgcggttaattcttcaactatccaagcctca 240 tattttggaacagacaagatcacccgtatcaacatagctggatggaaaacagatggcaaa 300 tggcagagagacatgtgcaatgtgttgctacagctggaagatataaattgcattaattta 360 gattggatcaacggttcacgggaatacatccatgctgtaaacaatctccgtgttgttggt420 gctgaggtggcttattttattgatgttctcatgaaaaaatttgaatattccccttctaaa480 gtgcacttgattggccacagcttgggagcacacctggctggggaagctgggtcaaggata540 ccaggccttggaagaataactggtaagcatgccctgcagttgggccttgagtgtgcaacc600 gagggctacctgttatctgctactctggctaacaatgtcaacttcgtagatacaaatcac660 atggatgcaactcccataatcccccagtggatgaggggcacttcgggaaccagtaaccct720 cttcctgttacttcctctctgtgcttatggttggctgatcttggctcggtctcactcgta780 tgtttgtggcctgaaatggcttccttctttgactgtaaccatgcccgaagttatcaattt840 tatgctgaaagcattcttaatcctgatgcatttattgcttatccttgtagatcctacaca900 tcttttaaagcaggaaattgcttcttttgttccaaagaaggttgcccaacaatgggtcat960 tttgctgatagatttcacttcaaaaatatgaagactaatggatcacattattttttaaac1020 acagggtccctttccccatttgcccgttggaggcacaaattgtctgttaaactcagtgga1080 agcgaagtcactcaaggaactgtctttcttcgtgtaggcggggcagttaggaaaactggg1140 gagtttgccattgtcagtggaaaacttgagccaggcatgacttacacaaaattaatcgat1200 gcagatgttaacgttggaaacattacaagtgttcagttcatctggaaaaaacatttgttt1260 gaagattctcagaataagttgggagcagaaatggtgataaatacatctgggaaatatgga1320 tataaatctaccttctgtagccaagacattatgggacctaatattctccagaacctgaaa1380 ccatgctaa 1389 <210> 30 <211> 768 <212> DNA
<213> Homo Sapiens <400> 30 atggtgctgctgctggtgatcctcatcccggtgctggtgagctcggccggcacgtcggcg60 cactacgagatgctgggcacctgccgcatggtctgcgacccctacgggggcaccaaggcg120 cccagcaccgctgccacgcccgaccgcggcctcatgcagtccctgcccaccttcatccag180 ggccccaaaggcgaggccggcaggcccgggaaggcgggtccgcgcgggccccccggagag240 cccgggccacccggccccatggggcccccgggcgagaagggcgagccgggccgccaaggc300 ctgccgggcccgcccggggcgcccggcctgaacgcggccggggccatcagcgccgccacc360 tacagcacggggcccaagatcgccttctacgccggcctcaagcggcagcatgaaggctac420 gaggtgctcaagttcgacgacgtggtcaccaacctcggaaaccactacgaccccaccacc480 ggcaagttcacctgctccatcccgggcatctacttcttcacctaccacgtcctgatgcgc540 ggaggggacggcaccagcatgtgggctgatctctgcaaaaacaaccaggtgcgtgctagt600 gcaattgcccaagatgctgatcagaattacgactatgccagtaacagtgtggttcttcat660 ttggagccgggagatgaagtctatatcaaattagatggcgggaaagcccatggaggaaac720 aacaacaaatacagcacgttttctggatttattatttatgctgactga 768 <210> 31 <211> 2355 <212> DNA
<213> Homo Sapiens <400> 31 atggagggcgacggcgggaccccatgggccctggcgctgctgcgcaccttcgacgcgggc60 gagttcacgggctgggagaaggtgggctcgggcggcttcgggcaggtgtacaaggtgcgc120 catgtccactggaagacctggctggccatcaagtgctcgcccagcctgcacgtcgacgac180 agggagcgcatggagcttttggaagaagccaagaagatggagatggccaagtttcgctac240 atcctgcctgtgtatggcatctgccgcgaacctgtcggcctggtcatggagtacatggag300 acgggctccctggaaaagctgctggcttcggagccattgccatgggatctccggttccga360 atcatccacgagacggcggtgggcatgaacttcctgcactgcatggccccgccactcctg420 cacctggacctcaagcccgcgaacatcctgctggatgcccactaccacgtcaagatttct480 gattttggtctggccaagtgcaacgggctgtcccactcgcatgacctcagcatggatggc540 ctgtttggcacaatcgcctacctccctccagagcgcatcagggagaagagccggctcttc600 gacaccaagcacgatgtatacagctttgcgatcgtcatctggggcgtgctcacacagaag660 aagccgtttgcagatgagaagaacatcctgcacatcatggtgaaggtggtgaagggccac720 cgccccgagctgccgcccgtgtgcagagcccggccgcgcgcctgcagccacctgatacgc780 ctcatgcagcggtgctggcagggggatccgcgagttaggcccaccttccaagaaattact840 tctgaaaccgaggacctgtgtgaaaagcctgatgacgaagtgaaagaaactgctcatgat 900 ctggacgtgaaaagccccccggagcccaggagcgaggtggtgcctgcgaggctcaagcgg 960 gcctctgcccccaccttcgataacgactacagcctctccgagctgctctcacagctggac 1020 tctggagtttcccaggctgtcgagggccccgaggagctcagccgcagctcctctgagtcc 1080 aagctgccatcgtccggcagtgggaagaggctctcgggggtgtcctcggtggactccgcc 1140 ttctcttccagaggatcactgtcgctgtcctttgagcgggaaccttcaaccagcgatctg 1200 ggcaccacagacgtccagaagaagaagcttgtggatgccatcgtgtccggggacaccagc 1260 aaactgatgaagatcctgcagccgcaggacgtggacctggcactggacagcggtgccagc 1320 ctgctgcacctggcggtggaggccgggcaagaggagtgcgccaagtggctgctgctcaac 1380 aatgccaaccccaacctgagcaaccgtaggggctccaccccgttgcacatggccgtggag 1440 aggagggtgcggggtgtcgtggagctcctgctggcgcggaagatcagtgtcaacgccaag 1500 gatgaggaccagtggacagccctccactttgcagcccagaacggggacgagtctagcaca 1560 cggctgctgttggagaagaacgcctcggtcaacgaggtggactttgagggccggacgccc 1620 atgcacgtggcctgccagcacgggcaggagaatatcgtgcgcatcctgctgcgccgaggc 1680 gtggacgtgagcctgcagggcaaggatgcctggctgccactgcactacgctgcctggcag 1740 ggccacctgcccatcgtcaagctgctggccaagcagccgggggtgagtgtgaacgcccag 1800 acgctggatgggaggacgccattgcacctggccgcacagcgcgggcactaccgcgtggcc 1860 cgcatcctcatcgacctgtgctccgacgtcaacgtctgcagcctgctggcacagacaccc 1920 ctgcacgtggccgcggagacggggcacacgagcactgccaggctgctcctgcatcggggc 1980 gctggcaaggaggccatgacctcagacggctacaccgctctgcacctggctgcccgcaac 2040 ggacacctggccactgtcaagctgcttgtcgaggagaaggccgatgtgctggcccgggga 2100 cccctgaaccagacggcgctgcacctggctgccgcccacgggcactcggaggtggtggag 2160 gagttggtcagcgccgatgtcattgacctgttcgacgagcaggggctcagcgcgctgcac 2220 ctggccgcccagggccggcacgcacagacggtggagactctgctcaggcatggggcccac 2280 atcaacctgcagagcctcaagttccagggcggccatggccccgccgccacgctcctgcgg 2340 cgaagcaagacctag 2355 <210> 32 <211> 759 <212> DNA
<213> Homo Sapiens <400> 32 atggcagcccccgccctgctgctcctagcactgctgctgcccgtgggggcctggcccggg60 ctgcccaggaggccctgtgtgcactgctgccgcccggcctggccccctggaccctatgcc120 cgggtgagtgacagggacctgtggaggggggacctgtggagggggctgcctcgagtacgg180 cccactatagacatcgaaatcctcaaaggtgagaagggtgaggccggcgtccgaggtcgg240 gccggcaggagcgggaaagaggggccgccaggcgcccggggcctgcagggccgcagaggc300 cagaaggggcaggtggggccgccgggcgccgcgtgccgacgtgcctacgccgccttctcc360 gtgggccggcgcgagggcctgcacagctccgaccacttccaggcggtgcccttcgacacg420 gagctggtgaacctggacggcgccttcgacctggccgcgggccgcttcctctgcacggtg480 cccggcgtctacttcctcagcctcaacgtgcacacctggaactacaaggagacctacctg540 cacatcatgctgaaccggcggcccgcggccgtgctctacgcgcagcccagcgagcgcagc600 gtcatgcaggcccagagcctgatgctgctgctggcggcgggcgacgccgtctgggtgcgc660 atgttccagcgcgaccgggacaacgccatctacggcgagcacggagacctctacatcacc720 ttcagcggccacctggtcaagccggccgccgagctgtag 759 <210> 33 <211> 1782 <212> DNA
<213> Homo Sapiens <400> 33 atgcccagctcgctgttcgcagacctggagcgcaacggcagcggcggcggcggcggcggc60 agcagcggagggggagagaccctggatgaccaaagagccctgcagctcgcgctcgaccag120 ctctccctgctggggctggacagtgacgagggcgcctctctgtacgacagcgagccgcgc180 aagaagagcgtgaacatgaccgagtgcgtgccagtacccagttctgagcatgtcgccgag240 atcgtggggcggcaaggtaggtcgaggagggatggggagctggatcccagcggcatctcc300 ccagatgacttttctgggattctcgggtttggttcgggacgactgcagtcactgggggag360 ggccaggcagccaatgggctgttcctcgagcgcctcgcgggtgggatccgctgcccagcc 420 cgtggcgcggcccgaggttgtaaaatcaaagcgctgcgggcgaagaccaatacttacatc 480 aagaccccagttcgcggggaggagcctgtctttgttgtgacgggcaggaaggaggatgtg 540 gccatggctcggagggagatcatctctgctgccgagcacttctccatgatccgcgcctcc 600 cggaataagaacacggcactcaacggcgcggtgcctgggccgcccaacctgcccgggcag 660 accaccatccaagtgcgggtaccctaccgcgtggtggggctcgtggtggggcccaaaggc 720 gccacaatcaagcgcatccagcagcagacgcacacgtacatcgtgacgcccagccgggat 780 aaggagccggtgttcgaggtgaccggcatgccagagaacgtggatcgcgctcgagaggag 840 attgaggcgcacattgctctgcgtaccggcggcatcattgagctcacagacgagaacgac 900 ttccacgccaacggcaccgatgtgggcttcgatctgcatcatgggtccggcggtgcttcc 960 acagactcttatttcggcggcgggaccagcagcagcgcagcggctacccagcgcctggcg 1020 gactacagcccccctagccccgccctgagctttgcgcacaacggaaacaataacaataac 1080 ggcaatgggtacacctacacagcggggggagaagcctcagtgccatcccccgacggctgc 1140 cccgagctgcagcccacttttgacccggctcccgctcccccacctggggcaccacttatc 1200 tgggcccagttcgagcggtccccgggaggcggacctgcagctccggtatcttcttcctgc 1260 tcttcttctgcatcttcgtctgcttcttcctcctccgtggtcttccccgggggtggcgcc 1320 agtgcgccctccaacgccaacctggggctattggtgcaccgccggctgcaccctggcacc 1380 agctgcccgcgcctgtctccacccttgcacatggccccgggggcgggagagcaccacctg 1440 gctcgccgggtgcgcagcgacccgggtggaggaggcctggcctacgccgcttatgccaac 1500 gggctgggggcacagctgcctggcttgcagccgtcggacacgtcgggctcctcctcttcg 1560 tccagctcctcctccagctcttcatcctcttcctccgggcttcggcgtaaaggcagccgc 1620 gactgctccgtgtgcttcgagagcgaagtgattgccgcgctggtgccctgtggccacaac 1680 ctcttctgcatggagtgcgccaatcgcatctgtgagaagagcgagcccgagtgcccggtc 1740 tgccacaccgcggtcactcaggccatccgcatcttttcttas 1782 <210> 34 <211> 1419 <212> DNA
<213> Homo sapiens <400> 34 atgcccagctcgctgttcgcagacctggagcgcaacggcagcggcggcggcggcggcggc 60 agcagcggagggggagagaccctggatgaccaaagagccctgcagctcgcgctcgaccag 120 ctctccctgctggggctggacagtgacgagggcgcctctctgtacgacagcgagccgcgc 180 aagaagagcgtgaacatgaccgagtgcgtgccagtacccagttctgagcatgtcgccgag 240 atcgtggggcggcaaggttgtaaaatcaaagcgctgcgggcgaagaccaatacttacatc 300 aagaccccagttcgcggggaggagcctgtctttgttgtgacgggcaggaaggaggatgtg 360 gccatggctcggagggagatcatctctgctgccgagcacttctccatgatccgcgcctcc 420 cggaataagaacacggcactcaacggcgcggtgcctgggccgcccaacctgcccgggcag 480 accaccatccaagtgcgggtaccctaccgcgtggtggggctcgtggtggggcccaaaggc 540 gccacaatcaagcgcatccagcagcagacgcacacgtacatcgtgacgcccagccgggat 600 aaggagccggtgttcgaggtgaccggcatgccagagaacgtggatcgcgctcgagaggag 660 attgaggcgcacattgctctgcgtaccggcggcatcattgagctcacagacgagaacgac 720 ttccacgccaacggcaccgatgtgggcttcgatctgcatcatgggtccggcgggtccggc 780 ccaggcagcctctggagcaagCCCaCCCCCagCatCaCgCCCaCCCCCggccgcaagcct 840 ttctctagctaccgcaacgaCagctccagctcgcttggcagtgcttccacagactcttat 900 ttcggcggcgggaccagcagcagcgcagcggctacccagcgcctggcggactacagccct 960 gcgccctccaacgccaacctggggctattggtgcaccgccggctgcaccctggcaccagc 1020 tgcccgcgcctgtctccacccttgcacatggccccgggggcgggagagcaccacctggct 1080 cgccgggtgcgcagcgacccgggtggaggaggcctggcctacgccgcttatgccaacggg 1140 ctgggggcacagctgcctggcttgcagccgtcggacacgtcgggctcctcctcttcgtcc 1200 agctcctcctccagctcttcatcctcttcctccgggcttcggcgtaaaggcagccgcgac 1260 tgctccgtgtgcttcgagagcgaagtgattgccgcgctggtgccctgtggccacaacctc 1320 ttctgcatggagtgcgccaatcgcatctgtgagaagagcgagcccgagtgcccggtctgc 1380 cacaccgcggtcactcaggccatccgcatcttttcttaa 1419 <210> 35 <211> 1824 <212> DNA

<213> Homo sapiens <400> 35 atgtggggcctggtgaggctcctgctggcctggctgggtggctggggctgcatggggcgt60 ctggcagccccagcccgggcctgggcagggtcccgggaacacccagggcctgctctgctg120 cggactcgaaggagctgggtctggaaccagttctttgtcattgaggaatatgctggtcca180 gagcctgttctcattggcaagctgcactcggatgttgaccggggagagggccgcaccaag240 tacctgttgaccggggagggggcaggcaccgtatttgtgattgatgaggccacaggcaat300 attcatgttaccaagagccttgaccgggaggaaaaggcgcaatatgtgctactggcccaa360 gccgtggaccgagcctccaaccggcccctggagcccccatcagagttcatcatcaaagtg420 caagacatcaacgacaatccacccatttttccccttgggccctaccatgccaccgtgccc480 gagatgtccaatgtcgggacatcagtgatccaggtgactgctcacgatgctgatgacccc540 agctatgggaacagtgccaagctggtgtacactgttctggatggactgcctttcttctct600 gtggacccccagactggagtggtgcgtacagccatccccaacatggaccgggagacacag660 gaggagttcttggtggtgatccaggccaaggacatgggcggccacatgggggggctgtca720 ggcagcactacggtgactgtcacgctcagcgatgtcaacgacaacccccccaagttccca780 cagagcctataccagttctccgtggtggagacagctggacctggcacactggtgggccgg840 ctccgggcccaggacccagacctgggggacaacgccctgatggcatacagcatcctggat900 ggggaggggtctgaggccttcagcatcagcacagacttgcagggtcgagacgggctcctc960 actgtccgcaagcccctagactttgagagccagcgctcctactccttccgtgtcgaggcc1020 accaacacgctcattgacccagcctatctgcggcgagggcccttcaaggatgtggcctct1080 gtgcgtgtggcagtgcaagatgccccagagccacctgccttcacccaggctgcctaccac1140 ctgacagtgcctgagaacaaggccccggggaccctggtaggccagatctccgcggctgac1200 ctggactcccctgccagcccaatcagatactccatcctcccccactcagatccggagcgt1260 tgcttctctatccagcccgaggaaggcaccatccatacagcagcacccctggatcgcgag1320 gctcgcgcctggcacaacctcactgtgctggctacagagctcgtcccttatacccctgct1380 tatgcctcaggggctcctccacccttttgtcttcatactgcatatgaaaactgcccttgt1440 atatgtggatatctgaatgtgtcagtgaaggcctatatgaatgtgcacatgtgggccatg1500 gtcttagtctttgcagaacacaaaggaggagggagaggaccagggaggcaggctgttgac1560 ggacagaagcagtcaactaggtgggagctgagccagaactgcaattatctcccaaagtcc1620 agagaaggggtccacccaggaaccagcatgagagctcaggcctctcaactccagggctcc1680 agaggcacacacaggaactgcacacgcatcgcctgccacactcgtgtgaatcccatcctg1740 tatcactcacctacacctgggcacagaactacatacacctgtggacatgaatatgcaccc1800 tcttatgccgagtcaaacacctga 1824 <210> 36 <211> 2346 <212> DNA
<213> Homo sapiens <400> 36 atgtggggcctggtgaggctcctgctggcctggctgggtggctggggctgcatggggcgt 60 ctggcagccccagcccgggcctgggcagggtcccgggaacacccagggcctgctctgctg 120 cggactcgaaggagctgggtctggaaccagttctttgtcattgaggaatatgctggtcca 180 gagcctgttctcattggcaagctgcactcggatgttgaccggggagagggccgcaccaag 240 tacctgttgaccggggagggggcaggcaccgtatttgtgattgatgaggccacaggcaat 300 attcatgttaccaagagccttgaccgggaggaaaaggcgcaatatgtgctactggcccaa 360 gccgtggaccgagcctccaaccggcccctggagcccccatcagagttcatcatcaaagtg 420 caagacatcaacgacaatccacccatttttCCCCttgggCCCtaCCatgCCaCCgtgCCC 480 gagatgtccaatgtcgggacatcagtgatccaggtgactgctcacgatgctgatgacccc 540 agctatgggaacagtgccaagctggtgtacactgttctggatggactgcctttcttctct 600 gtggacccccagactggagtggtgcgtacagccatccccaacatggaccgggagacacag 660 gaggagttcttggtggtgatccaggccaaggacatgggcggccacatgggggggctgtca 720 ggcagcactacggtgactgtcacgctcagcgatgtcaacgacaacccccccaagttccca 780 cagagcctataccagttctccgtggtggagacagctggacctggcacactggtgggccgg 840 ctccgggcccaggacccagacctgggggacaacgccctgatggcatacagcatcctggat 900 ggggaggggtctgaggccttcagcatcagcacagacttgcagggtcgagacgggctcctc 960 actgtccgcaagcccctagactttgagagccagcgctcctactccttccgtgtcgaggcc 1020 accaacacgctcattgacccagcctatctgcggcgagggcccttcaaggatgtggcctct 1080 aagaagagcgtgaacatgaccgagtgcgtgccagtacccagttctgagcatgtcgccgag 240 gtgcgtgtggcagtgcaagatgccccagagccacctgccttcacccaggctgcctaccac1140 ctgacagtgcctgagaacaaggccccggggaccctggtaggccagatctccgcggctgac1200 ctggactcccctgccagcccaatcagatactccatcctcccccactcagatccggagcgt1260 tgcttctctatccagcccgaggaaggcaccatccatacagcagcacccctggatcgcgag1320 gctcgcgcctggcacaacctcactgtgctggctacagagctcgacagttctgcacaggcc1380 tcgcgcgtgcaagtggccatccagaccctggatgagaatgacaatgctccccagctggct1440 gagccctacgatacttttgtgtgtgactctgcagctcctggccagctgattcaggtcatc1500 cgggccctggacagagatgaagttggcaacagtagccatgtctcctttcaaggtcctctg1560 ggccctgatgccaactttactgtccaggacaaccgagatggctccgccagcctgctgctg1620 ccctcccgccctgctccaccccgccatgccccctacttggttcccatagaactgtgggac1680 tgggggcagccggcgctgagcagcactgccacagtgactgttagtgtgtgccgctgccag1740 cctgacggctCtgtggcatcctgctggcctgaggctcacctctcagctgctgggctcagc1800 accggcgccctgcttgccatcatcacctgtgtgggtgccctgcttgccctggtggtgctc1860 ttcgtggccctgcggcggcagaagcaagaagcactgatggtactggaggaggaggacgtc1920 cgagagaacatcatcacctacgacgacgagggcggcggcgaggaggacaccgaggccttc1980 gacatcacggccttgcagaacccggacggggcggcccccccggcgcccggccctcccgcg2040 cgccgagacgtgttgccccgggcccgggtgtcgcgccagcccagaccccccggccccgcc2100 gacgtggcgcagctcctggcgctgcggctccgcgaggcggacgaggaccccggcgtaccc2160 ccgtacgactcggtgcaggtgtacggctacgagggccgcggctcctcttgcggctccctc2220 agctccctgggctccggcagcgaagccggcggcgcccccggccccgcggagccgctggac2280 gactggggtccgctcttccgcaccctggccgagctgtatggggccaaggagcccccggcc2340 ccctga 2346 <210> 37 <211> 1923 <212> DNA
<213> Homo Sapiens <400> 37 atggccagaggccattacatttatgtggatacctcctttggcaagcagggggagaaagct60 gtgctgctaagtcctgacttacaggctgaggaatggagctgcctccgtttggtctaccag120 ataaccacatcttcggagtctctgtcagatcccagccagctgaacctctacatgagattt180 gaagatgaaagctttgatcgcttgctttggtcagctaaggaaccttcagacagctggctc240 atagccagcttggatttgcaaaacagttccaagaaattcaagattttaatagaaggtgta300 ctaggacagggaaacacagccagcatcgcactatttgaaatcaagatgacaaccggctac360 tgtattgaatgtgactttgaagaaaatcatctctgtggctttgtgaaccgctggaatccc420 aatgtgaactggtttgttggaggaggaagtattcggaatgtccactccattctcccacag480 gatcacaccttcaagagtgaactgggccactacatgtacgtggactcagtttatgtgaag540 cacttccaggaggtggcacagctcatctccccgttgaccacggcccccatggctggctgc600 ctgtcattttattaccagatccagcaggggaatgacaatgtcttttccctttacactcgg660 gatgtggctggcctttacgaggaaatctggaaagcagacaggccagggaatgctgcctgg720 aaccttgcggaggtcgagttcacatgccattttcctctgcaggttatttttgaagttgct780 ttcaatggtcccaagggaggttatgttgccctggatgatatttcattctctcctgttcac840 tgccagaatcagacagaacttctgttcagtgccgtggaagccagctgcaattttgagcaa900 gatctctgcaacttttaccaagataaagaaggtccaggttggacccgagtgaaagtaaaa960 ccaaacatgtatcgggctggagaccacactacaggcttagggtattacctgctagccaac1020 acaaagttcacatctcagcctggctacattggaaggctctatgggccctccctaccagga1080 aacttgcagtattgtctgcgttttcattatgccatctatggatttttaaaaatgagtgac1140 accctagcagtttacatctttgaagagaaccatgtggttcaagagaagatctggtctgtg1200 ttggagtccccaaggggtgtttggatgcaagctgaaatcacctttaagaagcccatgcct1260 accaaggtggttttcatgagcctatgcaaaagtttctgggactgtgggcttgtagccctg1320 gatgacattacaatacaattgggaagctgctcatcttcagagaaacttccacctccacct1380 ggagagtgtactttcgagcaagatgaatgtacatttactcaggagaaaagaaaccggagc1440 agctggcacaggaggaggggagaaactcccacttcctacacaggaccaaagggagatcac1500 actactggggtaggctactacatgtacattgaggcctcccatatggtgtatggacaaaaa1560 gcacgcctcttgtccaggcctctgcgaggagtctctggaaaacactgcttgacctttttc1620 taccacatgtatggagggggcactggcctgctgagtgtttatctgaaaaaggaagaagac1680 agtgaagagtccctcttatggaggagaagaggtgaacagagcatttcctggctacgagca1740 ctgattgaatacagctgtgagaggcaacaccagataatttttgaagccattcgaggagta1800 tcaataagaa gtgatattgc cattgatgat gttaaatttc aggcaggacc ctgtggagaa 1860 atggaagata caactcaaca atcatcagga tattctgagg acttaaatga aattgagtat 1920 taa 1923 <210> 38 <211> 2061 <212> DNA
<213> Homo sapiens <400> 38 atgctgttaaggggcgtcctcctggcgttgcaagccctgcagctcgccggtgccctcgac60 ctgcccgctgggtcctgtgcctttgaagagagcacttgcggctttgactccgtgttggcc120 tctctgccgtggattttaaatgaggaaggccattacatttatgtggatacctcctttggc180 aagcagggggagaaagctgtgctgctaagtcctgacttacaggctgaggaatggagctgc240 ctccgtttggtctaccagataaccacatcttcggagtctctgtcagatcccagccagctg300 aacctctacatgagatttgaagatgaaagctttgatcgcttgctttggtcagctaaggaa360 ccttcagacagctggctcatagccagcttggatttgcaaaacagttccaagaaattcaag420 attttaatagaaggtgtactaggacagggaaacacagccagcatcgcactatttgaaatc480 aagatgacaaccggctactgtattgaatgtgactttgaagaaaatcatctctgtggcttt540 gtgaaccgctggaatcccaatgtgaactggtttgttggaggaggaagtattcggaatgtc600 cactccattctcccacaggatcacaccttcaagagtgaactgggccactacatgtacgtg660 gactcagtttatgtgaagcacttccaggaggtggcacagctcatctccccgttgaccacg720 gCCCCCatggctggctgcctgtcattttattaccagatccagcaggggaatgacaatgtc780 ttttccctttacactcgggatgtggctggcctttacgaggaaatctggaaagcagacagg840 ccagggaatgctgcctggaaccttgcggaggtcgagttcacatgccattttcctctgcag900 gttatttttgaagttgctttcaatggtcccaagggaggttatgttgccctggatgatatt960 tcattctctcctgttcactgccagaatcagacagaacttctgttcagtgccgtggaagcc1020 agctgcaattttgagcaagatctctgcaacttttaccaagataaagaaggtccaggttgg1080 acccgagtgaaagtaaaaccaaacatgtatcgggctggagaccacactacaggcttaggg1140 tattacctgctagccaacacaaagttcacatctcagcctggctacattggaaggctctat1200 gggccctccctaccaggaaacttgcagtattgtctgcgttttcattatgccatctatgga1260 tttttaaaaatgagtgacaccctagcagtttacatctttgaagagaaccatgtggttcaa1320 gagaagatctggtctgtgttggagtccccaaggggtgtttggatgcaagctgaaatcacc1380 tttaagaagcccatgcctaccaaggtggttttcatgagcctatgcaaaagtttctgggac1440 tgtgggcttgtagccctggatgacattacaatacaattgggaagctgctcatcttcagag1500 aaacttccacctccacctggagagtgtactttcgagcaagatgaatgtacatttactcag1560 gagaaaagaaaccggagcagctggcacaggaggaggggagaaactcccacttcctacaca1620 ggaccaaagggagatcacactactggggtaggctactacatgtacattgaggcctcccat1680 atggtgtatggacaaaaagcacgcctcttgtccaggcctctgcgaggagtctctggaaaa1740 cactgcttgacctttttctaccacatgtatggagggggcactggcctgctgagtgtttat1800 ctgaaaaaggaagaagacagtgaagagtccctcttatggaggagaagaggtgaacagagc1860 atttcctggctacgagcactgattgaatacagctgtgagaggcaacaccagataattttt1920 gaagccattcgaggagtatcaataagaagtgatattgccattgatgatgttaaatttcag1980 gcaggaccctgtggagaaatggaagatacaactcaacaatcatcaggatattctgaggac2040 ttaaatgaaattgagtattaa 2061 <210> 39 <211> 465 <212> DNA
<213> Homo Sapiens <400> 39 atgaccttgt ccccaacaca gccacctctg tttcacctgc cttacgtcca gaaatgcttt 60 atccctactg tggagcagct gactctgggg atcccatgcc agaatcatgg ggagatagac 120 catggccagg atatatttcc agcagagaag Ctctgtcatc tgcaggattg caaggtgaac 180 cttcacagag ctgcctgcgg tgagtgtatt gttgcaccca agacttccag cttcccttac 240 tgtcagggga cctgcctgac cctcaacagt gagcttcatc aatccaactt tgcactcaaa 300 gtttgcacta taagagggga gtgcctattg atctgttcct ggctctttca gacctgtagt 360 cccaccaagg tcattctctt ctccctaacg gtccaggatg acgaacgtaa gatgagcgtt 420 cactgtgtga acgcatcctt gatagagaag tgtggctgct cttga 465 <210> 40 <211> 277 <212> PRT
<213> Homo Sapiens <400> 40 Met Arg Gly Leu Val Met Ala Pro Leu Leu Ile Leu Leu Val Gly Gly Thr Glu Ala Phe Arg Tle Cys A1a Phe Asn Ala His Arg Leu Thr Leu Ala Lys Leu Thr Lys Glu Ser Val Met Asp Thr Leu Val Gln Ile Leu Ala Arg Cys Asp Ile Met Val Leu Gln Glu Val Val Asp Ser Ser Gln Asn Thr Val Pro Phe Leu Leu Gln Lys Leu Lys Ser Ser Arg Ser Tyr Ser Phe Leu Asn Ser Ser Leu Leu Gly Arg Ser Thr Tyr Lys Glu Lys Tyr Val Tyr Ile Tyr Arg Ser Asp Lys Thr Gln Val Leu Asn Phe Tyr Gln Tyr Asn Asp Thr Asp Asp Ile Phe Ala Arg Glu Pro Phe Val Ala His Phe Thr Leu Pro Ser Lys Thr Leu Pro Ser Val Va1 Leu Val Pro Leu His Thr Thr Pro Lys Asp Val Glu Lys Glu Leu Asn Ala Leu Tyr Asp Val Phe Leu Asp Val Tyr Gln Arg Trp Gln Asn Glu Asn Va1 Ile Leu Leu Gly Asp Phe Asn Ala Asp Cys Ala Ser Leu Thr Lys Lys Arg Leu Lys Ser Leu Leu Leu Arg Thr Lys Ala Gly Phe His Trp Val Ile Pro Asp Gly Glu Asp Thr Thr Val Arg Ala Ser Thr Asn Cys Thr Tyr Asp Arg Ile Val Val His Gly Gln Gly Cys Gln Met Leu Leu Lys Ala Ala Ala Thr Phe Asp Phe Pro Lys Arg Phe Gln Leu Thr Glu Glu Glu Ala Leu Arg Ile Ser Asp His Tyr Pro Val Glu Val Glu Leu Ser Gln Ala Thr Pro Leu Ser <210> 41 <211> 480 <212> PRT
<213> Homo Sapiens <400> 41 Met Leu Gly Arg Phe Gln Pro Phe Ser Leu Val Arg Ser Phe Arg Leu Gly Phe Gly Ala Cys Cys Tyr Pro Asn Gln Lys Cys Ala Thr Gln Thr Ile Arg Pro Pro Asp Ser Arg Cys Leu Val Gln Ala Val Ser Gln Asn Phe Asn Phe Ala Lys Asp Val Leu Asp Gln Trp Ser Gln Leu Glu Lys Asp Gly Leu Arg Gly Pro Tyr Pro Ala Leu Trp Lys Val Ser Ala Lys Gly Glu Glu Asp Lys Trp Ser Phe Glu Arg Met Thr Gln Leu Ser Lys Lys Ala Ala Ser Ile Leu Ser Asp Thr Cys Ala Leu Ser His Gly Asp Arg Leu Met Ile Ile Leu Pro Pro Thr Pro Glu Ala Tyr Trp Ile Cys Leu Ala Cys Val Arg Leu Gly Ile Thr Phe Val Pro Gly Ser Pro Gln Leu Thr Ala Lys Lys Ile Arg Tyr Gln Leu Arg Met Ser Lys Ala Gln Cys Ile Val Ala Asn Glu Ala Met Ala Pro Val Val Asn Ser Ala Val Ser Asp Cys Pro Thr Leu Lys Thr Lys Leu Leu Val Ser Asp Lys Ser Tyr Asp Gly Trp Leu Asp Phe Lys Lys Leu Ile Gln Val Ala Pro Pro Lys Gln Thr Tyr Met Arg Thr Lys Ser Gln Asp Pro Met Ala Ile Phe Phe Thr Lys Gly Thr Thr Gly Ala Pro Lys Met Val Glu Tyr Ser Gln Tyr Gly Leu Gly Met Gly Phe Ser Gln Ala Ser Arg Arg Trp Met Asp Leu Gln Pro Thr Asp Val Leu Trp Ser Leu Gly Asp Ala Phe Gly Gly Ser Leu Ser Leu Ser Ala Val Leu Gly Thr Trp Phe Gln Gly Ala Cys Val Phe Leu Cys His Met Pro Thr Phe Cys Pro Glu Thr Val Leu Asn Val Leu Ser Arg Phe Pro Ile Thr Thr Leu Ser Ala Asn Pro Glu Met Tyr Gln Glu Leu Leu Gln His Lys Cys Phe Thr Ser Tyr Arg Phe Lys Ser Leu Lys Gln Cys Val Ala Ala Gly Gly Pro I1e Ser Pro Gly Val Ile Glu Asp Trp Lys Arg Ile Thr Lys Leu Asp Ile Tyr Glu Gly Tyr Gly Gln Thr Glu Thr Gly Leu Leu Cys Ala Thr Ser Lys Thr Ile Lys Leu Lys Pro Ser Ser Leu Gly Lys Pro Leu Pro Pro Tyr Ile Val Gln Ile Val Asp Glu Asn Ser Asn Leu Leu Pro Pro Gly Glu Glu Gly Asn Ile Ala Ile Arg Ile Lys Leu Asn Gln Pro Ala Ser Leu Tyr Cys Pro His Met Val Ser Trp Glu Glu Tyr Ala Ser Ala Arg Gly His Met Leu Tyr Leu Thr Gly Asp Arg Gly Ile Met Asp Glu Asp Gly Tyr Phe Trp Trp Ser Gly Arg Val Asp Asp Val Ala Asn Ala Leu Gly Gln Arg Leu <210> 42 <211> 583 <212> PRT
<213> Homo Sapiens <400> 42 Met Leu Gly Arg Phe Gln Pro Phe Ser Leu Val Arg Ser Phe Arg Leu Gly Phe Gly Ala Cys Cys Tyr Pro Asn Gln Lys Cys Ala Thr Gln Thr Ile Arg Pro Pro Asp Ser Arg Cys Leu Val Gln Ala Val Ser Gln Asn Phe Asn Phe Ala Lys Asp Va1 Leu Asp Gln Trp Ser Gln Leu Glu Lys Asp Gly Leu Arg Gly Pro Tyr Pro Ala Leu Trp Lys Val Ser Ala Lys Gly Glu Glu Asp Lys Trp Ser Phe Glu Arg Met Thr Gln Leu Ser Lys Lys Ala Ala Ser Ile Leu Ser Asp Thr Cys Ala Leu Ser His Gly Asp Arg Leu Met Ile Ile Leu Pro Pro Thr Pro Glu Ala Tyr Trp Ile Cys Leu Ala Cys Val Arg Leu Gly Ile Thr Phe Val Pro Gly Ser Pro Gln Leu Thr Ala Lys Lys Ile Arg Tyr Gln Leu Arg Met Ser Lys Ala Gln Cys Ile Val Ala Asn Glu Ala Met Ala Pro Val Val Asn Ser Ala Val Ser Asp Cys Pro Thr Leu Lys Thr Lys Leu Leu Val Ser Asp Lys Ser Tyr Asp Gly Trp Leu Asp Phe Lys Lys Leu Ile Gln Val Ala Pro Pro Lys Gln Thr Tyr Met Arg Thr Lys Ser Gln Asp Pro Met Ala Ile Phe Phe Thr Lys Gly Thr Thr Gly Ala Pro Lys Met Val Glu Tyr Ser G1n Tyr Gly Leu Gly Met Gly Phe Ser Gln Ala Ser Arg Arg Trp Met Asp Leu Gln Pro Thr Asp Val Leu Trp Ser Leu Gly Asp Ala Phe Gly Gly Ser Leu Ser Leu Ser Ala Val Leu Gly Thr Trp Phe Gln Gly Ala Cys Val Phe Leu Cys His Met Pro Thr Phe Cys Pro Glu Thr Val Leu Asn Val Leu Ser Arg Phe Pro Ile Thr Thr Leu Ser Ala Asn Pro Glu Met Tyr Gln Glu Leu Leu Gln His Lys Cys Phe Thr Ser Tyr Arg Phe Lys Ser Leu Lys Gln Cys Val Ala Ala Gly G1y Pro Ile Ser Pro Gly Val Ile Glu Asp Trp Lys Arg Ile Thr Lys Leu Asp Ile Tyr Glu G1y Tyr Gly Gln Thr Glu Thr Gly Leu Leu Cys Ala Thr Ser Lys Thr Ile Lys Leu Lys Pro Ser Ser Leu Gly Lys Pro Leu Pro Pro Tyr Ile Val Gln Ile Val Asp Glu Asn Ser Asn Leu Leu Pro Pro Gly Glu Glu Gly Asn Ile Ala Ile Arg Ile Lys Leu Asn Gln Pro Ala Ser Leu Tyr Cys Pro His Met Val Ser Trp Glu Glu Tyr Ala Ser Ala Arg Gly His Met Leu Tyr Leu Thr Gly Asp Arg Gly Ile Met Asp Glu Asp Gly Tyr Phe Trp Trp Ser Gly Arg Val Asp Asp Val Ala Asn Ala Leu Gly Gln Arg Phe Ser Arg Pro Gly Ala Ala Ala Ala Ala Ser Ala Val Gly Ala Pro Pro Gly Gly Trp His Ser Leu Cys Ala Ser Val Pro Ile Leu Gln Val Val Lys Pro Pro Asn Val Leu Thr Pro Gln Phe Leu Ser His Asp Gln Gly Gln Leu Thr Lys Glu Leu Gln Gln His Ile Lys Ser Val Thr Gly Pro Cys Lys Tyr Gln Arg Lys Val Glu Phe Val Pro Glu Leu Pro Lys Thr Val Thr Gly Lys Ile Lys Arg Glu Leu Gln Val Trp Ser Asp Val Val Ser Ser Glu Leu Arg Asn Asp <210> 43 <211> 581 <212> PRT
<213> Homo Sapiens <400> 43 Met Pro Leu Lys His Tyr Leu Leu Leu Leu Val Gly Cys Gln Ala Trp Gly Ala Gly Leu Ala Tyr His Gly Cys Pro Ser Glu Cys Thr Cys Ser Arg Ala Ser Gln Val Glu Cys Thr Gly Ala Arg Ile Val Ala Val Pro Thr Pro Leu Pro Trp Asn Ala Met Ser Leu Gln Ile Leu Asn Thr His Ile Thr Glu Leu Asn Glu Ser Pro Phe Leu Asn Ile Ser Ala Leu I1e 65 70 . 75 80 Ala Leu Arg Ile Glu Lys Asn Glu Leu Ser Arg Ile Thr Pro Gly Ala Phe Arg Asn Leu Gly Ser Leu Arg Tyr Leu Ser Leu Ala Asn Asn Lys Leu Gln Val Leu Pro Ile Gly Leu Phe Gln Gly Leu Asp Ser Leu Glu Ser Leu Leu Leu Ser Ser Asn Gln Leu Leu Gln Ile Gln Pro Ala His Phe Ser Gln Cys Ser Asn Leu Lys Glu Leu Gln Leu His Gly Asn His Leu Glu Tyr Ile Pro Asp Gly Ala Phe Asp His Leu Val Gly Leu Thr l65 170 175 Lys Leu Asn Leu Gly Lys Asn Ser Leu Thr His Ile Ser Pro Arg Val Phe Gln His Leu Gly Asn Leu Gln Val Leu Arg Leu Tyr Glu Asn Arg Leu Thr Asp Ile Pro Met Gly Thr Phe Asp Gly Leu Val Asn Leu Gln Glu Leu Ala Leu Gln Gln Asn Gln Ile Gly Leu Leu Ser Pro Gly Leu Phe His Asn Asn His Asn Leu Gln Arg Leu Tyr Leu Ser Asn Asn His Ile Ser Gln Leu Pro Pro Ser Ile Phe Met Gln Leu Pro Gln Leu Asn Arg Leu Thr Leu Phe Gly Asn Ser Leu Lys Glu Leu Ser Leu Gly Ile Phe Gly Pro Met Pro Asn Leu Arg G1u Leu Trp Leu Tyr Asp Asn His Ile Ser Ser Leu Pro Asp Asn Val Phe Ser Asn Leu Arg Gln Leu Gln Val Leu Ile Leu Ser Arg Asn Gln Ile Ser Phe I1e Ser Pro Gly Ala Phe Asn G1y Leu Thr Glu Leu Arg Glu Leu Ser Leu His Thr Asn Ala Leu Gln Asp Leu Asp Gly Asn Val Phe Arg Met Leu Ala Asn Leu Gln Asn Ile Ser Leu Gln Asn Asn Arg Leu Arg Gln Leu Pro Gly Asn Ile Phe Ala Asn Val Asn Gly Leu Met Ala Ile Gln Leu Gln Asn Asn Gln Leu Glu Asn Leu Pro Leu Gly Ile Phe Asp His Leu Gly Lys Leu Cys Glu Leu Arg Leu Tyr Asp Asn Pro Trp Arg Cys Asp Ser Asp Ile Leu Pro Leu Arg Asn Trp Leu Leu Leu Asn Gln Pro Arg Leu Gly Thr Asp Thr Val Pro Val Cys Phe Ser Pro Ala Asn Val Arg Gly Gln Ser Leu Ile Ile Ile Asn Val Asn Val Ala Val Pro Ser Val His Val Pro Glu Val Pro Ser Tyr Pro Glu Thr Pro Trp Tyr Pro Asp Thr Pro Ser Tyr Pro Asp Thr Thr Ser Val Ser Ser Thr Thr Glu Leu Thr Ser Pro Val Glu Asp Tyr Thr Asp Leu Thr Thr Ile Gln Val Thr Asp Asp Arg Ser Val Trp Gly Met Thr His Ala His Ser Gly Leu Ala Ile Ala Ala Ile Val Ile Gly Ile Val Ala Leu Ala Cys Ser Leu Ala Ala Cys Val Gly Cys Cys Cys Cys Lys Lys Arg Ser Gln Ala Val Leu Met Gln Met Lys Ala Pro Asn Glu Cys <210> 44 <211> 628 <212> PRT
<213> Homo sapiens <400> 44 Met Pro Gly Ala Pro Asp Trp Ser Leu Asn Ser Ser Arg Asn Ala Arg 1 5 10 l5 Ser Leu Glu Gly Leu Pro Leu Cys Pro Trp Trp Ala Leu Phe Val Pro Arg Ala Ala Ala Leu Val Gly Leu Gln Arg Lys Gln Glu Asn Ser Ser Asp Ile Phe Phe Ser Ser Pro Phe Thr Val Thr Pro Asp Ala Leu Pro Thr Ala Ile Thr Trp Glu His Ile Pro Phe Ala Lys Leu Ala Gly Leu Ile Ala Gly Pro Leu Val Glu Met Cys Arg Gln Arg Leu Ser Lys Glu Phe Glu Ala Leu Lys Gly Glu Phe Arg Asp Leu Gly His Cys Leu Pro Gly Ala Gln Arg Gly Asn Arg Ile Thr Lys Arg Asn Lys Cys Gly Gln Ser Arg Gln Ala Leu Ile Gly Gln Arg Gln Glu Asp Ala Gly Ser Ala Pro Leu Gln Met His Pro Ser Val Ala Ala Leu Gly Ala Gly Ala A1a Leu Arg Glu Ile Gln Pro Leu Gln Arg Glu Pro Glu Leu Ser Ser Gly Pro Arg Asn Ser Arg Leu Leu Cys Trp Gly Ser Pro Ala Thr Trp Asn Pro Thr Tyr Leu Ser Arg Val Leu Gly Gln G1n Val Ala Val Thr Val Thr Glu Ala Gly Leu Gln Ala Val Pro Trp Gly Pro Ser Arg Glu Phe Asn Ala Lys Gly Ser Ser Ser Ala Ser Ile Arg Val Gly Gln Pro Gln Lys Leu Arg Leu Arg Val Gln Arg Ser Arg Arg Gln Cys Pro Pro Val Gln Ser Ser Gln Asp Leu Pro Pro Gly Gly Ser Gln Asp Gly Asp Leu Lys Glu Pro Thr Glu Arg Val Thr Arg Asp Leu Ser Ser Gly Ala Pro Arg Gly Arg Asn Leu Pro Ala Pro Asp Gln Pro Gln Pro Pro Leu Gln Arg Gly Thr Arg Leu Arg Leu Arg Gln Arg Arg Arg Arg Leu Leu Ile Lys Lys Met Pro Ala Ala Ala Thr Ile Pro Ala Asn Ser Ser Asp Ala Pro Phe Ile Arg Pro Gly Pro Gly Thr Leu Asp Gly Arg Trp Val Ser Leu His Arg Ser Gln G1n Glu Arg Lys Arg Val Met Gln Glu Ala Cys Ala Lys Tyr Arg Ala Ser Ser Ser Arg Arg Ala Val Thr Pro Arg His Val Ser Arg Ile Phe Val Glu Asp Arg His Arg Val Leu Tyr Cys Glu Val Pro Lys Ala Gly Cys Ser Asn Trp Lys Arg Val Leu Met Val Leu Ala Gly Leu Ala Ser Ser Thr Ala Asp Ile Gln His Asn Thr Va1 His Tyr Gly Ser Ala Leu Lys Arg Leu Asp Thr Phe Asp Arg Gln Gly Ile Leu His Arg Leu Ser Thr Tyr Thr Lys Met Leu Phe Val Arg Glu Pro Phe Glu Arg Leu Val Ser Ala Phe Arg Asp Lys Phe Glu His Pro Asn Ser Tyr Tyr His Pro Val Phe Gly Lys Ala Ile Leu Ala Arg Tyr Arg Ala Asn Ala Ser Arg Glu Ala Leu Arg Thr Gly Ser Gly Val Arg Phe Pro Glu Phe Val Gln Tyr Leu Leu Asp Val His Arg Pro Val Gly Met Asp Ile His Trp Asp His Val Ser Arg Leu Cys Ser Pro Cys Leu Ile Asp Tyr Asp Phe Val Gly Lys Phe Glu Ser Met Glu Asp Asp Ala Asn Phe Phe Leu Ser Leu Ile Arg Ala Pro Arg Asn Leu Thr Phe Pro Arg Phe Lys Asp Arg His Ser Gln Glu Ala Arg Thr Thr Ala Arg Ile Ala 580 ' 585 590 His Gln Tyr Phe Ala G1n Leu Ser Ala Leu Gln Arg Gln Arg Thr Tyr Asp Phe Tyr Tyr Met Asp Tyr Leu Met Phe Asn Tyr.Ser Lys Pro Phe Ala Asp Leu Tyr <210> 45 <211> 424 <212> PRT
<213> Homo sapiens <400> 45 Met Thr Leu Arg Pro Gly Thr Met Arg Leu Ala Cys Met Phe Ser Ser Ile Leu Leu Phe Gly Ala Ala Gly Leu Leu Leu Phe Ile Ser Leu Gln Asp Pro Thr Glu Leu Ala Pro Gln G1n Val Pro Gly Ile Lys Phe Asn Ile Arg Pro Arg Gln Pro His His Asp Leu Pro Pro Gly Gly Ser Gln 50 55 ~ 60 Asp Gly Asp Leu Lys Glu Pro Thr Glu Arg Val Thr Arg Asp Leu Ser Ser Gly Ala Pro Arg Gly Arg Asn Leu Pro Ala Pro Asp Gln Pro Gln Pro Pro Leu Gln Arg Gly Thr Arg Leu Arg Leu Arg Gln Arg Arg Arg Arg Leu Leu Ile Lys Lys Met Pro Ala Ala Ala Thr Ile Pro Ala Asn Ser Ser Asp Ala Pro Phe Ile Arg Pro Gly Pro Gly Thr Leu Asp Gly Arg Trp Val Ser Leu His Arg Ser Gln Gln Glu Arg Lys Arg Val Met Gln Glu Ala Cys Ala Lys Tyr Arg Ala Ser Ser Ser Arg Arg Ala Val Thr Pro Arg His Val Ser Arg Ile Phe Val Glu Asp Arg His Arg Val Leu Tyr Cys Glu Val Pro Lys Ala Gly Cys Ser Asn Trp Lys Arg Val Leu Met Val Leu Ala Gly Leu Ala Ser Ser Thr Ala Asp Ile Gln His Asn Thr Val His Tyr Gly Ser Ala Leu Lys Arg Leu Asp Thr Phe Asp Arg Gln Gly Ile Leu His Arg Leu Ser Thr Tyr Thr Lys Met Leu Phe Val Arg Glu Pro Phe Glu Arg Leu Val Ser Ala Phe Arg Asp Lys Phe Glu His Pro Asn Ser Tyr Tyr His Pro Val Phe Gly Lys Ala Ile Leu Ala Arg Tyr Arg Ala Asn Ala Ser Arg Glu Ala Leu Arg Thr Gly Ser G1y Val Arg Phe Pro Glu Phe Val Gln Tyr Leu Leu Asp Val His Arg Pro Val Gly Met Asp Ile His Trp Asp His Val Ser Arg Leu Cys Ser Pro Cys Leu Ile Asp Tyr Asp Phe Val Gly Lys Phe Glu Ser Met Glu Asp Asp Ala Asn Phe Phe Leu Ser Leu Ile Arg Ala Pro Arg Asn Leu Thr Phe Pro Arg Phe Lys Asp Arg His Ser Gln Glu Ala Arg Thr Thr Ala Arg Ile Ala His G1n Tyr Phe Ala Gln Leu Ser Ala Leu Gln Arg Gln Arg Thr Tyr Asp Phe Tyr Tyr Met Asp Tyr Leu Met Phe Asn Tyr Ser Lys Pro Phe Ala Asp Leu Tyr <210> 46 <211> 638 <212> PRT
<213> Homo Sapiens <400> 46 Met Ala Gly Gly Ser Ala Thr Thr Trp Gly Tyr Pro Val Ala Leu Leu Leu Leu Val Ala Thr Leu Gly Leu Gly Arg Trp Leu Gln Pro Asp Pro Gly Leu Pro Gly Leu Arg His Ser Tyr Asp Cys Gly Ile Lys Gly Met Gln Leu Leu Val Phe Pro Arg Pro Gly Gln Thr Leu Arg Phe Lys Val Val Asp Glu Phe Gly Asn Arg Phe Asp Val Asn Asn Cys Ser Ile Cys Tyr His Trp Val Thr Ser Arg Pro Gln Glu Pro Ala Val Phe Ser Ala Asp Tyr Arg Gly Cys His Val Leu Glu Lys Asp Gly Arg Phe His Leu Arg Val Phe Met Glu A1a Val Leu Pro Asn Gly Arg Val Asp Val Ala Gln Asp Ala Thr Leu Ile Cys Pro Lys Pro Asp Pro Ser Arg Thr Leu Asp Ser Gln Leu Ala Pro Pro Ala Met Phe Ser Val Ser Thr Pro Gln Thr Leu Ser Phe Leu Pro Thr Ser Gly His Thr Ser Gln Gly Ser Gly His Ala Phe Pro Ser Pro Leu Asp Pro Gly His Ser Ser Val His Pro Thr Pro Ala Leu Pro Ser Pro Gly Pro Gly Pro Thr Leu Ala Thr Leu Ala Gln Pro His Trp Gly Thr Leu Glu His Trp Asp Val Asn Lys Arg Asp Tyr Ile Gly Thr His Leu Ser Gln Glu Gln Cys Gln Val Ala Ser Gly His Leu Pro Cys Ile Val Arg Arg Thr Ser Lys Glu Ala Cys Gln Gln Ala Gly Cys Cys Tyr Asp Asn Thr Arg Glu Val Pro Cys Tyr Tyr Gly Asn Thr Ala Thr Val Gln Cys Phe Arg Asp Gly Tyr Phe Val Leu Val Val Ser Gln Glu Met Ala Leu Thr His Arg Ile Thr Leu Ala Asn Ile His Leu Ala Tyr Ala Pro Thr Ser Cys Ser Pro Thr Gln His Thr Glu Ala Phe Val Val Phe Tyr Phe Pro Leu Thr His Cys Gly Thr Thr Met Gln Val Ala Gly Asp Gln Leu Ile Tyr Glu Asn Trp Leu Val Ser Gly Ile His Ile Gln Lys Gly Pro Gln Gly Ser Ile Thr Arg Asp Ser Thr Phe Gln Leu His Val Arg Cys Val Phe Asn Ala Ser Asp Phe Leu Pro Ile Gln Ala Ser Ile Phe Pro Pro Pro Ser Pro Ala Pro Met Thr Gln Pro Gly Pro Leu Arg Leu Glu Leu Arg Ile Ala Lys Asp Glu Thr Phe Ser Ser Tyr Tyr Gly Glu Asp Asp Tyr Pro Ile Val Arg Leu Leu Arg Glu Pro Val His Val Glu Val Arg Leu Leu Gln Arg Thr Asp Pro Asn Leu Val Leu Leu Leu His Gln Cys Trp Gly Ala Pro Ser Ala Asn Pro Phe Gln Gln Pro Gln Trp Pro Ile Leu Ser Asp Gly Cys Pro Phe Lys Gly Asp Ser Tyr Arg Thr Gln Met Val Ala Leu Asp Gly Ala Thr Pro Phe Gln Ser His Tyr Gln Arg Phe Thr Val Ala Thr Phe Ala Leu 500 ~ 505 510 Leu Asp Ser Gly Ser Gln Arg Ala Leu Arg Gly Leu Val Tyr Leu Phe Cys Ser Thr Ser Ala Cys His Thr Ser Gly Leu Glu Thr Cys Ser Thr Ala Cys Ser Thr Gly Thr Thr Arg Gln Arg Arg Ser Ser Gly His Arg Asn Asp Thr Ala Arg Pro Gln Asp Ile Val Ser Ser Pro Gly Pro Val Gly Phe Glu Asp Ser Tyr Gly Gln Glu Pro Thr Leu Gly Pro Thr Asp Ser Asn Gly Asn Ser Ser Leu Arg Pro Leu Leu Trp Ala Val Leu Leu Leu Pro Ala Val Ala Leu Val Leu Gly Phe Gly Val Phe Val Gly Leu Ser Gln Thr Trp Ala Gln Lys Leu Trp Glu Ser Asn Arg Gln <210> 47 <211> 229 <212> PRT
<213> Homo Sapiens <400> 47 Met Lys Pro Leu Ala Gln Leu Leu Leu Phe Leu Leu Gln Phe Gln Lys 1 ~ 5 10 15 Gly Asn Leu Val Ser Gln Ser Ser Ser Thr Pro Leu Met Val Asn Gly Val Leu Gly Glu Ser Val Thr Leu Pro Leu Glu Phe Pro Ala Gly Glu Arg Ile Gln Phe Ile Thr Trp Leu Cys Asn Gly Thr Ser Phe Ala Phe Leu Glu Pro Tyr Glu Gly Lys Ser Pro Lys Ile Tyr Val Thr His Pro Lys Trp Gln Lys Arg Leu Ser Phe Thr Gln Ser Tyr Ser Pro Gln Leu Ser Asn Leu Glu Met Glu Asn Ile Gly Phe Tyr Ser Ala Gln Ile Ala Thr Glu Thr Ser Ala Lys Leu Ser Ser Tyr Thr Leu Arg Ile Phe Lys Gln Leu Pro Arg Pro Gln Val Arg Val Asp Ser Ile Ile Ser Glu Asn Gly Ile Cys Asn Ala Ile Leu Arg Cys Ser Val Glu Glu Gly Gly Glu Thr Ile Thr Tyr Glu Trp Thr Ser Met Gly Pro Gly Ala Ala Val Ser His Val Gly Leu His Asp Leu Asp Trp Ile Tyr Thr Cys Thr Ala Leu Asn Pro Val Ser Tyr Ser Asn Ser Thr Leu Thr Leu Ala Ala Gln Leu Cys Ala Ser Lys Ser Pro Leu Leu Val Ser Leu Ala Pro Leu Gly Asn Val Leu Ser Gly Leu <210> 48 <211> 310 <212> PRT
<213> Homo Sapiens <400> 48 Met Lys Pro Leu Ala Gln Leu Leu Leu Phe Leu Leu Gln Phe Gln Lys Gly Asn Leu Val Ser Gln Ser Ser Ser Thr Pro Leu Met Val Asn Gly Val Leu Gly Glu Ser Val Thr Leu Pro Leu Glu Phe Pro Ala Gly Glu Arg Ile Gln Phe Ile Thr Trp Leu Cys Asn Gly Thr Ser Phe Ala Phe Leu Glu Pro Tyr Glu Gly Lys Ser Pro Lys Ile Tyr Val Thr His Pro Lys Trp Gln Lys Arg Leu Ser Phe Thr Gln Ser Tyr Ser Pro Gln Leu Ser Asn Leu Glu Met Glu Asn Ile Gly Phe Tyr Ser Ala Gln Ile Ala Thr Glu Thr Ser Ala Lys Leu Ser Ser Tyr Thr Leu Arg Ile Phe Lys Gln Leu Pro Arg Pro Gln Val Arg Val Asp Ser Ile Ile Ser Glu Asn Gly Lle Cys Asn Ala Ile Leu Arg Cys Ser Val Glu Glu Gly Gly Glu Thr Ile Thr Tyr Glu Trp Thr Ser Met Gly Pro Gly Ala Ala Val Ser His Val Gly Leu His Asp Leu Asp Trp Ile Tyr Thr Cys Thr Ala Leu Asn Pro Val Ser Tyr Ser Asn Ser Thr Leu Thr Leu Ala Ala Gln Leu Cys Ala Ser Ser Lys Ala Ala Glu Gly Thr Tyr Cys Pro Val Lys Trp Ile Phe Leu Gly Asn Arg Leu Leu Leu Leu Val Phe Leu Gly Val Leu Arg Thr Trp His Ile Gln Ala Gln Val Leu Ser Lys Pro Leu Arg Pro Asn Ser Gly Glu Leu Val Asn Leu Ser Ser Ile Pro Tyr Pro Trp Glu Pro Ser His Thr Ala Asp Ala Thr Trp Leu Gly Lys Trp Gly Gly Ser Glu Gly Glu Arg Lys Ser Thr Trp Asn Ile Ser Thr Thr Lys Arg His Trp Lys Ser Phe Tyr Lys <210> 49 <211> 841 <212> PRT
<213> Homo sapiens <400> 49 Met Lys Leu Trp Ile His Leu Phe Tyr Ser Ser Leu Leu Ala Cys Ile Ser Leu His Ser G1n Thr Pro Val Leu Ser Ser Arg Gly Ser Cys Asp Ser Leu Cys Asn Cys Glu Glu Lys Asp Gly Thr Met Leu Ile Asn Cys Glu Ala Lys Gly Ile Lys Met Val Ser Glu Ile Ser Val Pro Pro Ser Arg Pro Phe Gln Leu Ser Leu Leu Asn Asn Gly Leu Thr Met Leu His Thr Asn Asp Phe Ser Gly Leu Thr Asn Ala Ile Ser Ile His Leu Gly Phe Asn Asn Ile Ala Asp Ile Glu Ile Gly Ala Phe Asn Gly Leu Gly Leu Leu Lys Gln Leu His Ile Asn His Asn Ser Leu Glu Ile Leu Lys Glu Asp Thr Phe His Gly Leu Glu Asn Leu Glu Phe Leu Gln Ala Asp Asn Asn Phe Ile Thr Val Ile Glu Pro Ser Ala Phe Ser Lys Leu Asn Arg Leu Lys Val Leu Ile Leu Asn Asp Asn Ala Ile Glu Ser Leu Pro Pro Asn Ile Phe Arg Phe Val Pro Leu Thr His Leu Asp Leu Arg Gly Asn Gln Leu Gln Thr Leu Pro Tyr Val Gly Phe Leu Glu His Ile Gly Arg Ile Leu Asp Leu Gln Leu Glu Asp Asn Lys Trp Ala Cys Asn Cys Asp Leu Leu Gln Leu Lys Thr Trp Leu Glu Asn Met Pro Pro Gln Ser Ile Ile Gly Asp Val Val Cys Asn Ser Pro Pro Phe Phe Lys Gly Ser Ile Leu Ser Arg Leu Lys Lys Glu Ser Ile Cys Pro Thr Pro Pro Val Tyr Glu Glu His Glu Asp Pro Ser Gly Ser Leu His Leu Ala Ala Thr Ser Ser Ile Asn Asp Ser Arg Met Ser Thr Lys Thr Thr Ser Ile Leu Lys Leu Pro Thr Lys Ala Pro Gly Leu Ile Pro Tyr Ile Thr Lys Pro Ser Thr Gln Leu Pro Gly Pro Tyr Cys Pro Ile Pro Cys Asn Cys Lys Val Leu Ser Pro Ser Gly Leu Leu Ile His Cys Gln Glu Arg Asn Ile Glu Ser Leu Ser Asp Leu Arg Pro Pro Pro Gln Asn Pro Arg Lys Leu Ile Leu Ala Gly Asn Ile Ile His Ser Leu Met Lys Ser Asp Leu Val Glu Tyr Phe Thr Leu Glu Met Leu His Leu Gly Asn Asn Arg Ile Glu Val Leu Glu Glu Gly Ser Phe Met Asn Leu Thr Arg Leu Gln Lys Leu Tyr Leu Asn Gly Asn His Leu Thr Lys Leu Ser Lys Gly Met Phe Leu Gly Leu His Asn Leu Glu Tyr Leu Tyr Leu Glu Tyr Asn Ala Ile Lys Glu Ile Leu Pro Gly Thr Phe Asn Pro Met Pro Lys Leu Lys Val Leu Tyr Leu Asn Asn Asn Leu Leu Gln Val Leu Pro Pro His Ile Phe Ser Gly Val Pro Leu Thr Lys Val Asn Leu Lys Thr Asn Gln Phe Thr His Leu Pro Val Ser Asn Ile Leu Asp Asp Leu Asp Leu Leu Thr Gln Ile Asp Leu Glu Asp Asn Pro Trp Asp Cys Ser Cys Asp Leu Val Gly Leu Gln Gln Trp Ile Gln Lys Leu Ser Lys Asn Thr Val Thr Asp Asp Ile Leu Cys Thr Ser Pro Gly His Leu Asp Lys Lys Glu Leu Lys Ala Leu Asn Ser Glu Ile Leu Cys Pro Gly Leu Val Asn Asn Pro Ser Met Pro Thr Gln Thr Ser Tyr Leu Met Val Thr Thr Pro A1a Thr Thr Thr Asn Thr Ala Asp Thr Ile Leu Arg Ser Leu Thr Asp Ala Val Pro Leu Ser Val Leu Ile Leu Gly Leu Leu Ile Met Phe Ile Thr Ile Val Phe Cys Ala Ala Gly Ile Val Val Leu Val Leu His Arg Arg Arg Arg Tyr Lys Lys Lys Gln Val Asp Glu Gln Met Arg Asp Asn Ser Pro Val His Leu Gln Tyr Ser Met Tyr Gly His Lys Thr Thr His His Thr Thr Glu Arg Pro Ser Ala Ser Leu Tyr Glu Gln His Met Val Ser Pro Met Val His Val Tyr Arg Ser Pro Ser Phe Gly Pro Lys His Leu Glu Glu Glu Glu Glu Arg Asn Glu Lys Glu Gly Ser Asp Ala Lys His Leu Gln Arg Ser Leu Leu Glu Gln Glu Asn His Ser Pro Leu Thr Gly Ser Asn Met Lys Tyr Lys Thr Thr Asn Gln Ser Thr Glu Phe Leu Ser Phe Gln Asp Ala Ser Ser Leu Tyr Arg Asn Ile Leu Glu Lys Glu Arg Glu Leu Gln Gln Leu Gly Ile Thr Glu Tyr Leu Arg Lys Asn Ile Ala Gln Leu Gln Pro Asp Met Glu Ala His Tyr Pro Gly Ala His Glu Glu Leu Lys Leu Met Glu Thr Leu Met Tyr Ser Arg Pro Arg Lys Val Leu Val Glu Gln Thr Lys Asn Glu Tyr Phe Glu Leu Lys Ala Asn Leu His Ala Glu Pro Asp Tyr Leu Glu Val Leu Glu Gln Gln Thr <210> 50 <211> 241 <212> PRT
<213> Homo Sapiens <400> 50 Met Gly Asn Pro Gly Leu Ala Trp Leu Val Leu Leu Gly Leu Val Leu Leu Leu Ser Ser Phe Met Glu Arg Gly Gly His Ser Pro Ser Pro Ala Ala Leu Ser Ala Met Glu Asn Leu Ile Thr Tyr Ala Val Gln Lys Gly His Leu Ser Ser Ser Tyr Val Gln Pro Leu Leu Val Lys Gly Glu Asn Cys Leu Ala Pro Arg Gln Lys Thr Ser Leu Lys Lys Ala Cys Pro Gly Val Val Pro Arg Ser Val Trp Gly Ala Arg Glu Thr His Cys Pro Arg 85 90 ~ 95 Met Thr Leu Pro Ala Lys Tyr Gly Ile Ile Ile His Thr Ala Gly Arg Thr Cys Asn Ile Ser Asp Glu Cys Arg Leu Leu Val Arg Asp Ile Gln Ser Phe Tyr Ile Asp Arg Leu Lys Ser Cys Asp Ile Gly Tyr Asn Phe Leu Val Gly Gln Asp Gly Ala Ile Tyr Glu Gly Val Gly Trp Asn Val Gln Gly Ser Ser Thr Pro Gly Tyr Asp Asp Ile Ala Leu Gly Ile Thr Phe Met Gly Thr Phe Thr Gly Ile Pro Pro Asn Ala Ala Ala Leu Glu Ala Ala Gln Asp Leu Ile Gln Cys Ala Met Val Lys Gly Tyr Leu Thr Pro Asn Tyr Leu Leu Val Gly His Ser Asp Val Ala Arg Thr Leu Ser Pro Gly Gln Ala Leu Tyr Asn Ile Ile Ser Thr Trp Pro His Phe Lys His <210> 51 <211> 369 <212> PRT
<213> Homo Sapiens <400> 51 Met Leu Pro Trp Leu Leu Val Phe Ser Ala Leu Gly Leu Gln Ala Trp Gly Asp Ser Ser Trp Asn Lys Thr Gln Ala Lys Gln Val Ser Glu Gly Leu Gln Tyr Leu Phe Glu Asn Ile Ser Gln Leu Thr Glu Lys Asp Val Ser Thr Thr Val Ser Arg Lys Ala Trp Gly Ala Glu Ala Val Gly Cys Ser Ile Gln Leu Thr Thr Pro Val Asn Val Leu Val Ile His His Val Pro Gly Leu Glu Cys His Asp Arg Thr Val Cys Ser Gln Arg Leu Arg Glu Leu Gln Ala His His Val His Asn Asn Ser Gly Cys Asp Val Ala Tyr Asn Phe Leu Val Gly Asp Asp Gly Arg Val Tyr Glu Gly Val Gly Trp Asn Ile Gln Gly Val His Thr Gln Gly Tyr Asn Asn Ile Ser Leu Gly Phe Ala Phe Phe Gly Thr Lys Lys Gly His Ser Pro Ser Pro Ala Ala Leu Ser Ala Met Glu Asn Leu Ile Thr Tyr Ala Val Gln Lys Gly His Leu Ser Ser Ser Tyr Val Gln Pro Leu Leu Val Lys Gly Glu Asn Cys Leu Ala Pro Arg Gln Lys Thr Ser Leu Lys Lys Ala Cys Pro Gly Val Val Pro Arg Ser Val Trp Gly Ala Arg Glu Thr His Cys Pro Arg Met Thr Leu Pro Ala Lys Tyr Gly I1e Ile I1e His Thr Ala Gly Arg Thr Cys Asn Ile Ser Asp Glu Cys Arg Leu Leu Val Arg~Asp Ile Gln Ser Phe Tyr Ile Asp Arg Leu Lys Ser Cys Asp Ile Gly Tyr Asn Phe Leu Val G1y Gln Asp Gly Ala Ile Tyr Glu Gly Val Gly Trp Asn Val Gln Gly Ser Ser Thr Pro Gly Tyr Asp Asp Ile Ala Leu Gly Ile Thr Phe Met Gly Thr Phe Thr Gly Ile Pro Pro Asn Ala Ala Ala Leu Glu Ala Ala Gln Asp Leu I1e Gln Cys Ala Met Val Lys Gly Tyr Leu Thr Pro Asn Tyr Leu Leu Val Gly His Ser Asp Val Ala Arg Thr Leu Ser Pro Gly Gln Ala Leu Tyr Asn Ile Ile Ser Thr Trp Pro His Phe Lys His <210> 52 <211> 382 <212> PRT
<213> Homo sapiens <400> 52 Met Ala Pro Arg Ala Gly Gln Pro Gly Leu Gln Gly Leu Leu Leu Val Ala Ala Ala Leu Ser Gln Pro Ala Ala Pro Cys Pro Phe Gln Cys Tyr Cys Phe Gly Gly Pro Lys Leu Leu Leu Arg Cys Ala Ser Gly Ala Glu Leu Arg Gln Pro Pro Arg Asp Val Pro Pro Asp Ala Arg Asn Leu Thr Ile Val Gly Ala Asn Leu Thr Val Leu Arg Ala Ala Ala Phe Ala Gly Gly Asp Gly Asp Gly Asp Gln Ala Ala Gly Val Arg Leu Pro Leu Leu Ser Ala Leu Arg Leu Thr His Asn His Ile Glu Val Val Glu Asp Gly Ala Phe Asp Gly Leu Pro Ser Leu Ala Ala Leu Asp Leu Ser His Asn Pro Leu Arg Ala Leu Gly Gly Gly Ala Phe Arg Gly Leu Pro Ala Leu Arg Ser Leu Gln Leu Asn His Ala Leu Val Arg Gly Gly Pro Ala Leu Leu Ala Ala Leu Asp Ala Ala Leu Ala Pro Leu Ala Glu Leu Arg Leu 165 ~ 170 175 Leu Gly Leu Ala Gly Asn Ala Leu Ser Arg Leu Pro Pro Ala Ala Leu Arg Leu Ala Arg Leu Glu Gln Leu Asp Val Arg Leu Asn Ala Leu Ala Gly Leu Asp Pro Asp Glu Leu Arg Ala Leu Glu Arg Asp Gly Gly Leu Pro Gly Pro Arg Leu Leu Leu Ala Asp Asn Pro Leu Arg Cys Gly Cys Ala Ala Arg Pro Leu Leu Ala Trp Leu Arg Asn Ala Thr Glu Arg Val Pro Asp Ser Arg Arg Leu Arg Cys Ala Ala Pro Arg Ala Leu Leu Asp Arg Pro Leu Leu Asp Leu Asp Gly Ala Arg Leu Arg Cys Ala Asp Ser Gly Ala Asp Ala Arg Gly Glu Glu Ala Glu Ala Ala Gly Pro Glu Leu Glu Ala Ser Tyr Val Phe Phe Gly Leu Val Leu Ala Leu Ile Gly Leu Ile Phe Leu Met Val Leu Tyr Leu Asn Arg Arg Gly Ile Gln Arg Trp Met Arg Asn Leu Arg Glu Ala Cys Arg Asp Gln Met Glu Gly Tyr His Tyr Arg Tyr Glu Gln Asp Ala Asp Pro Arg Arg Ala Pro Ala Pro Ala Ala Pro Ala Gly Ser Arg Ala Thr Ser Pro Gly Ser Gly Leu <210> 53 <211> 185 <212> PRT
<213> Homo Sapiens <400> 53 Met Met Leu Leu Leu Leu Cys Leu Gly Leu Thr Leu Val Cys Ala Gln 1 5 ' 10 15 Glu Glu Glu Asn Asn Asp Ala Val Thr Ser Asn Phe Asp Leu Ser Lys Ile Ser Gly Glu Trp Tyr Ser Val Leu Leu Ala Ser Asp Cys Arg Glu Lys Ile Glu Glu Asp Gly Ser Met Arg Val Phe Val Lys His Ile Asp Tyr Leu Gly Asn Ser Ser Leu Thr Phe Lys Leu His Glu Ile Glu Asn Gly Asn Cys Thr Glu Ile Asn Leu Ala Cys Lys Pro Thr Glu Lys Asn Ala Ile Cys Ser Thr Asp Tyr Asn Gly Leu Asn Val Ile Asp Ile Leu Glu Thr Asp Tyr Asp Asn Tyr Ile Tyr Phe Tyr Asn Lys Asn Ile Lys Asn Gly Glu Thr Phe Leu Met Leu Glu Leu Tyr Val Arg Thr Pro Asp Val Ser Ser Gln Leu Lys Glu Arg Phe Val Lys Tyr Cys Glu Glu His Gly Ile Asp Lys Glu Asn Ile Phe Asp Leu Thr Lys Val Asp Arg Cys Leu Gln Ala Arg Asp Glu Gly Ala Ala <210> 54 <211> 586 <212> PRT
<213> Homo sapiens <400> 54 Met His Tyr Asn Leu Gln Gly Pro Thr Arg Arg Ile Arg Ile Ser Leu Leu Asn Asp Gly Gly Leu Lys Ile Ala Asn Val Thr Lys Ala Asp Ala Gly Thr Tyr Thr Cys Met Ala Glu Asn Gln Phe Gly Lys Ala Asn Gly Thr Thr His Leu Val Val Thr Glu Pro Thr Arg Ile Thr Leu Ala Pro Ser Asn Met Asp Val Ser Val Gly Glu Ser Val Ile Leu Pro Cys Gln Val Gln His Asp Pro Leu Leu Asp Ile Ile Phe Thr Trp Tyr Phe Asn Gly Ala Leu Ala Asp Phe Lys Lys Asp Gly Ser His Phe Glu Lys Val Gly Gly Ser Ser Ser Gly Asp Leu Met Ile Arg Asn Ile Gln Leu Lys His Ser Gly Lys Tyr Val Cys Met Val Gln Thr Gly Val Asp Ser Val Ser Ser Ala Ala Asp Leu Ile Val Arg Gly Ser Pro Gly Pro Pro Glu Asn Val Lys Val Asp Glu Ile Thr Asp Thr Thr Ala Gln Leu Ser Trp Lys Glu Gly Lys Asp Asn His Ser Pro Val Ile Ser Tyr Ser Ile Gln Ala Arg Thr Pro Phe Ser Val Gly Trp Gln Thr Val Thr Thr Val Pro Glu Val Ile Asp Gly Lys Thr His Thr Ala Thr Val Val Glu Leu Asn Pro Trp Val Glu Tyr Glu Phe Arg Val Val Ala Ser Asn Lys Ile Gly Gly Gly Glu Pro Ser Leu Pro Ser Glu Lys Val Arg Thr Glu Glu Ala Val Pro Glu Val Pro Pro Ser Glu Val Asn Gly Gly Gly Gly Ser Arg Ser Glu Leu Val Ile Thr Trp Asp Pro Val Pro Glu Glu Leu Gln Asn Gly Glu Gly Phe Gly Tyr Val Val Ala Phe Arg Pro Leu Gly Val Thr Thr Trp Ile G1n Thr Val Val Thr Ser Pro Asp Thr Pro Arg Tyr Val Phe Arg Asn Glu Ser Ile Val Pro Tyr Ser Pro Tyr Glu Val Lys Val Gly Val Tyr Asn Asn Lys Gly Glu Gly Pro Phe Ser Pro Val Thr Thr Val Phe Ser Ala Glu Glu Glu Pro Thr Val Ala Pro Ser Gln Val Ser Ala Asn Ser Leu Ser Ser Ser Glu Ile Glu Val Ser Trp Asn Thr Ile Pro Trp Lys Leu Ser Asn Gly His Leu Leu Gly Tyr Glu Val Arg Tyr Trp Asn Gly Gly Gly Lys Glu Glu Ser Ser Ser Lys Met Lys Val A1a G1y Asn Glu Thr Ser Ala Arg Leu Arg Gly Leu Lys Ser Asn Leu Ala Tyr Tyr Thr Ala Val Arg Ala Tyr Asn Ser Ala Gly Ala Gly Pro Phe Ser Ala Thr Val Asn Va1 Thr Thr Lys Lys Thr Pro Pro Ser Gln Pro Pro Gly Asn Val Val Trp Asn Ala Thr Asp Thr Lys Val Leu Leu Asn Trp Glu Gln Val Lys Ala Met Glu Asn Glu Ser Glu Val Thr Gly Tyr Lys Val Phe Tyr Arg Thr Ser Ser Gln Asn Asn Val Gln Val Leu Asn Thr Asn Lys Thr Ser Ala Glu Leu Val Leu Pro Ile Lys Glu Asp Tyr Ile Ile Glu Val Lys Ala Thr Thr Asp Gly Gly Asp Gly Thr Ser Ser Glu Gln Ile Arg Ile Pro Arg Ile Thr Ser Met Asp Ala Arg Gly Ser Thr Ser Ala Ile Ser Asn Val His Pro Met Ser Ser Tyr Met Pro Ile Val Leu Phe Leu Ile Val Tyr Val Leu Trp <210> 55 <211> 1026 <212> PRT
<213> Homo Sapiens <400> 55 Met Leu Val Val Glu Arg Val Met Val Leu Pro Ile Gly Phe Pro Leu Gly Val Ser Asp Asp Ser Thr Leu His Gly Pro Ile Phe Ile Gln Glu Pro Ser Pro Val Met Phe Pro Leu Asp Ser Glu Glu Lys Lys Val Lys Leu Asn Cys Glu Val Lys Gly Asn Pro Lys Pro His Ile Arg Trp Lys Leu Asn Gly Thr Asp Val Asp Thr Gly Met Asp Phe Arg Tyr Ser Val Val Glu Gly Ser Leu Leu Ile Asn Asn Pro Asn Lys Thr Gln Asp Ala Gly Thr Tyr Gln Cys Thr Ala Thr Asn Ser Phe Gly Thr Ile Val Ser Arg Glu Ala Lys Leu Gln Phe Ala Tyr Leu Asp Asn Phe Lys Thr Arg Thr Arg Ser Thr Val Ser Val Arg Arg Gly Gln Gly Met Val Leu Leu Cys Gly Pro Pro Pro His Ser Gly Glu Leu Ser Tyr Ala Trp Ile Phe Asn Glu Tyr Pro Ser Tyr Gln Asp Asn Arg Arg Phe Val Ser Gln Glu Thr Gly Asn Leu Tyr Ile Ala Lys Val Glu Lys Ser Asp Val Gly Asn Tyr Thr Cys Val Val Thr Asn Thr Val Thr Asn His Lys Val Leu Gly Pro Pro Thr Pro Leu Ile Leu Arg Asn Asp Gly Val Met Gly Glu Tyr Glu Pro Lys Ile Glu Val Gln Phe Pro Glu Thr Val Pro Thr Ala Lys Gly Ala Thr Val Lys Leu Glu Cys Phe Ala Leu Gly Asn Pro Val Pro Thr Ile Ile Trp Arg Arg Ala Asp Gly Lys Pro I1e Ala Arg Lys Ala Arg Arg His Lys Ser Asn Gly Ile Leu Glu Ile Pro Asn Phe Gln Gln Glu Asp Ala Gly Leu Tyr Glu Cys Val Ala Glu Asn Ser Arg Gly Lys Asn Val Ala Arg Gly Gln Leu Thr Phe Tyr Ala Gln Pro Asn Trp Ile Gln Lys I1e Asn Asp Ile His Val Ala Met Glu Glu Asn Val Phe Trp Glu Cys Lys Ala Asn G1y Arg Pro Lys Pro Thr Tyr Lys Trp Leu Lys Asn Gly Glu Pro Leu Leu Thr Arg Asp Arg Ile Gln Ile Glu Gln Gly Thr Leu Asn Ile Thr Ile Val Asn Leu Ser Asp Ala Gly Met Tyr Gln Cys Leu Ala Glu Asn Lys His Gly Val Ile Phe Ser Asn Ala Glu Leu Ser Val Ile Ala Val Gly Pro Asp Phe Ser Arg Thr Leu Leu Lys Arg Val Thr Leu Val Lys Val Gly Gly Glu Val Val Ile Glu Cys Lys Pro Lys Ala Ser Pro Lys Pro Val Tyr Thr Trp Lys Lys Gly Arg Asp Ile Leu Lys Glu Asn Glu Arg Ile Thr Ile Ser Glu Asp Gly Asn Leu Arg Ile Ile Asn Val Thr Lys Ser Asp Ala Gly Ser Tyr Thr Cys Ile Ala Thr Asn His Phe Gly Thr Ala Ser Ser Thr Gly Asn Leu Val Val Lys Asp Pro Thr Arg Val Met Val Pro Pro Ser Ser Met Asp Val Thr Val Gly Glu Ser Ile Val Leu Pro Cys Gln Val Thr His Asp His Ser Leu Asp Ile Val Phe Thr Trp Ser Phe Asn Gly His Leu Ile Asp Phe Asp Arg Asp Gly Asp His Phe Glu Arg Val Gly Gly Asp Ser Ala Gly Asp Leu Met Ile Arg Asn Ile Gln Leu Lys His Ala Gly Lys Tyr Val Cys Met Val Gln Thr Ser Val Asp Arg Leu Ser Ala Ala Ala Asp Leu Ile Val Arg Gly Pro Pro Gly Pro Pro Glu Ala Val Thr Ile Asp Glu Ile Thr Asp Thr Thr Ala Gln Leu Ser Trp Arg Pro Gly Pro Asp Asn His Ser Pro Ile Thr Met Tyr Val Ile Gln Ala Arg Thr Pro Phe Ser Val Gly Trp Gln Ala Val Ser Thr Val Pro Glu Leu Ile Asp Gly Lys Thr Phe Thr Ala Thr Val Val Gly Leu Asn Pro Trp Val Glu Tyr Glu Phe Arg Thr Val Ala Ala Asn Val Ile Gly Ile Gly Glu Pro Ser Arg Pro Ser Glu Lys Arg Arg Thr Glu Glu Ala Leu Pro Glu Val Thr Pro Ala Asn Val Ser Gly Gly Gly Gly Ser Lys Ser Glu Leu Val Ile Thr Trp Glu Thr Val Pro Glu Glu Leu Gln Asn Gly Arg Gly Phe Gly Tyr Val Val Ala Phe Arg Pro Tyr Gly Lys Met Ile Trp Met Leu Thr Val Leu Ala Ser Ala Asp Ala Ser Arg Tyr Val Phe Arg Asn Glu Ser Val His Pro Phe Ser Pro Phe Glu Val Lys Val Gly Val Phe Asn Asn Lys Gly Glu Gly Pro Phe Ser Pro Thr Thr Val Val Tyr Ser Ala Glu Glu Glu Pro Thr Lys Pro Pro Ala Ser Ile Phe Ala Arg Ser Leu Ser Ala Thr Asp Ile Glu Val Phe Trp Ala Ser Pro Leu G1u Lys Asn Arg Gly Arg Ile Gln Gly Tyr Glu Va1 Lys Tyr Trp Arg His Glu Asp Lys Glu Glu Asn Ala Arg Lys Ile Arg Thr Val Gly Asn Gln Thr Ser Thr Lys Ile Thr Asn Leu Lys Gly Ser Val Leu Tyr His Leu Ala Val Lys Ala Tyr Asn Ser Ala Gly Thr Gly Pro Ser Ser Ala Thr Val Asn Val Thr Thr Arg Lys Pro Pro Pro Ser Gln Pro Pro Gly Asn Ile Ile Trp Asn Ser Ser Asp Ser Lys Ile Ile Leu Asn Trp Asp Gln Val Lys Ala Leu Asp Asn Glu Ser Glu Val Lys Gly Tyr Lys Val Leu Tyr Arg Trp Asn Arg Gln Ser Ser Thr Ser Val Ile Glu Thr Asn Lys Thr Ser Val Glu Leu Ser Leu Pro Phe Asp Glu Asp Tyr Ile Ile Glu Ile Lys Pro Phe Ser Asp Gly Gly Asp Gly Ser Ser Ser Glu Gln Ile Arg Ile Pro Lys I1e Ser Asn Ala Tyr Ala Arg G1y Ser Gly Ala Ser Thr Ser Asn Ala Cys Thr Leu Ser Ala Ile Ser Thr Ile Met Ile Ser Leu Thr Ala Arg Ser Ser Leu <210> 56 <211> 844 <212> PRT
<213> Homo sapiens <400> 56 Met Asp Asn Pro Gln Ala Leu Pro Leu Phe Leu Leu Leu Ala Ser Leu Val Gly Ile Leu Thr Leu Arg Ala Ser Ser Gly Leu Gln Gln Thr Asn Phe Ser Ser Ala Phe Ser Ser Asp Ser Lys Ser Ser Ser Gln Gly Leu Gly Val Glu Val Pro Ser Ile Lys Pro Pro Ser Trp Lys Val Pro Asp Gln Phe Leu Asp Ser Lys Ala Ser Ala Gly Ile Ser Asp Ser Ser Trp Phe Pro Glu Ala Leu Ser Ser Asn Met Ser Gly Ser Phe Trp Ser Asn Val Ser Ala Glu Gly Gln Asp Leu Ser Pro Val Ser Pro Phe Ser Glu Thr Pro Gly Ser Glu Val Phe Pro Asp Ile Ser Asp Pro Gln Val Pro Ala Lys Asp Pro Lys Pro Ser Phe Thr Val Lys Thr Pro Ala Ser Asn Ile Ser Thr Gln Val Ser His Thr Lys Leu Ser Val Glu Ala Pro Asp Ser Lys Phe Ser Pro Asp Asp Met Asp Leu Lys Leu Ser Ala Gln Ser Pro Glu Ser Lys Phe Ser Ala Glu Thr His Ser Ala Ala Ser Phe Pro Gln Gln Val Gly Gly Pro Leu Ala Val Leu Val Gly Thr Thr Ile Arg Leu Pro Leu Val Pro Ile Pro Asn Pro Gly Pro Pro Thr Ser Leu Val Val Trp Arg Arg Gly Ser Lys Val Leu Ala Ala Gly Gly Leu Gly Pro Gly Ala Pro Leu Ile Ser Leu Asp Pro Ala His Arg Asp His Leu Arg Phe Asp Gln Ala Arg Gly Val Leu Glu Leu Ala Ser Ala Gln Leu Asp Asp Ala Gly Va1 Tyr Thr Ala Glu Val Ile Arg Ala G1y Val Ser Gln Gln Thr His Glu Phe Thr Val Gly Val Tyr Glu Pro Leu Pro Gln Leu Ser Val Gln Pro Lys Ala Pro Glu Thr Glu Glu Gly Ala Ala Glu Leu Arg Leu Arg Cys Leu Gly Trp Gly Pro Gly Arg Gly Glu Leu Ser Trp Ser Arg Asp Gly Arg Ala Leu Glu Ala Ala Glu Ser Glu Gly Ala Glu Thr Pro Arg Met Arg Ser Glu Gly Asp Gln Leu Leu Ile Val Arg Pro Val Arg Ser Asp His Ala Arg Tyr Thr Cys Arg Val Arg Ser Pro Phe Gly His Arg Glu Ala Ala Ala Asp Val Ser Val Phe Tyr Gly Pro Asp Pro Pro Thr Ile Thr Val Ser Ser Asp Arg Asp Ala Ala Pro Ala Arg Phe Val Thr Ala Gly Ser Asn Va1 Thr Leu Arg Cys Ala Ala Ala Ser Arg Pro Pro Ala Asp Ile Thr Trp Ser Leu Ala Asp Pro Ala Glu Ala 435 440 4.45 Ala Val Pro Ala Gly Ser Arg Leu Leu Leu Pro Ala Val Gly Pro Gly His Ala Gly Thr Tyr Ala Cys Leu Ala Ala Asn Pro Arg Thr Gly Arg Arg Arg Arg Ser Leu Leu Asn Leu Thr Val Ala Asp Leu Pro Pro Gly Ala Pro Gln Cys Ser Val Glu Gly Gly Pro Gly Asp Arg Ser Leu Arg Phe Arg Cys Ser Trp Pro Gly Gly Ala Pro Ala Ala Ser Leu Gln Phe Gln Gly Leu Pro Glu Gly Ile Arg Ala Gly Pro Val Ser Ser Val Leu Leu Ala Ala Val Pro Ala His Pro Arg Leu Ser Gly Val Pro Ile Thr Cys Leu Ala Arg His Leu Val Ala Thr Arg Thr Cys Thr Val Thr Pro Glu Ala Pro Arg G1u Val Leu Leu His Pro Leu Val Ala Glu Thr Arg Leu Gly Glu Ala Glu Val Ala Leu Glu Ala Ser Gly Cys Pro Pro Pro Ser Arg Ala Ser Trp Ala Arg Glu Gly Arg Pro Leu Ala Pro Gly Gly Gly Ser Arg Leu Arg Leu Ser Gln Asp Gly Arg Lys Leu His Ile Gly Asn Phe Ser Leu Asp Trp Asp Leu Gly Asn Tyr Ser Val Leu Cys Ser Gly Ala Leu Gly Ala Gly Gly Asp Gln Ile Thr Leu Ile Asp Gly Pro Ala Leu Gly Arg Thr Ser Thr Tyr Arg Asp Trp Val Ser Leu Leu Ile Leu Gly Pro Gln Glu Arg Ser Ala Val Val Pro Leu Pro Pro Arg Asn Pro Gly Thr Trp Thr Phe Arg Ile Leu Pro Ile Leu Gly Gly Gln Pro G1y Thr Pro Ser Gln Ser Arg Val Tyr Arg Ala Gly Pro Thr Leu Ser His Gly Ala Ile Ala Gly Ile VaI Leu Gly Ser Leu Leu Gly Leu Ala Leu Leu Ala Val Leu Leu Leu Leu Cys Ile Cys Cys Leu Cys Arg Phe Arg Gly Lys Thr Pro Glu Lys Lys Lys His Pro Ser Thr Leu Val Pro Val Va1 Thr Pro Ser Glu Lys Lys Met His Ser Val Thr Pro Val Glu Ile Ser Trp Pro Leu Asp Leu Lys Val Pro Leu Glu Asp His Ser Ser Thr Arg Ala Tyr Gln Ala Thr Asp Pro Ser Ser Val Val Ser Val Gly Gly Gly Ser Lys Thr Val Arg A1a Ala Thr Gln Val <210> 57 <211> 782 <212> PRT
<213> Homo Sapiens <400> 57 Met Asp Asn Pro Gln Ala Leu Pro Leu Phe Leu Leu Leu Ala Ser Leu Val Gly Ile Leu Thr Leu Arg Ala Ser Ser Gly Leu Gln Gln Thr Asn Phe Ser Ser Ala Phe Ser Ser Asp Ser Lys Ser Ser Ser Gln Gly Leu Gly Val Glu Val Pro Ser Ile Lys Pro Pro Ser Trp Lys Val Pro Asp Gln Phe Leu Asp Ser Lys Ala Ser Ala Gly Ile Ser Asp Ser Ser Trp Phe Pro Glu Ala Leu Ser Ser Asn Met Ser Gly Ser Phe Trp Ser Asn Val Ser Ala Glu Gly Gln Asp Leu Ser Pro Val Ser Pro Phe Ser Glu Thr Pro Gly Ser Glu Val Phe Pro Asp Ile Ser Asp Pro Gln Val Pro Ala Lys Asp Pro Lys Pro Ser Phe Thr Val Lys Thr Pro Ala Ser Asn Ile Ser Thr Cln Val Ser His Thr Lys Leu Ser Va1 Glu Ala Pro Asp 145 a. ! 150 155 160 Ser Lys Phe Ser Pro Asp Asp Met Asp Leu Lys Leu Ser Ala Gln Ser Pro Glu Ser Lys Phe Ser Ala Glu Thr His Ser Ala Ala Ser Phe Pro Gln Gln Val Gly Gly Pro Leu Ala Val Leu Val Gly Thr Thr Ile Arg Leu Pro Leu Val Pro Ile Pro Asn Pro Gly Pro Pro Thr Ser Leu Val Val Trp Arg Arg Gly Ser Lys Val Leu Ala Ala Gly Gly Leu Gly Pro Gly A1a Pro Leu Ile Ser Leu Asp Pro Ala His Arg Asp His Leu Arg Phe Asp Gln Ala Arg Gly Val Leu Glu Leu Ala Ser Ala Gln Leu Asp Asp Ala Gly Val Tyr Thr Ala Glu Val Ile Arg Ala Gly Val Ser Gln Gln Thr His Glu Phe Thr Val Gly Val Tyr Glu Pro Leu Pro Gln Leu Ser Val Gln Pro Lys Ala Pro Glu Thr Glu Glu Gly Ala Ala Glu Leu Arg Leu Arg Cys Leu Gly Trp Gly Pro Gly Arg Gly Glu Leu Ser Trp Ser Arg Asp Gly Arg Ala Leu Glu Ala Ala Glu Ser Glu Gly Ala Glu Thr Pro Arg Met Arg Ser Glu Gly Asp Gln Leu Leu Ile Val Arg Pro Val Arg Ser Asp His Ala Arg Tyr Thr Cys Arg Val Arg Ser Pro Phe Gly His Arg Glu Ala Ala Ala Asp Val Ser Val Phe Tyr Gly Pro Asp Pro Pro Thr Ile Thr Val Ser Ser Asp Arg Asp Ala Ala Pro Ala Arg Phe Val Thr Ala Gly Ser Asn Val Thr Leu Arg Cys Ala Ala Ala Ser Arg Pro Pro Ala Asp Ile Thr Trp Ser Leu Ala Asp Pro Ala Glu Ala Ala Val Pro Ala Gly Ser Arg Leu Leu Leu Pro Ala Val Gly Pro Gly His Ala Gly Thr Tyr Ala Cys Leu Ala Ala Asn Pro Arg Thr Gly Arg Arg Arg Arg Ser Leu Leu Asn Leu Thr Val Ala Asp Leu Pro Pro Gly Ala Pro Gln Cys Ser Val Glu Gly Gly Pro Gly Asp Arg Ser Leu Arg Phe Arg Cys Ser Trp Pro Gly Gly Ala Pro Ala Ala Ser Leu Gln Phe Gln Gly Leu Pro Glu Gly Ile Arg Ala Gly Pro Val Ser Ser Val Leu Leu Ala Ala Val Pro Ala His Pro Arg Leu Ser Gly Val Pro Ile Thr Cys Leu Ala Arg His Leu Val Ala Thr Arg Thr Cys Thr Val Thr Pro Glu Ala Pro Arg Glu Val Leu Leu His Pro Leu Val Ala Glu Thr Arg Leu Gly Glu Ala G1u Val Ala Leu Glu Ala Ser Gly Cys Pro Pro Pro Ser Arg Ala Ser Trp Ala Arg Glu Gly Arg Pro Leu Ala Pro Gly Gly Gly Ser Arg Leu Arg Leu Ser Gln Asp Gly Arg Lys Leu His Ile Gly Asn Phe Ser Leu Asp Trp Asp Leu Gly Asn Tyr Ser Val Leu Cys Ser Gly Ala Leu Gly Ala Gly Gly Asp Gln Ile Thr Leu Ile Gly Pro Thr Leu Ser His Gly Ala Ile Ala Gly Ile Val Leu Gly Ser Leu Leu Gly Leu Ala Leu Leu Ala Val Leu Leu Leu Leu Cys Ile Cys Cys Leu Cys Arg Phe Arg Gly Lys Thr Pro Glu Lys Lys Lys His Pro Ser Thr Leu Val Pro Val Val Thr Pro Ser Glu Lys Lys Met His Ser Val Thr Pro Val Glu Ile Ser Trp Pro Leu Asp Leu Lys Val Pro Leu Glu Asp His Ser Ser Thr Arg Ala Tyr Gln Ala Thr Asp Pro Ser Ser Val Val Ser Val Gly Gly Gly Ser Lys Thr Val Arg Ala Ala Thr Gln Val <210> 58 <211> 262 <212> PRT
<213> Homo Sapiens <400> 58 , Met Asp Ser Leu Val Thr Ala Asn Thr Lys Phe Cys Phe Asp Leu Phe Gln Glu Ile Gly Lys Asp Asp Arg His Lys Asn Ile Phe Phe Ser Pro Leu Ser Leu Ser Ala Ala Leu G1y Met Val Arg Leu Gly Ala Arg Ser Asp Ser Ala His Gln I1e Asp Glu Ala Gly Ser Leu Asn Asn Glu Ser G1y Leu Val Ser Cys Tyr Phe Gly Gln Leu Leu Ser Lys Leu Asp Arg Ile Lys Thr Asp Tyr Thr Leu Ser Ile Ala Asn Arg Leu Tyr Gly Glu Gln Glu Phe Pro Ile Cys Gln Glu Tyr Leu Asp Gly Val Ile Gln Phe Tyr His Thr Thr Ile Glu Ser Val Asp Phe Gln Lys Asn Pro Glu Lys Ser Arg Gln Glu Ile Asn Phe Trp Val Glu Cys Gln Ser Gln Gly Lys Ile Lys Glu Leu Phe Ser Lys Asp Ala Ile Asn Ala Glu Thr Val Leu Val Leu Val Asn Ala Val Tyr Phe Lys Ala Lys Trp Glu Thr Tyr Phe Asp His Glu Asn Thr Val Asp Ala Pro Phe Cys Leu Asn Ala Asn Glu Asn Lys Ser Val Lys Met Met Thr Gln Lys Gly Leu Tyr Arg Ile Gly Phe Ile Glu Glu Val Lys Ala Gln Ile Leu Glu Met~Arg Tyr Thr Lys Gly Lys Leu Ser Met Phe Val Leu Leu Pro Ser His Ser Lys Asp Asn Leu Lys Gly Leu Glu Glu Val Asn Leu His Phe His Ile Ser Thr Lys Tyr Leu Met Ile Asp Leu <210> 59 <211> 394 <212> PRT
<213> Homo sapiens <400> 59 Met Asp Ser Leu Val Thr Ala Asn Thr Lys Phe Cys Phe Asp Leu Phe Gln Glu Ile Gly Lys Asp Asp Arg His Lys Asn Ile Phe Phe Ser Pro Leu Ser Leu Ser Ala Ala Leu Gly Met Val Arg Leu Gly Ala Arg Ser Asp Ser Ala His Gln Ile Asp Glu Val Leu His Phe Asn Lys Thr Thr Glu Pro Leu Asp Gln Gln Ala Gly Ser Leu Asn Asn Glu Ser Gly Leu Val Ser Cys Tyr Phe Gly Gln Leu Leu Ser Lys Leu Asp Arg Ile Lys Thr Asp Tyr Thr Leu Ser Ile Ala Asn Arg Leu Tyr Gly Glu Gln Glu Phe Pro Ile Cys Gln Glu Tyr Leu Asp Gly Val Tle Gln Phe Tyr His Thr Thr Ile Glu Ser Val Asp Phe Gln Lys Asn Pro Glu Lys Ser Arg Gln Glu Ile Asn Phe Trp Val Glu Cys Gln Ser Gln Gly Lys Ile Lys Glu Leu Phe Ser Lys Asp Ala Ile Asn Ala Glu Thr Val Leu Val Leu l65 170 175 Val Asn Ala Val Tyr Phe Lys Ala Lys Trp Glu Thr Tyr Phe Asp His Glu Asn Thr Val Asp Ala Pro Phe Cys Leu Asn Ala Asn Glu Asn Lys Ser Val Lys Met Met Thr Gln Lys Gly Leu Tyr Arg Ile Gly Phe Ile Glu Glu Val Lys Ala Gln Ile Leu Glu Met Arg Tyr Thr Lys Gly Lys Leu Ser Met Phe Val Leu Leu Pro Ser His Ser Lys Asp Asn Leu Lys Gly Leu Glu Glu Leu Glu Arg Lys Ile Thr Tyr Glu Lys Met Val Ala 260 ' 265 270 Trp Ser Ser Ser Glu Asn Met Ser Glu Glu Ser Val Val Leu Ser Phe Pro Arg Phe Thr Leu Glu Asp Ser Tyr Asp Leu Asn Ser Ile Leu Gln Asp Met Gly Ile Thr Asp Ile Phe Asp Glu Thr Arg Ala Asp Leu Thr Gly Ile Ser Pro Ser Pro Asn Leu Tyr Leu Ser Lys I1e Ile His Lys Thr Phe Val Glu Val Asp Glu Asn Gly Thr Gln Ala Ala Ala Ala Thr Gly Ala Val Val Ser Glu Arg Ser Leu Arg Ser Trp Val Glu Phe Asn Ala Asn His Pro Phe Leu Phe Phe Ile Arg His Asn Lys Thr Gln Thr Ile Leu Phe Tyr Gly Arg Val Cys Ser Pro <210> 60 <211> 471 <212> PRT
<213> Homo Sapiens <400> 60 Met Ser Val Pro Leu Leu Lys Ile Gly Val Val Leu Ser Thr Met Ala Met I1e Thr Asn Trp Met Ser Gln Thr Leu Pro Ser Leu Va1 Gly Leu Asn Thr Thr Lys Leu Ser Ala Ala Gly Gly Gly Thr Leu Asp Arg Ser Thr Gly Val Leu Pro Thr Asn Pro Glu Glu Ser Trp Gln Val Tyr Ser Ser Ala Gln Asp Ser Glu Gly Arg Cys Ile Cys Thr Val Val Ala Pro Gln Gln Thr Met Cys Ser Arg Asp Ala Arg Thr Lys Gln Leu Arg Gln Leu Leu Glu Lys Val Gln Asn Met Ser Gln Ser Ile Glu Val Leu Asp Arg Z~rg Thr Gln Arg Asp Leu Gln Tyr Val Glu Lys Met Glu Asn Gln Met Lys G1y Leu Glu Ser Lys Phe Lys Gln Ala Ile Lys Ala Lys Met Asp Glu Leu Arg Pro Leu Ile Pro Val Leu Glu Glu Tyr Lys Ala Asp Ala Lys Leu Val Leu Gln Phe Lys Glu Glu Val Gln Asn Leu Thr Ser Val Leu Asn Glu Leu Gln Glu Glu Ile Gly Ala Tyr Asp Tyr Asp Glu Leu Gln Ser Arg Val Ser Asn Leu Glu Glu Arg Leu Arg Ala Cys Met Gln Lys Leu Ala Cys Gly Lys Leu Thr Gly Ile Ser Asp Pro Val Thr Val Lys Thr Ser Gly Ser Arg Phe Gly Ser Trp Met Thr Asp Pro Leu Ala Pro Glu Gly Asp Asn Arg Val Trp Tyr Met Asp Gly Tyr His Asn Asn Arg Phe Val Arg Glu Tyr Lys Ser Met Val Asp Phe Met Asn Thr Asp Asn Phe Thr Ser His Arg Leu Pro His Pro Trp Ser Gly Thr Gly Gln Val Va1 Tyr Asn Gly Ser Ile Tyr Phe Asn Lys Phe Gln Ser His Ile Ile Ile Arg Phe Asp Leu Lys Thr Glu Thr Ile Leu Lys Thr Arg Ser Leu Asp Tyr Ala,Gly Tyr Asn Asn Met Tyr His Tyr Ala Trp Gly Gly His Ser Asp Ile Asp Leu Met Val Asp Glu Ser Gly Leu Trp Ala Val Tyr Ala Thr Asn Gln Asn Ala Gly Asn Ile Val Val Ser Arg Leu 355 360 . 365 Asp Pro Val Ser Leu Gln Thr Leu Gln Thr Trp Asn Thr Ser Tyr Pro Lys Arg Ser Ala Gly Glu Ala Phe Ile Ile Cys Gly Thr Leu Tyr Val Thr Asn Gly Tyr Ser Gly Gly Thr Lys Va1 His Tyr Ala Tyr Gln Thr Asn Ala Ser Thr Tyr Glu Tyr Ile Asp Ile Pro Phe Gln Asn Lys Tyr Ser His Ile Ser Met Leu Asp Tyr Asn Pro Lys Asp Arg Ala Leu Tyr Ala Trp Asn Asn Gly His Gln Ile Leu Tyr Asn Val Thr Leu Phe His Val Ile Arg Ser Asp Glu Leu <210> 61 <211> 485 <212> PRT
<213> Homo Sapiens <400> 61 Met Ser Val Pro Leu Leu Lys Ile Gly Val Val Leu Ser Thr Met Ala Met Ile Thr Asn Trp Met Ser Gln Thr Leu Pro Ser Leu Val Gly Leu Asn Thr Thr Lys Leu Ser Ala Ala Gly Gly Gly Thr Leu Asp Arg Ser Thr Gly Val Leu Pro Thr Asn Pro Glu Glu Ser Trp Gln Val Tyr Ser Ser Ala Gln Asp Ser Glu Gly Arg Cys Ile Cys Thr Val Va1 Ala Pro Gln Gln Thr Met Cys Ser Arg Asp Ala Arg Thr Lys Gln Leu Arg Gln Leu Leu Glu Lys Val Gln Asn Met Ser Gln Ser Ile Glu Val Leu Asp Arg Arg Thr Gln Arg Asp Leu Gln Tyr Val Glu Lys Met Glu Asn Gln Met Lys Gly Leu Glu Ser Lys Phe Lys Gln Val Glu Glu Ile Ile Ser Tyr Thr Trp Pro Arg Gln Phe Lys Ala Ile Lys Ala Lys Met Asp Glu Leu Arg Pro Leu Ile Pro Val Leu Glu Glu Tyr Lys Ala Asp Ala Lys Leu Val Leu Gln Phe Lys Glu Glu Val Gln Asn Leu Thr Ser Val Leu Asn Glu Leu Gln Glu Glu Ile Gly Ala Tyr Asp Tyr Asp Glu Leu Gln Ser Arg Val Ser Asn Leu Glu Glu Arg Leu Arg Ala Cys Met Gln Lys Leu Ala Cys Gly Lys Leu Thr Gly Ile Ser Asp Pro Val Thr Val Lys Thr Ser Gly Ser Arg Phe Gly Ser Trp Met Thr Asp Pro Leu Ala Pro Glu Gly Asp Asn Arg Val Trp Tyr Met Asp Gly Tyr His Asn Asn Arg Phe Val Arg Glu Tyr Lys Ser Met Val Asp Phe Met Asn Thr Asp Asn Phe Thr Ser His Arg Leu Pro His Pro Trp Ser Gly Thr Gly Gln Val Val Tyr Asn Gly Ser Ile Tyr Phe Asn Lys Phe Gln Ser His Ile Ile 305 ' 310 315 320 Ile Arg Phe Asp Leu Lys Thr Glu Thr Ile Leu Lys Thr Arg Ser Leu Asp Tyr Ala Gly Tyr Asn Asn Met Tyr His Tyr Ala Trp Gly Gly His Ser Asp Ile Asp Leu Met Val Asp Glu Ser Gly Leu Trp Ala Val Tyr Ala Thr Asn Gln Asnf~~ Gly Asn Ile Val Val Ser Arg Leu Asp Pro 370 ~' 375 380 Val Ser Leu Gln Thr Leu Gln Thr Trp Asn Thr Ser Tyr Pro Lys Arg Ser Ala Gly Glu Ala Phe Ile Ile Cys Gly Thr Leu Tyr Val Thr Asn Gly Tyr Ser Gly Gly Thr Lys Val His Tyr Ala Tyr Gln Thr Asn Ala Ser Thr Tyr Glu Tyr Ile Asp Ile Pro Phe Gln Asn Lys Tyr Ser His Ile Ser Met Leu Asp Tyr Asn Pro Lys Asp Arg Ala Leu Tyr Ala Trp Asn Asn Gly His Gln Ile Leu Tyr Asn Va1 Thr Leu Phe His Val Ile Arg Ser Asp Glu Leu <210> 62 <211> 286 <212> PRT
<213> Homo sapiens <400> 62 Met Leu His Leu Leu Ala Leu Phe Leu His Cys Leu Pro Leu Ala Ser Gly Asp Tyr Asp Ile Cys Lys Ser Trp Val Thr Thr Asp Glu Gly Pro Thr Trp Glu Phe Tyr Ala Cys Gln Pro Lys Val Met Arg Leu Lys Asp Tyr Val Lys Val Lys Val Glu Pro Ser Gly Ile Thr Cys Gly Asp Pro Pro Glu Arg Phe Cys Ser His Glu Asn Pro Tyr Leu Cys Ser Asn Glu Cys Asp Ala Ser Asn Pro Asp Leu Ala His Pro Pro Arg Leu Met Phe Asp Lys Glu Glu Glu Gly Leu Ala Thr Tyr Trp Gln Ser Ile Thr Trp 100 105 l10 Ser Arg Tyr Pro Ser Pro Leu Glu Ala Asn Ile Thr Leu Ser Trp Asn Lys Thr Val Glu Leu Thr Asp Asp Val Val Met Thr Phe Glu Tyr Gly l30 135 140 Arg Pro Thr Val Met Val Leu Glu Lys Ser Leu Asp Asn Gly Arg Thr Trp Gln Pro Tyr Gln Phe Tyr Ala Glu Asp Cys Met Glu Ala Phe Gly Met Ser Ala Arg Arg Ala Arg Asp Met Ser Ser Ser Ser Ala His Arg Val Leu Cys Thr Glu Glu Tyr Ser Arg Trp Ala Gly Ser Lys Lys Glu Lys His Val Arg Phe Glu Val Arg Asp Arg Phe Ala Ile Phe Ala Gly Pro Asp Leu Arg Asn Met Asp Asn Leu Tyr Thr Arg Leu Glu Ser Ala Lys Gly Leu Lys Glu Phe Phe Thr Leu Thr Asp Leu Arg Met Arg Leu Leu Arg Pro Ala Leu Gly Gly Thr Tyr Val Gln Arg Glu Asn Leu Tyr Lys Tyr Phe Tyr Ala Ile Ser Asn Ile Glu Val Ile Gly Arg <210> 63 <211> 533 <212> PRT
<213> Homo sapiens <400> 63 Met Leu His Leu Leu Ala Leu Phe Leu His Cys Leu Pro Leu Ala Ser Gly Asp Tyr Asp Ile Cys Lys Ser Trp Val Thr Thr Asp Glu Gly Pro Thr Trp Glu Phe Tyr Ala Cys Gln Pro Lys Val Met Arg Leu Lys Asp Tyr Val Lys Val Lys Val Glu Pro Ser Gly Ile Thr Cys Gly Asp Pro Pro Glu Arg Phe Cys Ser His Glu Asn Pro Tyr Leu Cys Ser Asn Glu Cys Asp Ala Ser Asn Pro Asp Leu Ala His Pro Pro Arg Leu Met Phe Asp Lys Glu Glu Glu Gly Leu Ala Thr Tyr Trp Gln Ser Ile Thr Trp Ser Arg Tyr Pro Ser Pro Leu Glu Ala Asn Ile Thr Leu Ser Trp Asn Lys Thr Val Glu Leu Thr Asp Asp Va1 Val Met Thr Phe Glu Tyr Gly Arg Pro Thr Val Met Val Leu Glu Lys Ser Leu Asp Asn Gly Arg Thr Trp Gln Pro Tyr Gln Phe Tyr Ala Glu Asp Cys Met Glu Ala Phe Gly Met Ser Ala Arg Arg Ala Arg Asp Met Ser Ser Ser Ser Ala His Arg Val Leu Cys Thr Glu Glu Tyr Ser Arg Trp Ala Gly Ser Lys Lys Glu Lys His Val Arg Phe Glu Val Arg Asp Arg Phe Ala Ile Phe Ala Gly Pro Asp Leu Arg Asn Met Asp Asn Leu Tyr Thr Arg Leu Glu Ser Ala Lys Gly Leu Lys Glu Phe Phe Thr Leu Thr Asp Leu Arg Met Arg Leu Leu Arg Pro Ala Leu Gly Gly Thr Tyr Val Gln Arg Glu Asn Leu Tyr Lys Tyr Phe Tyr Ala Ile Ser Asn Ile Glu Val Ile Gly Arg Cys Lys Cys Asn Leu His Ala Asn Leu Cys Ser Met Arg Glu Gly Ser Leu Gln Cys Glu Cys Glu His Asn Thr Thr Gly Pro Asp Cys Gly Lys Cys Lys Lys Asn Phe Arg Thr Arg Ser Trp Arg Ala Gly Ser Tyr Leu Pro Leu Pro His Gly Ser Pro Asn Ala Cys Thr Pro Pro Ser Pro Arg Glu Leu Gly Ala Asp Cys Glu Cys Tyr Gly His Ser Asn Arg Cys Ser Tyr Ile Asp Phe Leu Asn Val Val Thr Cys Val Ser Cys Lys His Asn Thr Arg Gly Gln His Cys Gln His Cys Arg Leu Gly Tyr Tyr Arg Asn Gly Ser Ala Glu Leu Asp Asp Glu Asn Val Cys Ile Glu Cys Asn Cys Asn Gln Ile Gly Ser Val His Asp Arg Cys Asn Glu Thr Gly Phe Cys Glu Cys Arg Glu Gly Ala Ala Gly Pro Lys Cys Asp Asp Cys Leu Pro Thr His Tyr Trp Arg Gln Gly Cys Tyr Pro Asn Val Cys Asp Asp Asp Gln Leu Leu Cys Gln Asn Gly Gly Thr Cys Leu Gln Asn Gln Arg Cys Ala Cys Pro Arg Gly Tyr Thr Gly Val Arg Cys Glu Gln Pro Arg Cys Asp Pro Ala Asp Asp Asp Gly Gly Leu Asp Cys Asp Arg Ala Pro Gly Ala Ala Pro Arg Pro Ala Thr Leu Leu Gly Cys Leu Leu Leu Leu Gly Leu Ala Ala Arg Leu Gly Arg <210> 64 <211> 495 <2l2> PRT
<213> Homo sapiens <400> 64 Met Phe Ala Asn Ser Pro Gly Cys Ser Asn Met Leu His Tyr Val Tyr Cys Ala Cys Gly His Gly Leu Gln Leu Val Arg Ser Val Ser Ser Ser Val Asp Glu Gly Gly Thr Cys His Cys Met Val His Leu Pro Asn Asn Pro I1e Pro Leu Glu Gln Leu Glu Gln Leu Gln Ser Thr Ala Gln Glu Leu Ile Cys Lys Tyr Glu Gln Lys Leu Ser Arg Cys Ala Arg Ala Ile Glu Asp Lys Asp Asn Glu Val Leu Glu Met Ser His Met Leu Lys Ser Trp Asn Pro Ser Ala Leu Ala Ser Pro Tyr Glu Asn Pro Gly Phe Asn Leu Leu Cys Leu Glu Leu Glu Gly Ala Gln Glu Leu Val Thr Gln Leu Lys Ala Met Gly Gly Val Ser Val Ala Gly Asp Leu Leu His Gln Leu Gln Ser Gln Val Thr Asn Ala Ser Leu Thr Leu Lys Leu Leu Ala Asp Ser Asp Gln Cys Ser Phe Gly Ala Leu Gln Gln Glu Val Asp Val Leu Glu Ser Gln Leu Ser Glu Cys Glu Arg Glu Lys Glu Lys Glu Gly Leu Trp Thr Pro Trp Thr Thr Pro Pro Pro Ala Ser Cys Ala His Gly Gly Leu Gln Glu Val Ser Lys Ser Leu Val Val Gln Leu Thr Arg Arg Gly Phe Ser Tyr Lys Ala Gly Pro Trp Gly Arg Asp Ser Ala Pro Asn Pro Ala Ser Ser Leu Tyr Trp Val Ala Pro Leu Arg Thr Asp Gly Arg Tyr Phe Asp Tyr Tyr Arg Leu Pro Pro Ser Tyr Asn Asp Leu Ala Leu Met Lys Asn Tyr Glu Glu Arg Lys Met Gly Tyr Gly Asp Gly Ser Gly Asn Val Val Tyr Lys Asn Phe Met Tyr Phe Asn Tyr Cys Gly Thr Ser Asp Met Ala Lys Met Asp Leu Ser Ser Asn Thr Leu Val Leu Trp Arg Leu Leu Pro Gly Ala Thr Tyr Asn Asn Arg Phe Ser Cys Ala Gly Val Pro Trp Lys Asp Leu Asp Phe Ala Gly Asp Glu Lys Gly Leu Trp Val Leu Tyr Ala Thr Glu Glu Ser Lys Gly Asn Leu Val Val Ser Arg Leu Asn Ala Ser Thr Leu Glu Val Glu Lys Thr Trp Arg Thr Ser Gln Tyr Lys Pro Ala Leu Ser Gly Ala Phe Met Ala Cys Gly Val Leu Tyr Ala Leu His Ser Leu Asn Thr His Gln Glu Glu Ile Phe Tyr Ala Phe Asp Thr Thr Thr Gly Gln Glu Arg Arg Leu Ser Ile Leu Leu Asp Lys Met Leu Glu Lys Leu Gln Gly Ile Asn Tyr Cys Pro Ser Asp His Lys Pro Tyr Val Phe Ser Asp Gly Tyr Leu Ile Asn Tyr Asp Leu Thr Phe Leu Thr Met Lys Thr Arg Leu Pro Arg Pro Pro Thr Arg Arg Pro Ser Gly Ala His Ala Pro Pro Lys Pro Va1 Lys Pro Asn Glu Ala Ser Arg Pro <210> 65 <211> 350 <212> PRT
<213> Homo sapiens <400> 65 Met Arg Asn His Lys Lys Val Thr Asn Ala Ser Leu Thr Leu Lys Leu Leu Ala Asp Ser Asp Gln Cys Ser Phe Gly Ala Leu Gln Gln Glu Val Asp Val Leu Glu Ser Gln Leu Ser Glu Ser Ser Cys Ala His Gly Gly Leu Gln Glu Val Ser Lys Ser Leu Val Val Gln Leu Thr Arg Arg Gly Phe Ser Tyr Lys Ala Gly Pro Trp Gly Arg Asp Ser Ala Pro Asn Pro Ala Ser Ser Leu Tyr Trp Val Ala Pro Leu Arg Thr Asp Gly Ser Tyr Gly Cys His Pro Ile Ile Leu Asn Ala Gly Thr Trp Pro Arg Tyr Phe Asp Tyr Tyr Arg Leu Cys Lys Ser Tyr Asn Asp Leu Ala Leu Leu Lys Asn Tyr Glu Glu Arg Lys Met Gly Tyr Gly Asp Gly Ser Gly Asn Val Val Tyr Lys Asn Phe Met Tyr Phe Asn Tyr Cys Gly Thr Ser Asp Met Ala Lys Met Asp Leu Ser Ser Asn Thr Leu Val Leu Trp Arg Leu Leu Pro Gly Ala Thr Tyr Asn Asn Arg Phe Ser Cys Ala Gly Val Pro Trp Lys Asp Leu Asp Phe Ala Gly Asp Glu Lys Gly Leu Trp Val Leu Tyr Ala Thr Glu Glu Ser Lys Gly Asn Leu Val Val Ser Arg Leu Asn Ala Ser Thr Leu Glu Val Glu Lys Thr Trp Arg Thr Ser Gln Tyr Lys Pro Ala Leu Ser Gly Ala Phe Met Ala Cys Gly Val Leu Tyr Ala Leu His Ser Leu Asn Thr His Gln Glu Glu Ile Phe Tyr Ala Phe Asp Thr Thr 260 265 270 , Thr Gly Gln Glu Arg Arg Leu Ser Ile Leu Leu Asp Lys Met Leu Glu Lys Leu Gln Gly Ile Asn Tyr Cys Pro Ser Asp His Lys Pro Tyr Val Phe Ser Asp Gly Tyr Leu Ile Asn Tyr Asp Leu Thr Phe Leu Thr Met Lys Thr Arg Leu Pro Arg Pro Pro Thr Arg Arg Pro Ser Gly Ala His Ala Pro Pro Lys Pro Val Lys Pro Asn Glu Ala Ser Arg Pro <210> 66 <211> 619 <212> PRT
<213> Homo Sapiens <400> 66 Met Gly Arg Gly Arg Ala Leu Leu Pro Ile Glu Met Leu Gln Leu Ser Leu Arg Glu Glu Ser Asp Thr Ala Arg Met Gly Ala Gln Glu Gln Ile Gly Leu Gln Asp Glu Ile Gln Ala A1a Asn Ala Gly Ile Ser Gly Ser Pro Gly Val Asp G1y Val Val Asp Gly Gly Ser Ser Arg Gly Asp Pro Ala Leu Thr Val Ser Val Cys Glu Val Pro Pro Val Arg Ser Pro Phe Arg Thr His Pro Gln Leu Pro Val Arg Leu Pro Arg Asn Leu Glu Phe Ser Va1 Pro Glu Arg Arg Thr Leu Arg Asn Arg Leu Thr Ser Ala Thr Leu Ala Pro Pro Thr Arg His Met Leu Leu Leu Leu Leu Leu Leu Pro Pro Leu Leu Cys Gly Arg Val Gly Ala Lys Glu Gln Lys Asp Tyr Leu Leu Thr Met Gln Lys Ser Val Thr Val Gln Glu Gly Leu Cys Val Ser Val Leu Cys Ser Phe Ser Tyr Pro Gln Asn Gly Trp Thr Ala Ser Asp Pro Val His Gly Tyr Trp Phe Arg Ala Gly Asp His Val Ser Arg Asn Ile Pro Val Ala Thr Asn Asn Pro Ala Arg Ala Val Gln Glu Glu Thr Arg Asp Arg Phe His Leu Leu Gly Asp Pro Gln Asn Lys Asp Cys Thr Leu Ser Ile Arg Asp Thr Arg Glu Ser Asp Ala Gly Thr Tyr Val Phe Cys Val Glu Arg Gly Asn Met Lys Trp Asn Tyr Lys Tyr Asp Gln Leu Ser Val Asn Val Thr Ala Leu Thr His Met Pro Thr Phe Ser Ile Pro Gly Thr Leu Glu Ser Gly His Pro Arg Asn Leu Thr Cys Ser Val Pro Trp Ala Cys Glu Gln Gly Thr Pro Pro Thr Ile Thr Trp Met Gly Ala Ser Val Ser Ser Leu Asp Pro Thr Ile Thr Arg Ser Ser Met Leu Ser Leu Ile Pro Gln Pro Gln Asp His Gly Thr Ser Leu Thr Cys Gln Val Thr Leu Pro Gly Ala Gly Val Thr Met Thr Arg Ala Val Arg Leu Asn Ile Ser Tyr Pro Pro Gln Asn Leu Thr Met Thr Val Phe Gln Gly Asp Gly Thr Ala Ser Thr Thr Leu Arg Asn Gly Ser Ala Leu Ser Val Leu Glu Gly Gln Ser Leu His Leu Val Cys Ala Val Asp Ser Asn Pro Pro Ala Arg Leu Ser Trp Thr Trp Gly Ser Leu Thr Leu Ser Pro Ser G1n Ser Ser Asn Leu Gly Val Leu Glu Leu Pro Arg Val His Val Lys Asp Glu Gly Glu Phe Thr Cys Arg Ala Gln Asn Pro Leu Gly Ser Gln His Ile Ser Leu Ser Leu Ser Leu Gln Asn Glu Tyr Thr Gly Lys Met Arg Pro Ile Ser Gly Val Thr Leu Gly Ala Phe Gly Gly Ala Gly Ala Thr Ala Leu Val Phe Leu Tyr Phe Cys Ile Ile Phe Val Val Val Arg Ser Cys Arg Lys Lys Ser Ala Arg Pro Ala Val Gly Val Gly Asp Thr Gly Met Glu Asp Ala Asn Ala Val Arg Gly Ser Ala Ser Gln Met Glu Glu Gly Thr Pro Gly Pro Pro Ser Trp Met Leu Ser Gly Ala Cys Trp Pro His Cys Ser Ala Leu Thr Pro Phe Ser Ser Ser Ile Gln Gly Pro Leu Ile Glu Ser Pro Ala Asp Asp Ser Pro Pro His His Ala Pro Pro Ala Leu Ala Thr Pro Ser Pro Glu Glu Gly Glu Ile Gln Tyr Ala Ser Leu Ser Phe His Lys Ala Arg Pro Gln Tyr Pro Gln Glu Gln Glu Ala Ile Gly Tyr Glu Tyr Ser Glu Ile Asn Ile Pro Lys <210> 67 <211> 490 <212> PRT
<213> Homo sapiens <400> 67 Met Leu Leu Leu Leu Leu Leu Leu Pro Pro Leu Leu Cys Gly Arg Val Gly Ala Lys Glu Gln Lys Asp Tyr Leu Leu Thr Met Gln Lys Ser Val Thr Val Gln Glu Gly Leu Cys Val Ser Val Leu Cys Ser Phe Ser Tyr Pro Gln Asn Gly Trp Thr Ala Ser Asp Pro Val His Gly Tyr Trp Phe Arg Ala Gly Asp His Val Ser Arg Asn Ile Pro Val Ala Thr Asn Asn Pro Ala Arg Ala Val Gln Glu Glu Thr Arg Asp Arg Phe His Leu Leu Gly Asp Pro Gln Asn Lys Asp Cys Thr Leu Ser Ile Arg Asp Thr Arg Glu Ser Asp Ala Gly Thr Tyr Val Phe Cys Val Glu Arg Gly Asn Met Lys Trp Asn Tyr Lys Tyr Asp Gln Leu Ser Val Asn Val Thr Ala Leu Thr His Met Pro Thr Phe Ser Ile Pro Gly Thr Leu Glu Ser Gly His Pro Arg Asn Leu Thr Cys Ser Val Pro Trp Ala Cys Glu Gln Gly Thr Pro Pro Thr Ile Thr Trp Met Gly Ala Ser Val Ser Ser Leu Asp Pro Thr Tle Thr Arg Ser Ser Met Leu Ser Leu I1e Pro Gln Pro Gln Asp His Gly Thr Ser Leu Thr Cys Gln Val Thr Leu Pro Gly Ala Gly Val Thr Met Thr Arg Ala Val Arg Leu Asn Ile Ser Tyr Pro Pro Gln Asn Leu Thr Met Thr Va1 Phe Gln Gly Asp Gly Thr Ala Ser Thr Thr Leu Arg Asn Gly Ser Ala Leu Ser Val Leu Glu Gly Gln Ser Leu His Leu Val Cys Ala Val Asp Ser Asn Pro Pro Ala Arg Leu Ser Trp Thr Trp Gly Ser Leu Thr Leu Ser Pro Ser Gln Ser Ser Asn Leu Gly Val Leu Glu Leu Pro Arg Val His Val Lys Asp Glu Gly Glu Phe Thr Cys Arg Ala Gln Asn Pro Leu Gly Ser Gln His Ile Ser Leu Ser Leu Ser Leu Gln Asn Glu Tyr Thr Gly Lys Met Arg Pro Ile Ser Gly Val Thr Leu Gly Ala Phe Gly Gly Ala Gly Ala Thr Ala Leu Val Phe Leu Tyr Phe Cys Ile Ile Phe Val Val Val Arg Ser Cys Arg Lys Lys Ser Ala Arg Pro Ala Val Gly Val Gly Asp Thr Gly Met Glu Asp Ala Asn Ala Val Arg G1y Ser Ala Ser G1n Gly Pro Leu Thr Glu Ser Trp Lys Asp Gly Asn Pro Leu Lys Lys Pro Pro Pro Ala Val Ala Pro Ser Ser Gly Glu Glu Gly Glu Leu His Tyr Ala Thr Leu Ser Phe His Lys Val Lys Pro Gln Asp Pro Gln Gly Gln Glu Ala Thr Asp Ser Glu Tyr Ser Glu Ile Lys Ile His Lys Arg Glu Thr Ala Glu Thr Gln Ala Cys Leu Arg Asn His Asn Pro Ser Ser Lys Glu Val Arg Gly <210> 68 <211> 462 <212> PRT
<213> Homo Sapiens <400> 68 Met Leu Pro Leu Trp Thr Leu Ser Leu Leu Leu Gly Ala Val Ala Gly Lys Glu Val Cys Tyr Glu Arg Leu Gly Cys Phe Ser Asp Asp Ser Pro Trp Ser Gly Ile Thr Glu Arg Pro Leu His Ile Leu Pro Trp Ser Pro Lys Asp Val Asn Thr Arg Phe Leu Leu Tyr Thr Asn Glu Asn Pro Asn Asn Phe Gln Glu Ile Ser Ala Val Asn Ser Ser Thr Ile Gln Ala Ser Tyr Phe Gly Thr Asp Lys Ile Thr Arg Ile Asn Ile Ala Gly Trp Lys Thr Asp Gly Lys Trp Gln Arg Asp Met Cys Asn Val Leu Leu Gln Leu Glu Asp Ile Asn Cys Ile Asn Leu Asp Trp Ile Asn Gly Ser Arg Glu Tyr Ile His Ala Val Asn Asn Leu Arg Val Val Gly Ala Glu Val Ala Tyr Phe Ile Asp Val Leu Met Lys Lys Phe Glu Tyr Ser Pro Ser Lys Val His Leu Ile Gly His Ser Leu Gly Ala His Leu Ala Gly Glu Ala Gly Ser Arg Ile Pro Gly Leu Gly Arg Ile Thr Gly Lys His Ala Leu Gln Leu Gly Leu Glu Cys Ala Thr Glu Gly Tyr Leu Leu Ser Ala Thr Leu Ala Asn Asn Val Asn Phe Val Asp Thr Asn His Met Asp Ala Thr Pro Ile Ile Pro Gln Trp Met Arg Gly Thr Ser Gly Thr Ser Asn Pro Leu Pro Val Thr Ser Ser Leu Cys Leu Trp Leu Ala Asp Leu Gly Ser Val Ser Leu Val Cys Leu Trp Pro Glu Met Ala Ser Phe Phe Asp Cys Asn His Ala Arg Ser Tyr Gln Phe Tyr Ala Glu Ser Ile Leu Asn Pro Asp Ala Phe Ile Ala Tyr Pro Cys Arg Ser Tyr Thr Ser Phe Lys Ala Gly Asn Cys Phe Phe Cys Ser Lys Glu Gly Cys Pro Thr Met Gly His Phe Ala Asp Arg Phe His Phe Lys Asn Met Lys Thr Asn Gly Ser His Tyr Phe Leu Asn Thr Gly Ser Leu Ser Pro Phe Ala Arg Trp Arg His Lys Leu Ser Val Lys Leu Ser Gly Ser Glu Val Thr Gln Gly Thr Val Phe Leu Arg Val Gly Gly Ala Val Arg Lys Thr Gly Glu Phe Ala Ile Val Ser Gly Lys Leu Glu Pro Gly Met Thr Tyr Thr Lys Leu Ile Asp Ala Asp Val Asn Val Gly Asn Ile Thr Ser Val Gln Phe Ile Trp Lys 56!69 Lys His Leu Phe Glu Asp Ser Gln Asn Lys Leu Gly Ala Glu Met Val Ile Asn Thr Ser Gly Lys Tyr Gly Tyr Lys Ser Thr Phe Cys Ser Gln Asp Ile Met Gly Pro Asn Ile Leu Gln Asn Leu Lys Pro Cys <210> 69 <211> 255 <212> PRT
<213> Homo Sapiens <400> 69 Met Val Leu Leu Leu Val Ile Leu Ile Pro Val Leu Val Ser Ser Ala Gly Thr Ser Ala His Tyr Glu Met Leu Gly Thr Cys Arg Met Val Cys Asp Pro Tyr Gly Gly Thr Lys Ala Pro Ser Thr Ala Ala Thr Pro Asp Arg Gly Leu Met Gln Ser Leu Pro Thr Phe Ile Gln Gly Pro Lys Gly Glu Ala Gly Arg Pro Gly Lys Ala Gly Pro Arg Gly Pro Pro Gly Glu Pro Gly Pro Pro Gly Pro Met Gly Pro Pro Gly Glu Lys G1y Glu Pro Gly Arg Gln Gly Leu Pro Gly Pro Pro Gly Ala Pro Gly Leu Asn Ala Ala Gly Ala Ile Ser Ala Ala Thr Tyr Ser Thr Gly Pro Lys Ile Ala Phe Tyr Ala Gly Leu Lys Arg Gln His Glu Gly Tyr Glu Val Leu Lys Phe Asp Asp Val Val Thr Asn Leu Gly Asn His Tyr Asp Pro Thr Thr 145 150 l55 160 Gly Lys Phe Thr Cys Ser Ile Pro Gly Ile Tyr Phe Phe Thr Tyr His Va1 Leu Met Arg G1y Gly Asp Gly Thr Ser Met Trp Ala Asp Leu Cys Lys Asn Asn Gln Val Arg Ala Ser Ala Ile Ala Gln Asp Ala Asp Gln Asn Tyr Asp Tyr Ala Ser Asn Ser Val Val Leu His Leu Glu Pro Gly Asp Glu Val Tyr Ile Lys Leu Asp Gly Gly Lys Aha His Gly Gly Asn Asn Asn Lys Tyr Ser Thr Phe Ser Gly Phe Ile Ile Tyr Ala Asp <210> 70 <211> 784 <212> PRT
<213> Homo Sapiens <400> 70 Met Glu Gly Asp Gly Gly Thr Pro Trp Ala Leu Ala Leu Leu Arg Thr Phe Asp Ala Gly Glu Phe Thr Gly Trp Glu Lys Val Gly Ser Gly Gly Phe Gly Gln Val Tyr Lys Va1 Arg His Val His Trp Lys Thr Trp Leu Ala Ile Lys Cys Ser Pro Ser Leu His Val Asp Asp Arg Glu Arg Met Glu Leu Leu Glu Glu Ala Lys Lys Met Glu Met Ala Lys Phe Arg Tyr Ile Leu Pro Val Tyr Gly Ile Cys Arg Glu Pro Val Gly Leu Val Met Glu Tyr Met Glu Thr G1y Ser Leu Glu Lys Leu Leu Ala Ser Glu Pro Leu Pro Trp Asp Leu Arg Phe Arg Ile Ile His Glu Thr Ala Val Gly Met Asn Phe Leu His Cys Met Ala Pro Pro Leu Leu His Leu Asp Leu Lys Pro Ala Asn Ile Leu Leu Asp Ala His Tyr His Val Lys Ile Ser Asp Phe Gly Leu Ala Lys Cys Asn Gly Leu Ser His Ser His Asp Leu Ser Met Asp Gly Leu Phe Gly Thr Ile Ala Tyr Leu Pro Pro Glu Arg Ile Arg Glu Lys Ser Arg Leu Phe Asp Thr Lys His Asp Val Tyr Ser Phe Ala Ile Val Ile Trp Gly Val Leu Thr Gln Lys Lys Pro Phe Ala Asp Glu Lys Asn Ile Leu His Ile Met Val Lys Val Val Lys Gly His Arg Pro Glu Leu Pro Pro Val Cys Arg Ala Arg Pro Arg Ala Cys Ser His Leu Ile Arg Leu Met Gln Arg Cys Trp G1n Gly Asp Pro Arg Val Arg Pro Thr Phe Gln Glu Ile Thr Ser Glu Thr Glu Asp Leu Cys Glu Lys Pro Asp Asp Glu Val Lys Glu Thr Ala His Asp Leu Asp Val Lys Ser Pro Pro Glu Pro Arg Ser Glu Val Val Pro Ala Arg Leu Lys Arg Ala Ser Ala Pro Thr Phe Asp Asn Asp Tyr Ser Leu Ser Glu Leu Leu Ser Gln Leu Asp Ser Gly Val Ser Gln Ala Val Glu Gly Pro Glu Glu Leu Ser Arg Ser Ser Ser Glu Ser Lys Leu Pro Ser Ser Gly Ser Gly Lys Arg Leu Ser Gly Val Ser Ser Val Asp Ser Ala Phe Ser Ser Arg Gly Ser Leu Ser Leu Ser Phe Glu Arg Glu Pro Ser Thr Ser Asp Leu Gly Thr Thr Asp Val Gln Lys Lys Lys Leu Val Asp Ala Ile Val Ser Gly Asp Thr Ser Lys Leu Met Lys Ile Leu Gln Pro Gln Asp Val Asp Leu Ala Leu Asp Ser Gly Ala Ser Leu Leu His Leu Ala Val Glu Ala Gly Gln Glu Glu Cys Ala Lys Trp Leu Leu Leu Asn Asn Ala Asn Pro Asn Leu Ser Asn Arg Arg Gly Ser Thr Pro Leu His Met Ala Val Glu Arg Arg Val Arg Gly Val Val Glu Leu Leu Leu Ala Arg Lys Ile Ser Val Asn Ala Lys Asp Glu Asp Gln Trp Thr Ala Leu His Phe Ala Ala Gln Asn Gly Asp Glu Ser Ser Thr Arg Leu Leu Leu Glu Lys Asn Ala Ser Val Asn Glu Val Asp Phe Glu Gly Arg Thr Pro Met His Val Ala Cys Gln His Gly Gln Glu Asn Ile Val Arg Ile Leu Leu Arg Arg Gly Val Asp Val Ser Leu Gln Gly Lys Asp Ala Trp Leu Pro Leu His Tyr Ala Ala Trp Gln Gly His Leu Pro Ile Val Lys Leu Leu Ala Lys Gln Pro Gly Val Ser Val Asn Ala Gln Thr Leu Asp Gly Arg Thr Pro Leu His Leu Ala Ala Gln Arg Gly His Tyr Arg Val Ala Arg Ile Leu Ile Asp Leu Cys Ser Asp Val Asn Val Cys Ser Leu Leu Ala Gln Thr Pro Leu His Val Ala Ala Glu Thr Gly His Thr Ser Thr Ala Arg Leu Leu Leu His Arg Gly Ala Gly Lys Glu Ala Met Thr Ser Asp Gly Tyr Thr Ala Leu His Leu Ala Ala Arg Asn Gly His Leu Ala Thr Val Lys Leu Leu Val Glu Glu Lys Ala Asp Val Leu Ala Arg Gly Pro Leu Asn Gln Thr Ala Leu His Leu Ala Ala Ala His Gly His Ser Glu Val Val Glu Glu Leu Val Ser Ala Asp Val Ile Asp Leu Phe Asp Glu Gln G1y Leu Ser Ala Leu His Leu Ala Ala Gln Gly Arg His Ala Gln Thr Val Glu Thr Leu Leu Arg His Gly Ala His Ile Asn Leu Gln Ser Leu Lys Phe Gln Gly Gly His Gly Pro Ala Ala Thr Leu Leu Arg Arg Ser Lys Thr <210> 71 <21l> 252 <212> PRT
<213> Homo sapiens <400> 71 Met Ala Ala Pro Ala Leu Leu Leu Leu Ala Leu Leu Leu Pro Val Gly 1 5 l0 15 Ala Trp Pro Gly Leu Pro Arg Arg Pro Cys Val His Cys Cys Arg Pro Ala Trp Pro Pro Gly Pro Tyr Ala Arg Val Ser Asp Arg Asp Leu Trp Arg Gly Asp Leu Trp Arg Gly Leu Pro Arg Val Arg Pro Thr Ile Asp Ile Glu Ile Leu Lys Gly Glu Lys Gly Glu Ala Gly Val Arg Gly Arg Ala Gly Arg Ser Gly Lys Glu Gly Pro Pro Gly Ala Arg Gly Leu Gln 85 90 ' 95 Gly Arg Arg Gly Gln Lys Gly Gln Val Gly Pro Pro Gly A1a Ala Cys l00 105 110 Arg Arg Ala Tyr Ala Ala Phe Ser Val Gly Arg Arg Glu Gly Leu His Ser Ser Asp His Phe Gln Ala Val Pro Phe Asp Thr Glu Leu Val Asn 130 135 l40 Leu Asp Gly Ala Phe Asp Leu Ala Ala Gly Arg Phe Leu Cys Thr Val Pro Gly Val Tyr Phe Leu Ser Leu Asn Val His Thr Trp Asn Tyr Lys Glu Thr Tyr Leu His Ile Met Leu Asn Arg Arg Pro Ala Ala Val Leu Tyr Ala Gln Pro Ser Glu Arg Ser Val Met Gln Ala Gln Ser Leu Met Leu Leu Leu Ala Ala Gly Asp Ala Val Trp Val Arg Met Phe Gln Arg Asp Arg Asp Asn Ala Ile Tyr Gly Glu His Gly Asp Leu Tyr Ile Thr Phe Ser Gly His Leu Val Lys Pro Ala Ala Glu Leu <210> 72 <211> 593 <212> PRT
<213> Homo sapiens <400> 72 Met Pro Ser Ser Leu Phe Ala Asp Leu Glu Arg Asn Gly Ser Gly Gly Gly Gly Gly Gly Ser Ser Gly Gly Gly Glu Thr Leu Asp Asp Gln Arg Ala Leu Gln Leu Ala Leu Asp Gln Leu Ser Leu Leu Gly Leu Asp Ser Asp Glu Gly Ala Ser Leu Tyr Asp Ser Glu Pro Arg Lys Lys Ser Val Asn Met Thr Glu Cys Val Pro Val Pro Ser Ser Glu His Val Ala Glu Ile Val Gly Arg Gln Gly Arg Ser Arg Arg Asp Gly Glu Leu Asp Pro Ser Gly Ile Ser Pro Asp Asp Phe Ser Gly Ile Leu Gly Phe Gly Ser Gly Arg Leu Gln Ser Leu Gly Glu Gly Gln Ala Ala Asn Gly Leu Phe Leu Glu Arg Leu Ala Gly Gly Ile Arg Cys Pro Ala Arg Gly Ala Ala Arg Gly Cys Lys Ile Lys Ala Leu Arg Ala Lys Thr Asn Thr Tyr Ile Lys Thr Pro Val Arg Gly Glu Glu Pro Val Phe Val Val Thr Gly Arg Lys Glu Asp Val Ala Met Ala Arg Arg Glu Ile Ile Ser Ala Ala Glu His Phe Ser Met Ile Arg Ala Ser Arg Asn Lys Asn Thr Ala Leu Asn Gly Ala Val Pro Gly Pro Pro Asn Leu Pro Gly Gln Thr Thr Ile Gln Val Arg Val Pro Tyr Arg Val Val Gly Leu Val Val Gly Pro Lys Gly Ala Thr Ile Lys Arg Ile Gln Gln Gln Thr His Thr Tyr Ile Val Thr Pro Ser Arg Asp Lys Glu Pro Val Phe Glu Val Thr Gly Met Pro Glu 260 ' 265 270 Asn Val Asp Arg Ala Arg Glu Glu Ile Glu Ala His Ile Ala Leu Arg Thr Gly Gly Ile Ile Glu Leu Thr Asp G1u Asn Asp Phe His Ala Asn Gly Thr Asp Val Gly Phe Asp Leu His His Gly Ser Gly Gly Ala Ser Thr Asp Ser Tyr Phe Gly Gly Gly Thr Ser Ser Ser Ala Ala Ala Thr Gln Arg Leu Ala Asp Tyr Ser Pro Pro Ser Pro Ala Leu Ser Phe Ala His Asn Gly Asn Asn Asn Asn Asn Gly Asn Gly Tyr Thr Tyr Thr Ala Gly Gly Glu Ala Ser Val Pro Ser Pro Asp Gly Cys Pro Glu Leu Gln Pro Thr Phe Asp Pro Ala Pro Ala Pro Pro Pro Gly Ala Pro Leu Ile Trp Ala Gln Phe Glu Arg Ser Pro Gly Gly Gly Pro Ala Ala Pro Val Ser Ser Ser Cys Ser Ser Ser Ala Ser Ser Ser Ala Ser Ser Ser Ser Val Val Phe Pro Gly Gly Gly Ala Ser Ala Pro Ser Asn Ala Asn Leu Gly Leu Leu Val His Arg Arg Leu His Pro Gly Thr Ser Cys Pro Arg Leu Ser Pro Pro Leu His Met Ala Pro Gly Ala Gly Glu His His Leu Ala Arg Arg Val Arg Ser Asp Pro Gly Gly Gly Gly Leu Ala Tyr Ala Ala Tyr Ala Asn Gly Leu Gly Ala Gln Leu Pro Gly Leu Gln Pro Ser Asp Thr Ser Gly Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser 5l5 520 525 Ser Ser Ser Ser Gly Leu Arg Arg Lys Gly Ser Arg Asp Cys Ser Val Cys Phe Glu Ser Glu Val Ile Ala Ala Leu Val Pro Cys Gly His Asn Leu Phe Cys Met Glu Cys Ala Asn Arg Ile Cys Glu Lys Ser Glu Pro Glu Cys Pro Val Cys His Thr Ala Val Thr Gln Ala I1e Arg Ile Phe Ser <210> 73 <211> 472 <212> PRT
<213> Homo sapiens <400> 73 Met Pro Ser Ser Leu Phe Ala Asp Leu Glu Arg Asn Gly Ser Gly Gly Gly Gly Gly Gly Ser Ser Gly Gly Gly Glu Thr Leu Asp Asp Gln Arg Ala Leu Gln Leu Ala Leu Asp Gln Leu Ser Leu Leu Gly Leu Asp Ser Asp Glu Gly Ala Ser Leu Tyr Asp Ser Glu Pro Arg Lys Lys Ser Val 50 55 . 60 Asn Met Thr Glu Cys Val Pro Val Pro Ser Ser Glu His Val Ala Glu Ile Val Gly Arg Gln Gly Cys Lys Ile Lys Ala Leu Arg Ala Lys Thr Asn Thr Tyr Ile Lys Thr Pro Val Arg Gly Glu Glu Pro Val Phe Val Val Thr Gly Arg Lys Glu Asp Val Ala Met Ala Arg Arg Glu Ile Ile Ser Ala Ala Glu His Phe Ser Met Ile Arg Ala Ser Arg Asn Lys Asn Thr Ala Leu Asn Gly Ala Val Pro Gly Pro Pro Asn Leu Pro Gly Gln Thr Thr Ile Gln Val Arg Val Pro Tyr Arg Val Val Gly Leu Val Val Gly Pro Lys Gly Ala Thr Ile Lys Arg Ile Gln Gln Gln Thr His Thr Tyr Ile Val Thr Pro Ser Arg Asp Lys Glu Pro Val Phe Glu Val Thr Gly Met Pro Glu Asn Val Asp Arg Ala Arg Glu Glu Ile Glu Ala His Ile Ala Leu Arg Thr Gly Gly Ile Ile Glu Leu Thr Asp Glu Asn Asp Phe His Ala Asn Gly Thr Asp Val Gly Phe Asp Leu His His Gly Ser Gly Gly Ser Gly Pro G1y Ser Leu Trp Ser Lys Pro Thr Pro Ser Ile Thr Pro Thr Pro Gly Arg Lys Pro Phe Ser Ser Tyr Arg Asn Asp Ser Ser Ser Ser Leu Gly Ser Ala Ser Thr Asp Ser Tyr Phe Gly Gly Gly Thr Ser Ser Ser Ala Ala Ala Thr G1n Arg Leu Ala Asp Tyr Ser Pro Ala Pro Ser Asn Ala Asn Leu Gly Leu Leu Val His Arg Arg Leu His Pro Gly Thr Ser Cys Pro Arg Leu Ser Pro Pro Leu His Met Ala Pro Gly Ala Gly Glu His His Leu Ala Arg Arg Val Arg Ser Asp Pro G1y Gly Gly Gly Leu Ala Tyr Ala Ala Tyr Ala Asn Gly Leu Gly Ala Gln Leu Pro Gly Leu Gln Pro Ser Asp Thr Ser Gly Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Gly Leu Arg Arg Lys Gly Ser Arg Asp Cys Ser Val Cys Phe Glu Ser Glu Val Ile Ala Ala Leu Val Pro Cys Gly His Asn Leu Phe Cys Met Glu Cys Ala Asn Arg Ile Cys Glu Lys Ser Glu Pro Glu Cys Pro Val Cys His Thr Ala Val Thr Gln Ala Ile Arg Ile Phe Ser <210> 74 <211> 607 <212> PRT
<213> Homo sapiens <400> 74 Met Trp Gly Leu Val Arg Leu Leu Leu Ala Trp Leu Gly Gly Trp Gly Cys Met Gly Arg Leu Ala Ala Pro Ala Arg Ala Trp Ala Gly Ser Arg Glu His Pro Gly Pro Ala Leu Leu Arg Thr Arg Arg Ser Trp Val Trp Asn Gln Phe Phe Val Ile Glu Glu Tyr Ala Gly Pro Glu Pro Val Leu 62!69 Ile G1y Lys Leu His Ser Asp Val Asp Arg Gly Glu Gly Arg Thr Lys Tyr Leu Leu Thr Gly Glu Gly Ala Gly Thr Val Phe Val Ile Asp Glu Ala Thr Gly Asn Ile His Val Thr Lys Ser Leu Asp Arg Glu Glu Lys Ala Gln Tyr Val Leu Leu Ala Gln Ala Val Asp Arg Ala Ser Asn Arg Pro Leu Glu Pro Pro Ser Glu Phe Ile Ile Lys Val Gln Asp Ile Asn Asp Asn Pro Pro Ile Phe Pro Leu Gly Pro Tyr His Ala Thr Val Pro Glu Met Ser Asn Val Gly Thr Ser Val Ile Gln Val Thr Ala His Asp 165 . 170 175 Ala Asp Asp Pro Ser Tyr Gly Asn Ser Ala Lys Leu Val Tyr Thr Val Leu Asp Gly Leu Pro Phe Phe Ser Val Asp Pro Gln Thr Gly Val Val Arg Thr Ala Ile Pro Asn Met Asp Arg Glu Thr Gln Glu Glu Phe Leu Val Val Ile Gln Ala Lys Asp Met Gly Gly His Met Gly Gly Leu Ser Gly Ser Thr Thr Val Thr Val Thr Leu Ser Asp Val Asn Asp Asn Pro Pro Lys Phe Pro Gln Ser Leu Tyr Gln Phe Ser Val Val Glu Thr Ala Gly Pro Gly Thr Leu Val Gly Arg Leu Arg Ala Gln Asp Pro Asp Leu Gly Asp Asn Ala Leu Met Ala Tyr Ser Ile Leu Asp Gly Glu Gly Ser Glu Ala Phe Ser Ile Ser Thr Asp Leu Gln Gly Arg Asp Gly Leu Leu Thr Val Arg Lys Pro Leu Asp Phe Glu Ser Gln Arg Ser Tyr Ser Phe Arg Val Glu Ala Thr Asn Thr Leu Ile Asp Pro Ala Tyr Leu Arg Arg Gly Pro Phe Lys Asp Val Ala Ser Val Arg Val Ala Val Gln Asp Ala Pro Glu Pro Pro Ala Phe Thr Gln Ala Ala Tyr His Leu Thr Val Pro Glu Asn Lys Ala Pro Gly Thr Leu Val Gly Gln Ile Ser Ala Ala Asp Leu Asp Ser Pro Ala Ser Pro Ile Arg Tyr Ser Ile Leu Pro His Ser 405 4l0 415 Asp Pro Glu Arg Cys Phe Ser Ile Gln Pro Glu Glu Gly Thr Ile His Thr Ala Ala Pro Leu Asp Arg Glu Ala Arg Ala Trp His Asn Leu Thr Val Leu Ala Thr Glu Leu Val Pro Tyr Thr Pro Ala Tyr Ala Ser Gly Ala Pro Pro Pro Phe Cys Leu His Thr Ala Tyr Glu Asn Cys Pro Cys Ile Cys Gly Tyr Leu Asn Val Ser Val Lys Ala Tyr Met Asn Val His Met Trp Ala Met Val Leu Val Phe Ala Glu His Lys Gly Gly Gly Arg Gly Pro Gly Arg Gln Ala Val Asp Gly Gln Lys Gln Ser Thr Arg Trp Glu Leu Ser Gln Asn Cys Asn Tyr Leu Pro Lys Ser Arg Glu Gly Val His Pro Gly Thr Ser Met Arg Ala Gln Ala Ser Gln Leu Gln Gly Ser Arg Gly Thr His Arg Asn Cys Thr Arg Ile Ala Cys His Thr Arg Val Asn Pro Ile Leu Tyr His Ser Pro Thr Pro Gly His Arg Thr Thr Tyr Thr Cys Gly His Glu Tyr Ala Pro Ser Tyr Ala Glu Ser Asn Thr <210> 75 <211> 781 <212> PRT
<213> Homo sapiens <400> 75 Met Trp Gly Leu Val Arg Leu Leu Leu Ala Trp Leu Gly Gly Trp Gly Cys Met Gly Arg Leu Ala Ala Pro Ala Arg Ala Trp Ala Gly Ser Arg Glu His Pro Gly Pro Ala Leu Leu Arg Thr Arg Arg Ser Trp Val Trp Asn Gln Phe Phe Val Ile Glu Glu Tyr Ala Gly Pro Glu Pro Val Leu Ile Gly Lys Leu His Ser Asp Val Asp Arg Gly Glu Gly Arg Thr Lys Tyr Leu Leu Thr Gly Glu Gly Ala Gly Thr Val Phe Val Ile Asp Glu Ala Thr Gly Asn Ile His Val Thr Lys Ser Leu Asp Arg Glu Glu Lys Ala Gln Tyr Val Leu Leu Ala Gln Ala Va1 Asp Arg Ala Ser Asn Arg Pro Leu Glu Pro Pro Ser Glu Phe Ile Ile Lys Val Gln Asp Ile Asn Asp Asn Pro Pro Ile Phe Pro Leu Gly Pro Tyr His Ala Thr Val Pro Glu Met Ser Asn Val Gly Thr Ser Val Ile Gln Val Thr Ala His Asp Ala Asp Asp Pro Ser Tyr Gly Asn Ser Ala Lys Leu Val Tyr Thr Val l80 185 190 Leu Asp Gly Leu Pro Phe Phe Ser Val Asp Pro Gln Thr Gly Val Val Arg Thr Ala Ile Pro Asn Met Asp Arg Glu Thr Gln Glu Glu Phe Leu Val Val Ile Gln Ala Lys Asp Met Gly Gly His Met Gly Gly Leu Ser Gly Ser Thr Thr Val Thr Val Thr Leu Ser Asp Val Asn Asp Asn Pro Pro Lys Phe Pro Gln Ser Leu Tyr Gln Phe Ser Val Val Glu Thr Ala Gly Pro Gly Thr Leu Val Gly Arg Leu Arg Ala Gln Asp Pro Asp Leu Gly Asp Asn Ala Leu Met Ala Tyr Ser Ile Leu Asp Gly Glu Gly Ser Glu Ala Phe Ser Ile Ser Thr Asp Leu Gln Gly Arg Asp Gly Leu Leu Thr Val Arg Lys Pro Leu Asp Phe Glu Ser Gln Arg Ser Tyr Ser Phe Arg Val Glu Ala Thr Asn Thr Leu Ile Asp Pro Ala Tyr Leu Arg Arg Gly Pro Phe Lys Asp Val Ala Ser Val Arg Val Ala Val Gln Asp Ala Pro Glu Pro Pro A1a Phe Thr Gln Ala Ala Tyr His Leu Thr Val Pro Glu Asn Lys Ala Pro Gly Thr Leu Val Gly Gln Ile Ser Ala Ala Asp Leu Asp Ser Pro Ala Ser Pro Ile Arg Tyr Ser Ile Leu Pro His Ser Asp Pro Glu Arg Cys Phe Ser Ile Gln Pro Glu Glu Gly Thr Ile His Thr Ala Ala Pro Leu Asp Arg Glu Ala Arg Ala Trp His Asn Leu Thr Val Leu Ala Thr Glu Leu Asp Ser Ser Ala Gln Ala Ser Arg Val Gln Val Ala Ile Gln Thr Leu Asp Glu Asn Asp Asn Ala Pro Gln Leu Ala Glu Pro Tyr Asp Thr Phe Val Cys Asp Ser A1a Ala Pro Gly Gln Leu Ile Gln Val Ile Arg Ala Leu Asp Arg Asp Glu Val Gly Asn Ser Ser His Val Ser Phe Gln Gly Pro Leu Gly Pro Asp Ala Asn Phe Thr Val Gln Asp Asn Arg Asp Gly Ser Ala Ser Leu Leu Leu Pro Ser Arg Pro Ala Pro Pro Arg His Ala Pro Tyr Leu Val Pro Ile Glu Leu Trp Asp Trp Gly Gln Pro Ala Leu Ser Ser Thr Ala Thr Val Thr Val Ser Val Cys Arg Cys Gln Pro Asp Gly Ser Val Ala Ser Cys Trp Pro Glu Ala His Leu Ser Ala Ala Gly Leu Ser Thr Gly Ala Leu Leu Ala Ile Ile Thr Cys Val Gly Ala Leu Leu Ala Leu Val Val Leu Phe Val Ala Leu Arg Arg Gln Lys Gln Glu Ala Leu Met Va1 Leu Glu Glu Glu Asp Val Arg Glu Asn Ile Ile Thr Tyr Asp Asp Glu Gly Gly Gly Glu Glu Asp Thr Glu Ala Phe Asp Ile Thr Ala Leu Gln Asn Pro Asp Gly Ala Ala Pro Pro Ala Pro Gly Pro Pro Ala Arg Arg Asp Va1 Leu Pro Arg Ala Arg Val Ser Arg Gln Pro Arg Pro Pro Gly Pro Ala Asp Val Ala Gln Leu Leu Ala Leu Arg Leu Arg Glu Ala Asp Glu Asp Pro Gly Val Pro Pro Tyr Asp Ser Val Gln Val Tyr Gly Tyr Glu Gly Arg Gly Ser Ser Cys Gly Ser Leu Ser Ser Leu Gly Ser Gly Ser Glu Ala Gly Gly Ala Pro Gly Pro Ala Glu Pro Leu Asp Asp Trp Gly Pro Leu Phe Arg Thr Leu Ala Glu Leu Tyr Gly Ala Lys Glu Pro Pro Ala Pro <210> 76 <211> 640 <212> PRT

<213> Homo sapiens <400> 76 Met Ala Arg Gly His Tyr Ile Tyr Val Asp Thr Ser Phe Gly Lys Gln Gly Glu Lys Ala Val Leu Leu Ser Pro Asp Leu Gln Ala Glu Glu Trp Ser Cys Leu Arg Leu Val Tyr Gln Ile Thr Thr Ser Ser Glu Ser Leu Ser Asp Pro Ser Gln Leu Asn Leu Tyr Met Arg Phe Glu Asp Glu Ser Phe Asp Arg Leu Leu Trp Ser Ala Lys Glu Pro Ser Asp Ser Trp Leu Ile Ala Ser Leu Asp Leu Gln Asn Ser Ser Lys Lys Phe Lys Tle Leu Ile Glu Gly Val Leu Gly Gln Gly Asn Thr Ala Ser Ile Ala Leu Phe Glu Ile Lys Met Thr Thr Gly Tyr Cys Ile Glu Cys Asp Phe Glu Glu Asn His Leu Cys Gly Phe Val Asn Arg Trp Asn Pro Asn Val Asn Trp Phe Val Gly Gly Gly Ser Ile Arg Asn Val His Ser Ile Leu Pro Gln Asp His Thr Phe Lys Ser Glu Leu Gly His Tyr Met Tyr Val Asp Ser Val Tyr Val Lys His Phe Gln Glu Val Ala Gln Leu I1e Ser Pro Leu Thr Thr Ala Pro Met Ala Gly Cys Leu Ser Phe Tyr Tyr Gln Ile Gln Gln Gly Asn Asp Asn Val Phe Ser Leu Tyr Thr Arg Asp Val Ala Gly Leu Tyr Glu Glu Ile Trp Lys Ala Asp Arg Pro Gly Asn Ala Ala Trp Asn Leu Ala Glu Va1 Glu Phe Thr Cys His Phe Pro Leu Gln Val Ile Phe Glu Val Ala Phe Asn Gly Pro Lys Gly Gly Tyr Val Ala Leu Asp Asp Ile Ser Phe Ser Pro Val His Cys Gln Asn Gln Thr Glu Leu Leu Phe Ser Ala Val Glu Ala Ser Cys Asn Phe Glu Gln Asp Leu Cys Asn Phe Tyr Gln Asp Lys Glu Gly Pro Gly Trp Thr Arg Val Lys Val Lys Pro Asn Met Tyr Arg Ala Gly Asp His Thr Thr Gly Leu Gly Tyr Tyr Leu Leu Ala Asn Thr Lys Phe Thr Ser Gln Pro Gly Tyr Ile Gly Arg Leu Tyr Gly Pro Ser Leu Pro Gly Asn Leu Gln Tyr Cys Leu Arg Phe His Tyr Ala Ile Tyr Gly Phe Leu Lys Met Ser Asp Thr Leu Ala Val Tyr Ile Phe Glu Glu Asn His Val Val Gln Glu Lys Ile Trp Ser Val Leu Glu Ser Pro Arg Gly Val Trp Met Gln Ala Glu Ile Thr Phe Lys Lys Pro Met Pro Thr Lys Val Val Phe Met Ser Leu Cys Lys Ser Phe Trp Asp Cys Gly Leu Val Ala Leu Asp Asp Ile Thr Ile Gln Leu Gly Ser Cys Ser Ser Ser Glu Lys Leu Pro Pro Pro Pro Gly Glu Cys Thr Phe Glu Gln Asp Glu Cys Thr Phe Thr Gln Glu Lys Arg Asn Arg Ser Ser Trp His Arg Arg Arg Gly Glu Thr Pro Thr Ser Tyr Thr Gly Pro Lys Gly Asp His Thr Thr Gly Val Gly Tyr Tyr Met Tyr Ile Glu Ala Ser His Met Val Tyr Gly Gln Lys Ala Arg Leu Leu Ser Arg Pro Leu Arg Gly Val Ser Gly Lys His Cys Leu Thr Phe Phe Tyr His Met Tyr Gly G1y Gly Thr Gly Leu Leu Ser Val Tyr Leu Lys Lys Glu Glu Asp Ser Glu Glu Ser Leu Leu Trp Arg Arg Arg Gly Glu Gln Ser Ile Ser Trp Leu Arg Ala Leu Ile Glu Tyr Ser Cys Glu Arg Gln His Gln Ile Ile Phe Glu Ala Ile Arg Gly Val Ser Ile Arg Ser Asp Ile Ala Ile Asp Asp Val Lys Phe Gln Ala Gly Pro Cys Gly Glu Met Glu Asp Thr Thr Gln Gln Ser Ser Gly Tyr Ser Glu Asp Leu Asn Glu Ile Glu Tyr <210> 77 <211> 686 <212> PRT
<213> Homo Sapiens <400> 77 Met Leu Leu Arg Gly Va1 Leu Leu Ala Leu Gln Ala Leu Gln Leu Ala Gly Ala Leu Asp Leu Pro Ala Gly Ser Cys Ala Phe Glu Glu Ser Thr Cys Gly Phe Asp Ser Val Leu Ala Ser Leu Pro Trp Ile Leu Asn Glu Glu Gly His Tyr Ile Tyr Val Asp Thr Ser Phe Gly Lys Gln Gly Glu Lys Ala Val Leu Leu Ser Pro Asp Leu Gln Ala Glu Glu Trp Ser Cys Leu Arg Leu Val Tyr Gln Ile Thr Thr Ser Ser Glu Ser Leu Ser Asp Pro Ser Gln Leu Asn Leu Tyr Met Arg Phe Glu Asp Glu Ser Phe Asp Arg Leu Leu Trp Ser Ala Lys Glu Pro Ser Asp Ser Trp Leu Ile Ala Ser Leu Asp Leu Gln Asn Ser Ser Lys Lys Phe Lys Ile Leu Ile Glu Gly Val Leu Gly Gln Gly Asn Thr Ala Ser Ile Ala Leu Phe Glu Ile Lys Met Thr Thr Gly Tyr Cys Ile Glu Cys Asp Phe Glu Glu Asn His Leu Cys Gly Phe Val Asn Arg Trp Asn Pro Asn Val Asn Trp Phe Val Gly Gly Gly Ser Ile Arg Asn Val His Ser Ile Leu Pro Gln Asp His Thr Phe Lys Ser Glu Leu Gly His Tyr Met Tyr Val Asp Ser Val Tyr Val Lys His Phe G1n Glu Val Ala Gln Leu Ile Ser Pro Leu Thr Thr Ala Pro Met Ala Gly Cys Leu Ser Phe Tyr Tyr Gln Ile Gln Gln Gly Asn Asp Asn Val Phe Ser Leu Tyr Thr Arg Asp Val Ala Gly Leu Tyr Glu Glu Ile Trp Lys Ala Asp Arg Pro Gly Asn Ala Ala Trp Asn Leu Ala Glu Val Glu Phe Thr Cys His Phe Pro Leu Gln Val Ile Phe Glu Val Ala Phe Asn Gly Pro Lys Gly Gly Tyr Val Ala Leu Asp Asp Ile Ser Phe Ser Pro Val His Cys Gln Asn Gln Thr Glu Leu Leu Phe Ser Ala Val Glu Ala Ser Cys Asn Phe Glu Gln Asp Leu Cys Asn Phe Tyr Gln Asp Lys Glu Gly Pro Gly Trp Thr Arg Val Lys Val Lys Pro Asn Met Tyr Arg Ala Gly Asp His Thr Thr Gly Leu Gly Tyr Tyr Leu Leu Ala Asn Thr Lys Phe Thr Ser Gln Pro Gly Tyr Ile Gly Arg Leu Tyr Gly Pro Ser Leu Pro Gly Asn Leu Gln Tyr Cys Leu Arg Phe His Tyr Ala Ile Tyr Gly Phe Leu Lys Met Ser Asp Thr Leu Ala Val Tyr Ile Phe Glu Glu Asn His Val Val Gln Glu Lys Ile Trp Ser Val Leu Glu Ser Pro Arg Gly Val Trp Met Gln Ala Glu Ile Thr Phe Lys Lys Pro Met Pro Thr Lys Val Val Phe Met Ser Leu Cys Lys Ser Phe Trp Asp Cys G1y Leu Val Ala Leu Asp Asp Ile Thr Ile Gln Leu Gly Ser Cys Ser Ser Ser Glu Lys Leu Pro Pro Pro Pro Gly Glu Cys Thr Phe Glu Gln Asp Glu Cys Thr Phe Thr Gln Glu Lys Arg Asn Arg Ser Ser Trp His Arg Arg Arg Gly Glu Thr Pro Thr Ser Tyr Thr Gly Pro Lys Gly Asp His Thr Thr Gly Val Gly Tyr Tyr Met Tyr Ile Glu Ala Ser His Met Val Tyr Gly Gln Lys Ala Arg Leu Leu Ser Arg Pro Leu Arg Gly Val Ser Gly Lys His Cys Leu Thr Phe Phe Tyr His Met Tyr Gly Gly Gly Thr Gly Leu Leu Ser Val Tyr Leu Lys Lys Glu Glu Asp Ser Glu Glu Ser Leu Leu Trp Arg Arg Arg Gly Glu Gln Ser Ile Ser Trp Leu Arg Ala Leu Ile Glu Tyr Ser Cys Glu Arg Gln His Gln Ile Ile Phe Glu Ala Ile Arg Gly Val Ser Ile Arg Ser Asp Ile Ala Ile Asp Asp Val Lys Phe Gln Ala Gly Pro Cys Gly Glu Met Glu Asp Thr Thr Gln Gln Ser Ser Gly Tyr Ser Glu Asp Leu Asn Glu Ile Glu Tyr <210> 78 <211> 154 <212> PRT
<213> Homo Sapiens <400> 78 Met Thr Leu Ser Pro Thr Gln Pro Pro Leu Phe His Leu Pro Tyr Val Gln Lys Cys Phe Ile Pro Thr Val Glu Gln Leu Thr Leu Gly Ile Pro Cys Gln Asn His Gly Glu Ile Asp His Gly Gln Asp Ile Phe Pro Ala Glu Lys Leu Cys His Leu Gln Asp Cys Lys Val Asn Leu His Arg Ala Ala Cys Gly Glu Cys Ile Val Ala Pro Lys Thr Ser Ser Phe Pro Tyr Cys Gln Gly Thr Cys Leu Thr Leu Asn Ser Glu Leu His Gln Ser Asn Phe Ala Leu Lys Val Cys Thr Ile Arg Gly Glu Cys Leu Leu Ile Cys Ser Trp Leu Phe Gln Thr Cys Ser Pro Thr Lys Val Ile Leu Phe Ser Leu Thr Val Gln Asp Asp Glu Arg Lys Met Ser Val His Cys Val Asn Ala Ser Leu Ile Glu Lys Cys Gly Cys Ser,

Claims (7)

What is claimed is:

1. An isolated polypeptide selected from the group consisting of:
(a) an isolated polypeptide encoded by a polynucleotide comprising a sequence set forth in Table I;
(b) an isolated polypeptide comprising a polypeptide sequence set forth in Table I; and (c) a polypeptide sequence of a gene set forth in Table I.

2. An isolated polynucleotide selected from the group consisting of:
(a) an isolated polynucleotide comprising a polynucleotide sequence set forth in Table I;
(b) an isolated polynucleotide of a gene set forth in Table I;
(c) an isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide set forth in Table I;
(d) an isolated polynucleotide encoding a polypeptide set forth in Table I;
(e) a polynucleotide which is an RNA equivalent of the polynucleotide of (a) to (d);
or a polynucleotide sequence complementary to said isolated polynucleotide.

3. An expression vector comprising a polynucleotide capable of producing a polypeptide of claim 1 when said expression vector is present in a compatible host cell.

4. A process for producing a recombinant host cell which comprises the step of introducing an expression vector comprising a polynucleotide capable of producing a polypeptide of claim 1 into a cell such that the host cell, under appropriate culture conditions, produces said polypeptide.

5. A recombinant host cell produced by the process of claim 4.

6. A membrane of a recombinant host cell of claim 5 expressing said polypeptide.

7. A process for producing a polypeptide which comprises culturing a host cell of claim 5 under conditions sufficient for the production of said polypeptide and recovering said polypeptide from the culture.
43~